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Abstract 
In recent years, microRNAs have emerged as important regulators in various biological 
processes, as a new class of biomarkers, and as novel therapeutic drugs for many diseases, 
including cardiovascular diseases. Tumour suppressor microRNA-22 (miRNA-22 or miR-
22) has been reported to regulate cardiac aging and to play a role in hematopoietic cell 
differentiation and maturation. Moreover, DNA methylation, a major modification of 
eukaryotic genomes, plays an essential role in mammalian development. Methyl CpG-
binding protein 2 (MECP2) is capable of binding specifically to methylated DNA and is 
involved in gene silencing. The main objectives of this PhD project were to determine the 
functional impact of miRNA-22 and its target gene, MECP2, in smooth muscle cell (SMC) 
differentiation and to delineate the molecular mechanism involved.  
Mouse embryonic stem (ES) cells were seeded on collagen-coated flasks in differentiation 
medium to promote SMC differentiation. MiRNA-22 was significantly upregulated during 
SMC differentiation from ES cells. Enforced expression of miRNA-22 by its mimic or 
knockdown of miR-22 by its antagomiR promoted or inhibited SMC differentiation from 
ES cells, respectively. As expected, miRNA-22 overexpression in stem cells promoted 
SMC differentiation in vivo. Consistently, a similar change in miR-22 expression and a 
similar functional role for miRNA-22 were observed during SMC differentiation from 
adventitia stem/progenitor cells isolated from murine blood vessels. MECP2, the founding 
member of the family of methyl CpG binding domain proteins, was identified by several 
computational miRNA target prediction tools as one of the top targets of miR-22. Methyl 
CpG binding domain proteins bind specifically to methylated and unmethylated DNA and 
recruit distinct interacting protein partners to establish a repressive or active chromatin 
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environment. Interestingly, expression of the gene encoding MECP2 decreased 
significantly during SMC differentiation. MECP2 decreased dramatically in miRNA-22–
overexpressing cells, but significantly increased after miRNA-22 knockdown in 
differentiating stem cells. Moreover, luciferase assays showed that miR-22 substantially 
inhibited wild-type, but not mutant, MECP2-3′-UTR luciferase activity. In addition, 
modulation of MECP2 expression levels affected the expression of multiple SMC-specific 
marker genes in differentiated ES cells. At the mechanistic level, our data showed that 
MECP2 transcriptionally repressed SMC gene expression by modulating various SMC 
transcription factors as well as several established SMC differentiation regulators. 
Additionally, enrichment of H3K9 trimethylation around the promoter regions of SMC 
transcription factors and other known differentiation regulator genes increased after 
MECP2 overexpression, suggesting that modulation of DNA methylation is another 
mechanism underlying MECP2-mediated gene expression during SMC differentiation 
from stem cells. Finally, miR-22 was upregulated by platelet-derived growth factor-BB 
and transforming growth factor-β through a transcriptional mechanism during SMC 
differentiation. 
Taken together, the findings obtained from my PhD project strongly suggest that miR-22 
plays an important role in SMC differentiation from both embryonic and adventitial stem 
cells and that epigenetic regulation through MECP2 is required for miR-22–mediated SMC 
differentiation. 
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Chapter 1 
1. Introduction  
1.1. Cardiovascular disease 
1.1.1. Atherosclerosis, vascular smooth muscle cells, and stem 
cells 
Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood 
vessels. According to the latest data from the World Health Organization (WHO), CVD 
is the leading cause of death globally (31.4%), accounted for around 17.5 million deaths 
in 2012 (Figure 1) (WHO, 2014). Moreover, it causes 4.35 million deaths in Europe 
annually (Mendis et al., 2011). Most instances of CVD could be prevented through 
population-wide strategies that address behavioural risk factors such as tobacco use, 
unhealthy diet, obesity, physical inactivity, and the harmful use of alcohol (Mendis et al., 
2011). There are four main types of CVD: coronary heart disease (CHD) that leads to 
myocardial infarction (Buschdorf and Stratling), stroke, peripheral arterial disease, and 
aortic disease (Mendis et al., 2011, Sheridan et al., 2009).  
The underlying cause of CVD, atherosclerosis, also known as arteriosclerotic vascular 
disease, is a chronic inflammatory disease initiated by endothelial dysfunction 
(Kaperonis et al., 2006), and it usually occurs inside medium to large size of arteries as a 
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result of plaque building up from fat, cholesterol, calcium and other substances found in 
the blood and vascular wall (Go et al., 2014, Ross and Glomset, 1973).  
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Figure 1 Distribution of major causes of death including CVD, in 2012. 
CVD was a major cause of death in 2012, accounting for 31.4% of all deaths as this pie 
chart described. The data shown in the pie chart were retrieved from WHO published 
statistical results in 2014 (WHO, 2014). 
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Injuries
Other causes
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As mentioned above, atherosclerosis is a progressive disease in which lipids, 
inflammatory cells, and vascular smooth muscle cells (VSMCs) accumulate in the 
neointima layer (the inner layer of the artery) of the artery and form a plaque with fibrous 
cap. Neointima formation is a common feature of atherosclerosis and restenosis after 
balloon angioplasty. The neointima is a new or thickened layer of arterial intima formed 
by the migration and proliferation of cells from the blood vessel media or other 
surrounding tissues. After an artery is injured, leukocytes and monocytes enter the intima, 
where they become foam cells and express scavenger receptors that internalize modified 
lipoproteins and form the fatty streak. The region of the intima with the fatty streak is 
called the neointima. A high-fat Western diet combined with other risk factors damages 
the lining of the artery, known as the endothelium. Endothelium has already been proved 
that it is not a simple lining of cells on the inner arterial wall (Galley and Webster, 2004). 
Healthy endothelium plays an important role in the free passage process of molecules 
and cells into the underlying interstitium. It is also a dynamic endocrine organ that 
secretes a numerous vascular protective molecules such as nitric oxide and prostaglandin.  
Together, they play an important role in inhibiting leukocyte adhesion and migration, 
platelet adhesion and aggregation and vascular smooth muscle cell proliferation and 
migration(Landmesser et al., 2004). However, endothelium dysfunction, resulting from 
smoking, hypertension, diabetes, genetic alterations, elevated plasma homocysteine 
concentrations and infectious microorganisms, can cause an overexpression of some cell 
adhesion molecules (CAMs) such as vascular cell adhesion molecule-1 (VCAM-1) and 
intracellular cell adhesion molecules (ICAMs). This upregulation of CAMs is the first 
step of leukocyte recruitment to the site of lesion that allows more leukocytes to adhere 
onto the endothelium and enter the intima through a process known as diapedesis (Libby 
et al., 2010, Orlandi and Bennett, 2010, Libby, 2002), initiating local inflammation. The 
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recruited leukocytes ingest the oxidised low-density cholesterol in the intimal layer of the 
vascular wall, causing foam cell formation (Johnson, 2014).  
Clinical manifestations occur once the atheroma has evolved beyond the formation of the 
fatty streak. At this point, VSMCs accumulate in the plaque, where they adopt a 
synthetic phenotype. They then proliferate, secrete copious amounts of extracellular 
matrix (Djarmati et al.), increase the size of the atherosclerotic lesion. The VSMCs in the 
plaque, which differ from medial VSMCs, are capable to engulf aggregated low-density-
lipoprotein (LDL) that trapped in the intima.  Increasing evidences suggesting that the 
elevated levels of LDL cholesterol in the blood leads to lipid accumulation in vascular 
wall (Galkina and Ley, 2009, Dushkin, 2012). Hence, intimal VSMCs contribute further 
to foam cell formation.  
VSMCs that reside in the middle layer of the vessel, the media, have a contractile 
phenotype with an elongated, spindle-shaped morphology. Synthetic VSMCs 
alternatively have cobblestone morphology and a secretory function. The synthetic 
phenotype constitutes the majority of phenotypes displayed by VSMCs in embryological 
development. Traditionally, atherosclerotic VSMCs were thought to originate solely 
from VSMCs within the media layer. In recent years, this assumption has been 
questioned (Wang et al., 2015, Tsai et al., 2012, Hu and Xu, 2011, Bai et al., 2010, 
Torsney and Xu, 2011, Campagnolo et al., 2011, Kirton and Xu, 2010, Xu, 2008, 
Zampetaki et al., 2008, Adams et al., 2007b, Adams et al., 2007a, Xu, 2007, Xu, 2006, 
Roberts et al., 2005, Torsney et al., 2005). 
VSMCs may directly or indirectly participate in the formation of the vascular lesions. 
Transplant arteriosclerotic is an example of vascular lesion that results from organ 
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transplantation (Xu, 2006).  Xu’s group has further demonstrated that VSMCs contribute 
to transplant arteriosclerosis partly through progenitor cell differentiation in lesions on 
the vessel wall. And the accelerated arteriosclerosis transplant is the major barrier to 
long-term survival of patients (Xu, 2006, Xu, 2008). According to the traditional view, 
intimal SMCs in transplant arteriosclerotic lesions were originally thought to be derived 
from the donor vessels rather than recipient vessel (Ross, 1986). However, recent data 
obtained from different laboratories demonstrated a different view. Hillebrands et al used 
the rat model to show that all neointimal VSMCs in both aortic and cardiac allografts 
were originated from the recipient (Hillebrands et al., 2001). Hu et al. also found that 40% 
of VSMCs in arteriosclerotic lesions were derived from recipients and 60% from the 
grafted vessel in mouse model (Hu et al., 2002). In contrast,  transplant arteriosclerosis of 
cardiac allografts varies in human model and VSMCs with a low percentage were found 
to be recipient derived (Glaser et al., 2002). These results suggested an important role of 
VSMC migration and proliferation in arteriosclerosis, and without a doubt the role of 
VSMCs in transplant arteriosclerosis is valuable for medical researches and discussions, 
regardless of the origination of the VSMCs. 
Circulating or vascular stem/progenitor cells have recently been identified as a source of 
atherosclerotic/neointima VSMCs. They are thought to derive from the arterial wall 
(Sainz et al., 2006, Hu et al., 2004) or the circulation (Simper et al., 2002). Torsney and 
colleagues  confirmed the presence of vascular progenitor cells in human atherosclerotic 
vessels by detecting stem/progenitor cell markers such as CD34, stem cell antigen-1 
(Sca-1), c-kit and VEGF receptor 2 (VEGFR2) in normal and diseased human arteries 
from patients undergoing coronary artery bypass surgery (Torsney et al., 2007). 
Moreover, for treating damaged vasculature, Scott et al. documented that stem cells have 
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great potential in the field of regenerative medicine, and hence could provide solutions to 
the problem of vascular repair and regeneration (Scott et al., 2013). Recent evidence 
indicates that stem/progenitor cells are abundant in the vessel wall, in which laminar 
shear stress can stimulate these cells to differentiate towards the endothelial lineage, 
while cyclic strain results in smooth muscle differentiation (Zhang et al., 2013). In 
samples taken from the proximal ascending aorta, progenitor cell number was two- to 
three-fold higher in the adventitia than in the internal mammary artery (Torsney et al., 
2007). These vascular progenitors are important in atherosclerosis, as demonstrated in 
study by using animal models of vein grafts (Hu et al., 2002). Importantly, using the 
same vein graft model, the same group also demonstrated that stem/progenitor cells 
derived from adventitia could differentiate into SMCs in vitro and/or in vivo and 
contribute to atherosclerotic lesion formation and progression (Hu et al., 2004). In 
addition, Zhang et al. speculated that human smooth muscle progenitors in the human-
circulating blood contribute to the pathogenesis of vascular diseases, and vascular stem 
cells are closely related to vascular repair and disease development (Zhang et al., 2013). 
On other hand, progenitor cells in the circulation and adventitia were confirmed that it 
contribute to endothelial repair and SMC accumulation (Xu, 2006). 
Rapid advancements in stem/progenitor cell research in recent years have paved the way 
to novel therapies in cardiovascular disease, although questions remain (Sheng et al., 
2013). Nevertheless, the molecular mechanisms behind stem/progenitor cell 
differentiation into VSMCs and the implications for CVD will undoubtedly lead to the 
development of new drugs for the prevention of CVD.  
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1.1.2 Regenerative medicine techniques in cardiovascular 
disease 
Regenerative medicine is a rapidly developing field with the ultimate goal of repairing, 
replacing, or regenerating cells, tissues, or organs lost or damaged because of disease, 
injury, or ageing. For cardiovascular regeneration, growing evidence suggests that 
impaired cardiac and vascular functions resulting from CVD can be restored/improved 
by endogenous or exogenous stem/progenitor cells. Findings from clinical trials also 
demonstrate the potential capacity of adult and embryonic stem cells to regenerate 
damaged tissues/organs and improve their respective functions (Packer et al., 2013).  
Furthermore, adult and embryonic stem cells are under intense evaluation for use in 
regenerative medicine because they have the potential for unlimited self-renewal; the 
ability to differentiate into a wide range of specialized cell types, including vascular 
endothelial cells (Zeng et al., 2006, Xiao et al., 2006) and smooth muscle cells (SMCs) 
(Xiao et al., 2007b, Xiao et al., 2012, Pepe et al., 2010, Huang et al., 2013, Yu et al., 
2015); and the ability to secrete cytokines and growth factors to support endogenous 
tissue/organ repair (Murata et al., 2010). The exact mechanism of action behind stem and 
progenitor cell regeneration is still uncertain, but does not appear to occur solely through 
the replacement or regeneration of lost cells. Strong evidence suggests that transplanted 
stem cells promote endogenous cellular repair by inducing paracrine cell-to-cell 
signalling, such as the production of cytokines or other factors (Kinkaid et al., 2010). 
Although the exact benefit of regenerative medicine to patients has yet to be determined 
and the translation of ongoing research into clinical treatments is some way off, no one 
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doubts that regenerative medicine will eventually offer new, additional, or 
complementary treatment options for patients with CVD.  
 
1.2. Stem cell 
1.2.1. Characteristics and classification of stem cells 
Stem cells are undifferentiated cells that can differentiate into specialized cells and 
divide (through mitosis) to produce more stem cells. Two important properties of all 
stem cells are the capability of unlimited self-renewal and the capacity to differentiate 
into various cell lineages (also known as pluripotency) of many tissue types (Cogle et 
al., 2003). Although this dual functionality has been much studied, the search for 
molecular signatures of ‘stemness’ and pluripotency is only now beginning to gather 
momentum. Stem cells are classified into four types: two physiological types present at 
different stages of life, embryonic stem cells (ES cells) and adult stem cells (ASCs); 
one engineered or ‘induced’ type, induced pluripotent stem (iPS) cells; and one 
pathological type present in cancers with some stem properties, cancer stem cells 
(CSCs) (Herreros-Villanueva et al., 2014). In the past decades, the majority of stem cell 
studies have focused on ES cells, and the knowledge generated from ES cell studies has 
guided investigations of the other three types of stem cells. 
The second class of stem cells is ASCs, also known as somatic stem cells (SSCs), are 
thought to be postnatal derivatives of ES cells present throughout the body, including 
the skin, brain, bone marrow, intestine, and neural tissue. At least three of the core 
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ES cell transcription factors (OCT4, KLF4, and SOX2) have been reported to be 
regulated in ASCs (Alvarez et al., 2012). ASCs are primarily involved in maintaining 
and repairing/regenerating specific tissues; under certain circumstances, they may 
contribute to disease development. The ASCs for potential use in stem cell therapy are 
autologous; because they are usually harvested from the patient, there are almost no 
immunologic barriers. However, unlike ES cells, ASCs do not fully retain their 
proliferative and multi-lineage differentiation capabilities in aging humans (Boyette and 
Tuan, 2014), meaning they only maintain the capacity to differentiate into specific cell 
lineages from a given germ layer based on their origin. Furthermore, the same group 
also proved that ASCs are limited in quantity because of their lower capacity to divide 
during in vitro culture (Boyette and Tuan, 2014). Hematopoietic stem cells (HSCs) 
have been used in clinical settings for years to reconstitute the immune system in 
cancer and other illnesses, while other ASCs have been used as gene delivery 
vectors to enhance tissue regeneration, destroy cancer cells, and regenerate 
cartilage and bone (Boyette and Tuan, 2014). 
Fifty years ago, Sir John Gurdon succeeded in a ground-breaking work to generate 
cloned frogs by transferring the nucleus of a tadpole's somatic cell into an oocyte, thus 
demonstrating that cells retain genetic information and can be rejuvenated by artificial 
treatment to again acquire pluripotency (Gurdon, 1962). Numerous other studies of 
nuclear reprogramming have since been conducted. In 2006, Shinya Yamanaka’s lab 
first generated the induced pluripotent stem cells (iPSCs) by transducing four key 
transcription factors, OCT4, SOX2, c-Myc, and KLF4, which are artificially 
engineered into adult cells (Takahashi and Yamanaka, 2006). iPSC generation is a 
milestone achievement in stem cell research, not only breaking the dogma that somatic 
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cell differentiation is an irreversible process, but also creating new avenues in disease 
modelling and regenerative medicine that avoid the controversial use or destruction of 
embryos required for ESC generation.  
The final type of stem cell, CSC, is found within tumours. CSCs can self-renew, 
produce differentiated progeny, and drive tumorigenesis. The ability of cancer cells to 
form non-adherent spheroids in in vitro culture is frequently used as a surrogate marker 
for the stemness of CSCs (Alvarez et al., 2012). 
Since the first report in 1998, human ESCs have been viewed as a key component of 
future treatments for diseases such as Parkinson's disease and spinal cord injury 
(Thomson, 1998). However, clinical applications and research using human ESCs face 
several barriers, including ethical concerns about the use of human embryos and 
scientific concerns about immune rejection after transplantation, which could be 
overcome by iPSC technology. Since Yamanaka’s group discovered iPSCs in 2006, 
accumulating evidence has demonstrated that iPSCs have properties similar to those of 
ES cells (unlimited self-renewal and the ability to differentiate into different cell types 
derived from the three germ layers: endoderm, mesoderm, and ectoderm), indicating 
that iPS cell technologies can be applied in medical science, in particular for regenerative 
medicine and human disease modelling (Takahashi and Yamanaka, 2006, Okano and 
Yamanaka, 2014).  
Pluripotent stem cells have been used as a critical tool in regenerative medicine and 
tissue engineering for clinical cell therapies to treat devastating and incurable diseases, 
including type 1 diabetes, blindness, damaged articular cartilage, neurological 
diseases, Parkinson’s disease (PD), corneal diseases, and terminal cardiovascular 
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diseases (Boyette and Tuan, 2014, Hayashi et al., 2012, Kikuchi et al., 2011). 
Furthermore, the use of iPSCs in regenerative medicine to treat other diseases, including 
CVD, is under investigation worldwide (Chi et al., 2015, Wong et al., 2013, Egashira et 
al., 2011).  
One important concern for iPS cell generation is the cellular source. Ideally, human 
iPSCs should be obtained using minimally invasive procedures associated with the 
lowest possible risk. In 2007, human iPSCs were first established from dermal 
fibroblasts by Yamanaka’s group (Takahashi et al., 2007). Thereafter, cord blood (CB) 
stem cells were reprogrammed to iPSCs by retroviral transduction with only two factors 
(OCT4 and SOX2) in 2 weeks and without the need for additional chemical compounds 
(Giorgetti et al., 2010). Moreover, another report has suggested that iPSCs can be 
generated easily from CD34
+
 cord blood cells by repressing p53 expression through the 
addition of a lentiviral p53 short-hairpin RNA expression vector (Takenaka et al., 2010). 
 
1.2.2. Embryonic stem (ES) cells 
Embryogenesis is often viewed as a progressive loss of developmental capacity from a 
‘totipotent’ zygote. However, in reality, the mammalian egg is a highly specialized and 
restricted cell, and its developmental potential is unlocked through the formation of 
epiblast cells in the inner cell mass (ICM) of the blastocyst (Selwood and Johnson, 
2006).  
ES cells have unlimited self-renewal capacity and pluripotency, defined as the ability to 
- 36 - 
 
differentiate into most cell types within an organism. Thus, ES cells hold great promise 
for regenerative medicine and serve as an excellent in vitro model system with which to 
study early development in mammals. Because ES cells can give rise to functional 
gametes, they have been used extensively to create genetically engineered lines of mice 
for developmental, genetic, and biomedical research (Capecchi, 2005). ES cells are 
pluripotent stem cells derived from the ICM of a mammalian blastocyst, an early-stage 
embryo approximately 3.5 days post coitum (Nichols and Smith, 2012). ES cells were 
first derived in 1981 by explanting blastocysts or ICMs from mice, and their pluripotency 
was demonstrated by their ability to contribute to the development of all tissues in mice 
after the injection of isolated ES cells into host blastocysts (Evans and Kaufman, 1981, 
Martin, 1981). Human ES cells, first isolated in 1998 by Thomson and colleagues, have 
the potential to form derivatives of all three embryonic germ layers (Thomson, 1998). In 
2004, a new standard protocol was first established to generate human ES cells efficiently 
by supplementing FGF/activin into the cell culture system (Cowan et al., 2004).  
Studies in experimental mammalian embryology have mainly focused on mouse embryos. 
Structures in the mouse embryo, including the placenta, extra-embryonic membranes, and 
the egg cylinder, are very similar to the corresponding structures in the human embryo. 
Nonetheless, human ES cells will be particularly valuable for investigating human 
embryonic development.  
For ES cell studies, the initial challenge scientists need to overcome is maintaining the 
undifferentiated status of ES cells and their two major properties, self-renewal and 
pluripotency, during in vitro culture and maintenance. As mentioned earlier, mouse ES 
cell lines were initially obtained from the blastocysts of the Sv129 strain as round colonies 
on a layer of chemically arrested mouse embryonic fibroblasts (MEFs), known as a 
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‘feeder layer’ (Evans and Kaufman, 1981), indicating that MEFs might provide essential 
factors for maintaining undifferentiated ES cells. ES cell lines have also been established 
from single cells isolated following epiblast microdissection at embryonic day 4.5 (E4.5) 
(Brook and Gardner, 1997). Leukaemia inhibitory factor (LIF) derived from feeder layer 
cells is the critical factor in inhibiting ES differentiation and supporting the proliferation 
of undifferentiated stem cells (Williams et al., 1988). LIF is a cytokine produced by the 
endometrium that promotes blastocyst implantation (Stewart et al., 1992). GP130, the 
receptor for LIF, is expressed in ES cells and mediates ES cell self-renewal and 
pluripotency by phosphorylating the transcription factor STAT3 (Williams et al., 1988). 
Using a constitutively activated form of STAT3, Yokota’s group has shown that 
activation of this transcription factor alone is sufficient to support ES cell self-renewal at a 
high density in serum-supplemented medium (Matsuda et al., 1999). Although STAT3 
signalling is sufficient to support mouse ES cell self-renewal, this pathway is not 
responsible for the self-renewal of human ES cells (Smith, 2001, Thomson, 1998, Sato et 
al., 2004). Instead, Sato et al. found that activation of the Wnt pathway, mediated by 6-
bromoindirubin-3′-oxime (BIO), a specific pharmacological inhibitor of glycogen 
synthase kinase-3 (GSK-3), can support the undifferentiated phenotype of both human 
and mouse ES cells and sustain the expression of some ES cell-specific transcription 
factors, such as Oct-3/4, Rex-1, and Nanog (Sato et al., 2004). 
Evidence suggests that not only GP130, but also a class I cytokine receptor, the low-
affinity LIF receptor (LIF-R), can mediate the actions of LIF via heterodimerization 
(Gearing et al., 1991, Gearing and Bruce, 1992, Davis et al., 1993). Utilising self-renewal 
and pluripotency as surrogate markers to evaluate whether ES cells remain in the 
undifferentiated state, studies have shown that oncostatin M (OSM), cardiotrophin (CT-1), 
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and ciliary neurotrophic factor (CNTF), which are LIF-related cytokines, can act through 
the same receptor complex (in the case of CNTF, additionally including the CNTF-Rα 
subunit) and similarly sustain ES cell self-renewal (Conover et al., 1993, Rose et al., 1994, 
Wolf et al., 1994, Yoshida et al., 1994, Pennica et al., 1995). Furthermore, ES cells can 
also be derived and maintained in vitro using a combination of interleukin-6 and soluble 
interleukin-6 receptor (IL-6/sIL-6R) (Nichols et al., 1994, Yoshida et al., 1994). Hitoshi et 
al. found that granulocyte colony-stimulating factor receptor (G-CSF-R) could signal ES 
cell self-renewal (Niwa et al., 1998). Surprisingly, G-CSF-R is a cytokine receptor that is 
evolutionarily related to GP130 and LIF-R, but is not expressed in ES cells (Gearing et al., 
1991, Chambers et al., 1997).  
Because pluripotency is considered one of the most important ES cell properties, it is 
critical to retain pluripotency by preventing differentiation. Studies over the past few years 
have revealed the role of some transcription factor networks and epigenetic processes in 
the maintenance of ES cell pluripotency; these include OCT3/4, Nanog, SOX2, Esrrb, and 
Klf4 (Pesce and Scholer, 2001, Pesce et al., 1998, Ambrosetti et al., 1997, Niwa et al., 
2000, Mitsui et al., 2003, Boyer et al., 2005, Boyer et al., 2006, Kaji et al., 2009, Kalmar 
et al., 2009). In addition, a paper published in Nature Genetics suggested that DNA 
modification, histone or chromatin structure changing also can more or less affect the 
activities of the genes targeted by these transcription factors (Jaenisch and Bird, 2003).  
Oct3/4, a member of the POU transcription factor family, is encoded by Pou5f1 and is a 
central player in ES cell self-renewal and differentiation into specific lineages (Pardo et al., 
2010, Nichols et al., 1998). It has been reported that Oct3/4 can directly inhibit ES cell 
differentiation towards the trophectoderm by interacting with Cdx2, an inducer of 
trophectoderm differentiation, to form a repressor complex (Niwa et al., 2005). Sox2 is 
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widely believed to cooperate with Oct3/4 in activating Oct3/4 target genes (Yuan et al., 
1995). Nevertheless, OCT3/4 can associate with SOX2 to form a complex that suppresses 
the expression of Cdx2 (Niwa et al., 2005). Interestingly, Oct3/4 and Sox2 are 
transcriptionally regulated by an enhancer containing a composite element recognized by 
Oct4 and Sox2 (Chew et al., 2005, Okumura-Nakanishi et al., 2005). Nanog, the variant 
homeodomain-containing protein, which was isolated in a functional cDNA screen in ES 
cells, cooperates with STAT3 to drive ES cell self-renewal (Chambers et al., 2003). As 
mentioned earlier, three essential transcription factors, OCT3/4, SOX2, and Nanog, have 
essential roles in early development and are required for the propagation of 
undifferentiated ES cells in culture. In this respect, some studies have provided new 
evidence to support that OCT3/4, Nanog, and SOX2 co-regulate stem cell pluripotency by 
co-occupying a substantial portion of their target genes, including STAT3, HESX1, FGF-2, 
and TCF (Pan and Thomson, 2007, Boyer et al., 2005, Chew et al., 2005, Pan et al., 2006). 
Estrogen-related-receptor beta (Esrrb) has also been found to coordinate with two master 
regulators of the ES cell genetic program, Oct4 and Nanog, by binding to the proximal 5′-
untranslated region of the Oct4 gene (van den Berg et al., 2008, Zhang et al., 2008). 
Kruppel-like factor 4 (KLF4) has been identified as a direct target of STAT3. 
Importantly, regulation of KLF4 by either LIF or Stat3 supports LIF-independent ES cell 
self-renewal (Hall et al., 2009, Niwa et al., 2009). KLF4 can also bind to the promoters 
of Oct3/4 target genes, such as left-right determination factor 1 (Lefty1) which is a 
related members of the TGF-β family of growth factors (Meno et al., 1996), and regulate 
ES cell pluripotency in co-operation with Oct3/4 and Sox2 (Nakatake et al., 2006). 
 
- 40 - 
 
1.2.3. ES cell differentiation  
The potential to differentiate into multiple cell lineages is the main feature of ES cells. ES 
cells can differentiate into any kind of cell under the appropriate culture conditions after 
removal of LIF and/or basic fibroblast growth factor. To date, three major culture 
conditions have been used for in vitro ES cell differentiation: embryoid body (EB) 
formation, which mimics in vivo embryonic development by culturing ES cells in a 
suspension condition for more than 14 days and allowing ES cells to differentiate into 
multiple cell lineages and form a very compact cellular aggregate in floating conditions; a 
feeder cell co-culture method in which feeder cells provide ES cells an intimate cell 
contact and secrete factor(s) that promote ES cell proliferation and differentiation; and an 
extracellular matrix-coated condition that supports the differentiation of ES cells. 
EBs, three-dimensional cell structures formed in suspension culture by ES cells, comprise 
cells from three embryonic germ layers (Thomson, 1998, Doetschman et al., 1985). EB 
formation used a number of approaches, such as bacterial-grade dish, methylcellulose-
coated plate, low-adherent micro-well plate and the hanging drops method.  
The first supporting evidence for a feeder-cell culture approach was reported in 1977. 
Bone marrow-derived adherent cells were able to support the prolonged proliferation and 
differentiation of genetically incompatible stem cells and precursor cells (Dexter et al., 
1977). Adherent growth-arrested but viable and bioactive cells (primary cells or 
immobilized cell lines) have typically been used as feeder layer cells. Specifically, 
Thomson’s paper reported that ES cells attached to a mouse embryonic fibroblast feeder 
layer displayed a continuously undifferentiated status, suggesting that the feeder layer 
cells provided an excellent environment for ES cell proliferation and long-term 
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maintenance in vitro (Thomson, 1998). Moreover, OP9 stromal cells, derived from new-
born bone marrow of the mouse calvaria model, can induce ES cell differentiation 
toward blood cells of the erythroid, myeloid, and B cell lineages (Nakano et al., 1994). In 
addition to OP9 co-cultures, stromal cells from the aorta-gonad-mesonephros (AGM) 
region have also been used to support the haematopoiesis of mouse and human ES cells, 
suggesting that AGM stromal cells are involved in early stem cell development and 
hematopoietic differentiation (Weisel et al., 2006). Such a notion was further supported 
by the finding that co-culturing GM stromal cells with mouse ES cells induces ES cell 
differentiation into Mac-1
+
 myeloid cells and B220
+
 B cells (Lim et al., 2013). 
Found within mammalian tissues, the extracellular matrix (Djarmati et al.) is a complex 
structural entity that surrounds and supports cells (Tien and Nelson, 2014). The ECM 
regulates various cellular processes, including cell differentiation (Adams and Watt, 1993, 
Badylak, 2005), growth, adhesion, proliferation, morphology, and gene expression 
(Kleinman et al., 2003). In recent years, a considerable effort has been put into the 
research to study how ECM components regulate stem cell behaviours; increasing 
evidence suggests that the ECM complex can induce differentiation from ES cells into 
SMCs and endothelial cells (Luo et al., 2013, Xiao et al., 2006, Xiao et al., 2007a). Many 
ECM molecules, the respective receptors, and their functional significance in stem cell 
biology have been characterized by different groups. One of the major challenges in 
ECM research is establishing the specific differentiation conditions appropriate for 
different cell types. Another challenge in ECM research is unravelling the signalling 
pathways through which the ECM regulates cell-lineage–specific gene transcription. 
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1.3. Smooth muscle cell (SMC) differentiation 
1.3.1. Smooth muscle cells  
The accumulation of SMCs in the intima plays a crucial role in the pathogenesis of 
vascular lesions, including atherosclerosis and restenosis (Yoshida and Owens, 2005). 
Therefore, understanding the cellular and molecular mechanisms that underlie VSMC 
differentiation is essential for developing new approaches to the prevention and 
treatment of these diseases. 
VSMCs originate from at least seven different progenitor sources during embryonic 
development: the neural crest, proepicardium, serosal mesothelium, secondary heart field, 
somite, mesoangioblast, and stem/progenitor cells (Majesky, 2007). Importantly, SMCs 
with different embryological origins display a distinct cellular function. Moreover, unlike 
other terminally differentiated somatic cells, SMCs can undergo phenotypic changes in 
vitro and in vivo, switching between secretory and contractile phenotypes, thus obscuring 
our conceptual understanding of terminal differentiation in these cells (Majesky, 2007, 
Yoshida and Owens, 2005). 
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1.3.2. SMC differentiation from stem cells and the mechanisms 
involved 
Accumulating evidence indicates that vascular stem/progenitor cells play a major role in 
various cardiovascular diseases, including atherosclerosis and angioplasty restenosis 
(Adams et al., 2007a). SMC differentiation is a critical process during cardiovascular 
system formation and development, and SMC proliferation is related to cardiovascular 
disease, as in atherosclerosis. Understanding the transcriptional regulatory circuitry of 
SMC differentiation from stem cells is fundamental to understanding human 
cardiovascular system development and realizing the therapeutic potential of these cells 
(Xiao et al., 2010, Kane et al., 2011). To understand the mechanism of SMC 
differentiation from ES cells, researchers have established several in vitro differentiation 
strategies to induce SMC differentiation from stem cells (Xie et al., 2007, Xie et al., 
2011b, Xiao et al., 2007a).  
The first reported method for SMC differentiation used P19 cells, an embryonic 
carcinoma cell line derived from an embryo-derived teratocarcinoma in mice. The P19 
cell line has properties similar to those of normal ES cells, including unlimited self-
renewal ability and pluripotency (Rideg et al., 1994). P19 cells can differentiate into 
fibroblast-like cells that express high levels of smooth muscle actin protein in the 
presence of either 5 × 10
7
 M retinoic acid (RA) for 2 days or 1% DMSO for 4 days 
(Rudnicki et al., 1990). Furthermore, Owens’s group reported that P19 cells treated for 
48 h with 1 × 10
6
 M RA exhibited a profound change in cell morphology and expressed a 
high level of smooth muscle α-actin. Additionally, in the same study, the authors 
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observed that a clonal line derived from RA-treated P19 cells stably expressed multiple 
SMC specific markers, such as SMαA and SM-MHC (Blank et al., 1995). 
To improve the efficiency of SMC differentiation from P19 cells, A404 cells, a P19-
derived clonal cell line with an actin alpha 2 (ACTA2) promoter/intron-driven 
puromycin resistance gene, has been used (Manabe and Owens, 2001). In cells incubated 
with all-trans RA (atRA) for two days and screened for 5 days with puromycin, more 
than 90% of the differentiating A404 cells expressed ACTA2, calponin (CNN1), and/or 
smooth muscle myosin heavy chain (SM-MHC), suggesting that most of the cells were 
SMCs (Manabe and Owens, 2001, Spin et al., 2004).  
Unsurprisingly, a similar method has been successfully applied to SMC differentiation 
from ES cells. Undifferentiated ES cells were induced to differentiate into EBs for 6 days 
and then incubated with 1 × 10
-8
 mol/L atRA and 0.5 × 10
-3
 mol/L dibutyryl-cAMP (db-
cAMP) for 4 days. Data showed that ~67% of the cells within EBs were SMC-like cells, 
compared to 10% in untreated EBs (Drab et al., 1997, Sinha et al., 2004). Via a similar 
strategy, SMCs were also successfully derived from human ES cells. CD34
+
 cells, 
intermediate vascular stem/progenitor cells, were first isolated from differentiating 
human ES cells and then induced to differentiate into SMCs by platelet-derived growth 
factor-BB (PDGF-BB). However, it is noteworthy to mention that apart from the SMC 
genes, the differentiated SMC-like cells also expressed the endothelial markers 
angiopoietin-2 and Tie2, indicating that the SMC differentiation process was 
incomplete (Ferreira et al., 2007, Xie et al., 2007).  
To increase SMC differentiation efficiency and simplify the SMC differentiation protocol, 
our group has established a two-dimensional (2D) in vitro SMC differentiation model 
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from ES cells using type IV collagen as a cellular base membrane (Xiao et al., 2007a). 
Applying this simple but efficient SMC differentiation model, our group has identified 
and isolated an intermediate vascular stem/progenitor cell population, which are positive 
for stem cell antigen-1–positive cells (Sca-1+) from day 3–4 differentiating ES cells. 
Such vascular stem/progenitor cells can be induced to differentiate into both functional 
SMCs (Xiao et al., 2007b) and endothelial cells (Xiao et al., 2006, Zeng et al., 2006) by 
PDGF-BB and VEGF/shear stress, respectively. A highly purified SMC population 
(more than 95% of cells express high levels of various SMC markers) can be derived 
from Sca-1
+ 
cells by culturing them on collagen IV pre-coated flasks with SMC 
differentiation medium for several passages (Xiao et al., 2007b). Interestingly, another 
cell population, VEGFR2+ progenitor cells, has also been identified and isolated from 
the differentiating ES cells using similar methods (Yamashita et al., 2000, Sone et al., 
2003), providing another vascular stem/progenitor cell population with the potential to 
differentiate into SMCs and endothelial cells. 
Importantly, with our SMC differentiation model, our group has uncovered a fairly 
complicated SMC differentiation regulatory network comprising integrin/receptor 
pathways, redox signalling molecules, transcription factors, nuclear/chromatin proteins, 
histone deacetylases (HDACs), and microRNAs. Specifically, Xiao’s group has 
demonstrated for the first time that collagen IV plays a crucial role in the early stage of 
SMC differentiation and that integrin (α1, β1, and αv)-FAK/ paxillin -PI 3-kinase-
mitogen-activated protein kinase and PDGF receptor-beta signalling pathways are 
involved in SMC differentiation (Xiao et al., 2007b). Xiao and his colleagues were the 
first to report that the differentiation of mouse ES cells towards the SMC lineage is 
mediated by Nox4-produced H2O2 (Xiao et al., 2009). The group also showed that 
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PDGF-BB promotes the differentiation of ES cells towards the SMC lineage via the 
upregulation of histone deacetylase 7 (HDAC7) transcription/splicing (Margariti et al., 
2009) and that transcription factor Sp1 is required for PDGF-BB-regulated HDAC7 
activation (Zhang et al., 2010b). Moreover, Xiao’s group was the first to report that 
reactive oxygen species (ROS) balance and transcription factor nuclear factor erythroid 
2-related factor 3 (Nrf3) play a crucial role in SMC differentiation from stem cells (Pepe 
et al., 2010) and that the fine interactions between Nrf3 and another ROS mediator, 
phospholipase A2, group 7 (Pla2g7), are essential for SMC lineage specification from 
stem/progenitor cells in vitro and in vivo (Xiao et al., 2012). Using a nuclear proteomics 
approach, Xiao’s group has further defined important roles for three nuclear/chromatin 
proteins, chromo box protein homolog 3 (Cbx3), heterogeneous nuclear 
ribonucleoprotein A2/B1 (hnRNPA2B1), and hnRNPA1, in SMC differentiation from 
stem/progenitor cells and in chick embryonic arteriogenesis (Wang et al., 2012, Xiao et 
al., 2011, Huang et al., 2013). Xiao’s group has also investigated the functional 
implications of microRNAs in SMC differentiation from stem cells (Yu et al., 2015, 
Zhao et al., 2015), as discussed in detail in the next section.  
Other researchers have identified other signalling molecules and pathways involved in 
VSMC differentiation, proliferation, and development, including Notch, Wnt, 
Akt/FoxO/Myocd, RhoA/ROCK, ERK 1/2, p38MAPKα, and the G protein-mediated 
pathway (Chang et al., 2012, Marinou et al., 2012, Althoff et al., 2012, Zhang et al., 
2012b, Long et al., 2013, Pagiatakis et al., 2012, Yang et al., 2013b). Although these 
studies have significantly increased our understanding of the complicated process of 
SMC differentiation, the full molecular mechanisms underlying SMC differentiation 
from stem cells remain to be elucidated.  
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1.4. MicroRNA 
1.4.1. MiRNA and its biogenesis 
MicroRNAs (miRNAs) are endogenous, highly conserved, short, non-coding, 22-
nucleotide RNAs that constitute a novel class of gene expression regulators with 
important roles in various aspects of development, homeostasis, and disease (Wightman et 
al., 1991, Wightman et al., 1993, Vasudevan et al., 2007, Vasudevan et al., 2008). The 
noncoding miRNAs were initially discovered over 30 years ago in the nematode 
Caenorhabditis elegans as a pair of RNAs derived from the Lin-4 gene that specifically 
bound to a partially complementary target in the 3′-untranslated region (UTR) of Lin-14 
mRNA (Ambros and Horvitz, 1984). Subsequent findings showed that the amount of 
LIN-14 protein was reduced by Lin-4 miRNA without a noticeable change in the level of 
Lin-14 mRNA (Wightman et al., 1991). Since the let-7 miRNA was found, mature 
miRNA are named using the prefix ‘miR’ followed by a unique identifying number (e.g. 
miRNA-34). An additional lower case letter is added after the number if the same miRNA 
precursor gives rise to miRNAs with different nucleotide sequences (e.g. miRNA-34a, 
miRNA-34b, and miRNA-34c). Perron’s and Provost’s group has suggested that up to 90% 
of human genes are regulated by miRNAs (Perron and Provost, 2008). As of July 2014, 
approximately 35,828 mature miRNAs from 223 species (including 2588 miRNAs from 
Homo sapiens and 1915 from Mus muscles) had been reported and included in ‘miRBase: 
the microRNA database’ (http://www.mirbase.org/), which includes published 
microRNA sequences with associated annotations and provides a gene naming and 
nomenclature function in the miRBase Registry. Growing evidence suggests that miRNAs 
are involved in critical developmental and cellular processes, including cell cycle, cell 
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survival, apoptosis, migration, and differentiation (Zhao and Srivastava, 2007, Fazi and 
Nervi, 2008).  
As shown in Figure 2, the primary miRNA (pri-miRNA), which has a stem-loop 
structure containing the mature miRNA sequence, is first transcribed in the nucleus from 
the miRNA gene by ribonuclease III (RNase III) (Winter et al., 2009). The Drosha and 
DGCR8/Pasha complex, also called the microprocessor complex, cleaves the stem-loop of 
the pri-miRNA and generates the miRNA precursor (pre-miRNA), a small hairpin-shaped 
RNA of approximately 65 nucleotides. Thereafter, the pre-miRNA is exported to the 
cytoplasm in a Ran-GTP/Exportin-5-dependent mechanism (Figure 2) (Winter et al., 
2009). In the cytoplasm, the pre-miRNA is processed by another RNase III enzyme, Dicer, 
an endonuclease of ~200 kDa specific for dsRNAs that plays an important role in 
controlling development and metabolism. Dicer cleaves the stem-loop structure and 
generates the mature microRNA (about 20–22 nucleotides) as part of a short RNA duplex 
(Fu et al., 2015b). Like Drosha, Dicer associates with an RNA-binding protein, the 
double-stranded RNA-binding domain protein called Tar RNA binding protein (TRBP) 
in humans, to stabilize and enhance the cleavage of the pre-miRNA (Chendrimada et al., 
2005). Yuanshuai et al. reported that Dicer plays diverse roles in development and 
metabolism in various tissues and that Dicer expression is higher in the brain than in 
other tissues examined (Fu et al., 2015a, Bernstein et al., 2001, Hammond, 2015). 
The double-stranded miRNA duplex is separated into two strands by a helicases complex 
[e.g. p68, p72, RNA helicase A (RHA), RCK/p54, TNRC6B, Gemin3/4, and human 
Mov10 or its D. melanogaster orthologue Armitage] (Winter et al., 2009). The functional 
strand of the mature miRNA is loaded together with Argonaute (Ago2) proteins into the 
RNA-induced silencing complex (RISC), where it guides RISC to silence target mRNAs 
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through mRNA cleavage, translational repression, or deadenylation. The passenger strand 
(star strand) is degraded (Winter et al., 2009). Normally, the functional strand of the 
mature miRNA is fully incorporated with active RISC and participates in gene regulation. 
However, studies suggest that the star strand can also be loaded into RISC to regulate 
target gene expression (Ghildiyal et al., 2010, Okamura et al., 2009). Although multiple 
studies have been conducted, the exact mechanism by which the miRNA strand is 
selected from the double stranded duplex is still not clear. 
Traditionally, mature miRNAs have been thought to suppress gene expression by 
inducing mRNA cleavage (Yekta et al., 2004) or mRNA decay (Giraldez et al., 2006, Wu 
et al., 2006) or by inhibiting mRNA translation (Filipowicz et al., 2008) by 
targeting/binding a specific RNA sequence within the 3′-UTR. However, recent evidence 
suggests that miRNAs can also target the 5′-UTR or coding region of their target genes 
(Tay et al., 2008). Moreover, in some cases, miRNAs can upregulate gene expression 
(Vasudevan et al., 2007). 
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Figure 2 MiRNA biogenesis pathway. 
The general miRNA biogenesis pathway begins with primary miRNA (pri-miRNA) 
transcription by RNA polymerase II. The pri-miRNA is converted to pre-miRNA by the 
Drosha and DGCR8 complex. After export from nucleus, the stem-loop structure of the 
pre-miRNA is cleaved by Dicer and its partners TRBP/PACT complex to form the 
double-stranded miRNA duplex (Winter et al., 2009).  
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1.4.2. MiRNAs and their targets 
Defining miRNA target genes is a critical step in all miRNA studies because it is key to 
understanding the biological role of the miRNA. Moreover, validated targets provide the 
best biomarker(s) for determining the efficacy of an miRNA mimic or inhibitor in clinical 
miRNA therapeutics. Several general approaches were used in this PhD project to predict 
and identify miRNA targets: bioinformatics target prediction, miRNA/mRNA interactions, 
and the influence of miRNA on a target protein translation (Thomson et al., 2011, Kuhn et 
al., 2008). 
Using bioinformatics tools for predicting target genes of miRNAs is a relatively 
straightforward and commonly used approach through pairing the miRNAs with target 
mRNAs using standard Watson-Crick rules. Generally, the most important determinant 
for target gene binding is the seed sequence of the miRNA, which is normally the first 6-8 
nucleotides at 5-terminus of miRNAs. This will lead to a great number of candidate 
targets being predicted, many of which are false positives. Therefore, all bioinformatics 
target prediction algorithms also use additional factors to improve accuracy of target gene 
prediction (Hammond, 2015, Ekimler and Sahin, 2014). The most popular target 
prediction algorithms in miRNA research are TargetScan, miRanda and PicTar (Kuhn et 
al., 2008). 
Gene-specific experimental validation of miRNAs is a series of methods commonly used 
to verify individual miRNA/mRNA interactions using the well-established techniques of 
qRT-PCR, luciferase reporter assays, and western blot (Thomson et al., 2011). Generally, 
the upregulation/downregulation of target genes by a given miRNA is observed at the 
protein or mRNA level using western blot or qRT-PCR, respectively. Luciferase reporter 
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assays have been employed extensively to demonstrate a direct link whereby expression 
of a 3′-UTR luciferase reporter is altered through manipulation of a regulatory miRNA. 
MiRNA binding site mutation is also applied to provide direct evidence that the miRNA 
binding site(s) are required for target gene regulation by miRNAs. The reporter assay is 
a rapid and reproducible assay that quickly eliminates any predicted miRNA binding 
site that is not functional. In contrast, the disadvantages of reporter assays are that 
they are labour intensive, dependent on the region selected for cloning, and sensitive 
to variations in protocol (Lytle et al., 2007, Kong et al., 2008, Hendrickson et al., 
2009). 
Several new technologies and methods have also been used to study potential miRNA 
targets, including biochemical isolation of miRNA/mRNA complexes and proteomic 
analysis (Hammond, 2015). Biochemical target identification is a method used to isolate 
and identify the mRNA targets of miRNAs through the association of miRNA/RISC 
complexes. RISC is immunoprecipitated using anti-Argonaute antibodies, with or 
without prior RNA crosslinking, and bound target RNAs are identified through 
microarray analysis or next-generation sequencing. Quantitative proteomic analysis is 
used to directly detect the effect of a miRNA on target protein production; it is possibly 
more reflective of the true target set, but is also technically challenging (Ekimler and 
Sahin, 2014).  
As mentioned earlier, miRNAs mainly target homologous sites in 3′-UTR to suppress 
target gene translation and/or degrade target mRNA through a mechanism known as RNA 
interference (Liu et al., 2012). However, evidence also indicates that miRNAs can 
positively regulate gene expression. In 2007, Vasudevan et al. were the first to report 
that miRNAs directly associate with Argonaute (AGO) and fragile X mental 
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retardation-related protein 1 (FXR1) and interact with AU-rich elements (AREs) 
within the 3′-UTR of target genes to activate target gene translation in HEK293 cells. 
Importantly, miR-369-3 regulated translational activity only under cell cycle arrest 
conditions, while traditional translational repression was observed when the cells 
were switched back to the proliferative state (Vasudevan et al., 2007).  
 
1.4.3. MiRNAs, SMC differentiation, and cardiovascular 
development 
Tuschl’s group first reported that many miRNAs are expressed in a tissue-specific manner, 
suggesting that certain miRNAs are important for cell/tissue specification (Landgraf et al., 
2007). The contribution of miRNAs to ES cell differentiation was confirmed in later 
studies using ES cells deficient in Dicer and Drosha, the two enzymes important for 
miRNA biogenesis. Murchison and colleagues reported that Dicer-deficient mice died at 
embryonic day 7.5 with an undetectable level of multipotent stem cells, decreased 
expression of mature microRNAs, and a defect in gene silencing (Murchison et al., 2005). 
Importantly, the authors observed that Dicer deficiency compromised the proliferation of 
ES cells, suggestion that miRNAs affect ES cell proliferation (Murchison et al., 2005). 
Other studies using Dicer- or Drosha-deficient ES cells also suggest that miRNAs play a 
role in ES cell self-renewal and differentiation (Wang et al., 2007, Oberdoerffer et al., 
2005). Accordingly, deletion of Dicer in SMCs results in widespread loss of miRNA 
expression in SMCs and contractile function in resistance arteries (Albinsson et al., 2011). 
In another study, disruption of Drosha in VSMCs of mice not only led to the 
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dysregulation of miRNA expression, but also resulted in embryonic lethality and a 
reduction in cell proliferation (Fan et al., 2013), suggesting a functional role of miRNAs 
in VSMC functions and development. An essential role of miRNAs in cardiovascular 
development was also demonstrated in a study of Dicer-deficient mice; the loss of 
miRNAs severely impaired heart and blood vessel development (Yang et al., 2005). 
Furthermore, it has been shown that deletion of Dicer in vascular smooth muscle caused 
late embryonic lethality at embryonic day 16 to 17 owing to decreased SMC proliferation 
and differentiation, which resulted in thinner vessel walls, impaired contractility, and 
haemorrhage (Albinsson et al., 2010). Taken together, these findings clearly suggest that 
miRNAs play an important role in SMC function and cardiovascular development.  
A detailed understanding of the involvement of any given miRNA in SMC function and 
cardiovascular development remains to be established through the study of the functional 
importance of individual miRNAs in these processes. In this regard, growing evidence 
suggests that several miRNAs (e.g. miR-1, miR-10a, miR-34a, miR-133, miR-638, miR-
143, miR-145, miR-206, miR-221, miR-222, and miR-223) are involved in SMC 
proliferation, phenotype switching, differentiation, actin remodelling, and migration in 
vitro or in vivo. Specifically, it is well established that miR-221 and miR-222 levels, 
assessed via microarray analysis, are upregulated in vascular walls with neointimal lesion 
formation (Ji et al., 2007). Davis and colleagues showed that miRNA-221 modulates 
VSMC proliferation and phenotype switching in response to PDGF signalling, leading to 
downregulation of targets, a tyrosine kinase receptor for the peptide growth factor (c-Kit) 
and a tumour suppressor (p27Kip1) (Davis et al., 2009). In addition, miRNA-222 was also 
found to be involved in VSMC proliferation and neointimal hyperplasia by targeting p27 
(Kip1) and p57 (Kip2) (Liu et al., 2009). Moreover, Chen’s group uncovered at first time 
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that miRNA-10 regulates SMC differentiation from ES cells by targeting histone 
deacetylase 4 (HDAC4). The authors identified NF-kappaB (NF-κB) signalling as a 
requirement for miR-10 activation by RA during SMC differentiation (Huang et al., 2010). 
The study, published by Davis and colleagues, demonstrated that TGF-β promotes VSMC 
differentiation by increasing the expression of miRNA-21 and miRNA-199a, that TGF-β 
modulates miRNA-21 by promoting the processing of pri-miRNA-21 into pre-miRNA-21 
by the Drosha complex, and that programmed cell death 4 (PDCD4) is the target gene of 
miRNA-21 during VSMC differentiation (Davis et al., 2008). Moreover, clear  evidence 
suggests that the mouse miR-143/145 cluster is involved in neointimal lesions and the 
contractile phenotype of VSMCs in vivo (Boettger et al., 2009) and that miRNA-145 
modulates VSMC differentiation and proliferation, alone or in combination with miRNA-
143 in vitro (Rangrez et al., 2011, Cheng et al., 2009, Cordes et al., 2009). Additionally, 
Yamaguchi et al. showed that miRNA-145 regulates the differentiation and proliferation 
of SMCs derived from human ES cells by directly targeting Kruppel-like factor 4 and 5 
(KLF4 and 5) (Yamaguchi et al., 2011). Studies from other groups have also 
demonstrated that miRNA-143/145 acts as an integral component of the regulatory 
network controlling SMC cytoskeletal remodelling and phenotypic switching during 
vascular disease (Rangrez et al., 2011). Furthermore, miRNA-143/145 is implicated in 
impaired VSMC differentiation in an animal model (Norata et al., 2012).  
Results presented by Torella et al. showed that miR-133 is a key regulator of vascular 
smooth muscle cell phenotypic switching in both in vitro and in vivo, suggesting a 
potential therapeutic application for vascular diseases (Torella et al., 2011). Using a highly 
efficient in vitro model of retinoid acid (RA)-induced ESC/SMC differentiation, Chen’s 
group showed that miRNA-1 promotes SMC differentiation from ES cells through the 
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inhibition of KLF4 (Xie et al., 2011a). In 2012, Metzinger’s group reported that 
overexpression of miRNA-223 increased VSMC proliferation and markedly enhanced 
VSMC migration. As a complement to the in vitro findings, the authors also observed 
vascular calcification in ApoE knockout mice, with significant downregulation of miR-
143 and miR-145 and upregulation of miR-223 in samples (Rangrez et al., 2012). The 
results suggest that altered expression of miR-223 plays a part in VSMC migration and 
calcification in in vivo and in vitro.  
Recently, a role for miRNA-206 as a regulator of pulmonary arterial SMC proliferation, 
apoptosis, and differentiation was suggested (Jalali et al., 2012). Most recently, miR-34a 
was identified by our group as another important miRNA involved in SMC differentiation 
from stem cells in vivo and in vitro. Importantly, we provided compelling evidence to 
demonstrate that miR-34a mediates SMC differentiation by upregulating its target gene 
SirT1, and that SirT1 is a transcriptional activator of SMC differentiation genes (Yu et al., 
2015). 
Despite enormous efforts, the significance and exact role of other individual miRNAs in 
SMC differentiation and cardiovascular system development are incompletely understood. 
Further investigation is required.  
 
1.4.4. MiRNA-22 and its regulatory roles  
1.4.4.1. Role in cell cycle regulation and cancers 
MiRNA-22 is a highly evolutionarily conserved microRNA expressed in various primary 
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tissues and cell lines (Landgraf et al., 2007). MYC, the human homologue of a retroviral 
oncogene, has a well-established role in regulating cell cycle progression and cell 
survival (Meyer and Penn, 2008). MiRNA-22 has been suggested to function as a tumour 
suppressor by modulating cell cycle arrest through 1) the direct repression of MYC 
binding protein (MYCBP) expression and subsequent reduction of oncogenic c-Myc 
activity (Xiong et al., 2010); 2) the direct suppression of EVI-1 oncogene expression 
(Patel et al., 2010); and 3) the direct reduction of estrogen receptor alpha (ERα) level 
(Pandey and Picard, 2009).  
Moreover, miRNA-22 potently inhibits cancer cell proliferation and growth by targeting 
the c-Myc binding partner Max. MiRNA-22 causes cell cycle arrest in the G1 phase and 
reduces the amount of Max available for c-Myc binding, thereby altering the 
transcriptional output of the Myc-Max complex (Ting et al., 2010). Furthermore, 
miRNA-22 negatively regulates cell proliferation and increases cell cycle length in 
cerebellar granular neuronal precursors by reducing Max protein level and N-Myc/Max-
dependent promoter activity (Berenguer et al., 2013). Guo et al. have suggested that 
miRNA-22 acts as tumour suppressor by targeting a specific target site within the 3′-
UTR of the Sp1 gene and inhibiting gastric cancer cell migration and invasion (Guo et al., 
2013). MiRNA-22 was also found to suppress gastric cancer cell growth, proliferation, 
and invasion, in part by inhibiting cluster of differentiation 151 (CD151) (Wang et al., 
2014). Concomitantly, miR-22 associated with miR-200C can target the proto-oncogene 
protein Wnt-1 to inhibit gastric cancer growth, suggesting miRNA-200C and miRNA-22 
as potential gene therapy targets for gastric cancer (Tang et al., 2013). Additionally, 
another study reported that knockdown of miRNA-22 was significantly associated with 
the malignant development of gastric cancer and that this microRNA functioned as an 
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independent prognostic factor for patients, hinting that miRNA-22 might have 
therapeutic potential for patients with gastric cancer (Wang et al., 2013).  
Phosphatase and tensin homolog (PTEN), another well-known tumour suppressor that 
modulates cell cycle progression and cell survival in many cell types, is repressed by 
miRNA-22, which directly targets its 3′-UTR, resulting in hyperactivation of AKT and 
transformation of bronchial epithelial cells (Poliseno et al., 2010, Bar and Dikstein, 
2010). Notably, miRNA-22 itself can be upregulated by AKT, suggesting that miRNA-
22 forms a feed-forward circuit with AKT in its regulation. 
MiRNA-22 has also been implicated in a number of diseases, such as lung cancer and 
colorectal cancer (Ling et al., 2012, Zhang et al., 2012a, Xu et al., 2011). Moreover, 
miRNA-22 has been suggested to represent a novel predictive biomarker for pemetrexed-
based treatment of non-small cell lung cancer (Franchina et al., 2014).   
 
1.4.4.2. Other functions 
In addition to decreasing cell motility and inhibiting cell invasion in vitro, miRNA-22 
also restores the cellular senescence program in cancer cells and acts as a tumour 
suppressor by directly targeting three genes involved in the senescence programme, 
CDK6, SIRT1, and Sp1 (Xu et al., 2011). A recent study found that miRNA-22 
modulated the survival and longevity of dendritic cells through the YWHAZ signalling 
pathway (Min et al., 2013)). Furthermore, miRNA-22 has also been described as a 
regulator of cardiac protection. In one study, exosomes enriched with miR-22 and 
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secreted from mesenchymal stem cells played a protective role in cardiomyocytes after 
myocardial infarction (Feng et al., 2014). Finally, a study reported in 2013 suggests that 
miR-22 plays a role in cardiac ageing, cardiomyocyte hypertrophy, or cardiac 
decompensation by regulating the target gene mimecan (osteoglycin, OGN) (Jazbutyte et 
al., 2013).  
 
1.5. Methyl CpG binding protein 2 (MECP2) 
1.5.1. Gene regulation by MECP2  
DNA methylation is a major determinant in the epigenetic silencing of genes. Post-
translational modification of core histones serves to lay down epigenetic states at the level 
of the genetic blueprint (DNA), whereas nucleosome positioning and non-coding RNAs 
(ncRNAs) facilitate the formation of epigenetic states (Du et al., 2015). MECP2 is the 
founding member of a family of methyl CpG-binding proteins that contain a methyl-CpG-
binding domain (MBD). The main reported function of these proteins is to silence gene 
expression by preventing the binding of activating transcription factors or by recruiting 
enzymes that catalyse histone post-translational modifications into chromatin-remodelling 
complexes that in turn alter the structure of chromatin and actively promote transcriptional 
repression (Miranda and Jones, 2007, Cohen et al., 2008). However, studies suggest that 
that MeCP2 plays a complex role, coordinating either transcriptional repression or 
activation, depending on the molecular context (Figure 3) (Cohen et al., 2008, Chahrour 
et al., 2008).  
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Figure 3 Gene activation or repression by MECP2 
MECP2 can function as an activator or a repressor to regulate the expression of various 
genes. The functions of MECP2 are dependent on the DNA methylation status of the 
relevant genomic region (Cohen et al., 2008, Chahrour et al., 2008). 
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1.5.2. MECP2 and human diseases 
Genetic mutations of MECP2 have been found in a numerous human diseases. One well-
documented disease is Rett syndrome (Coughlan et al.), an X-linked disorder that affects 
the development of the brain. It can cause severe physical and mental disability in children 
and lead to severe mental retardation in females (Pohodich and Zoghbi, 2015). Mutations 
in the X-linked gene encoding MECP2 are the primary genetic causes of RTT. New 
evidence from animal studies suggests that, apart from genetic mutations, various post-
translational modifications, such as phosphorylation, regulate the function of MECP2 in 
learning and memory, drug addiction, depression-like behaviour, and the response to anti-
depressant treatment (Yang and Pan, 2014, Zimmermann et al., 2015). Genetic evidence 
to support the causal role of MECP2 in RTT comes from the MECP2+/- mouse model. 
Johnson and colleagues found that ~20% of female MECP2+/- mice exhibited RTT-like 
breathing abnormalities that began as early as 3 weeks of age. Interestingly, breathing 
abnormalities were also present in male mice with the MECP2 gene deletion (Johnson et 
al., 2015).  
Moreover, accumulating evidence indicates that MECP2 is also involved in other 
diseases. A recent study showed that MECP2 regulates lipid metabolism reprogramming 
via repression of the key gene peroxisome proliferator-activated receptor gamma 
(Tsukamoto, 2015). X-ray-induced inhibition of lung cancer cells is mediated by 
enhanced expression of the Axin gene via genomic DNA demethylation and histone 
acetylation. Mechanically, it has been shown that MECP2 represses histone deacetylase, 
leading to transcriptional activation of the Axin gene via histone acetylation, thus 
suggesting a role for MECP2 in cancer prevention (Yang et al., 2013a, Esteller, 2005). 
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MECP2 has also been reported to interact with lens epithelium-derived growth factor p75 
(LEDGF/p75), a transcriptional co-activator and binding partner of human 
immunodeficiency virus (HIV) integrase (Aqil et al., 2015). MECP2 expression is highly 
upregulated in human monocytic cells expressing HIV-1 Nef protein during the early 
phase of the viral replication cycle, suggesting that MECP2 indirectly activates HIV 
integrase via its interaction with LEDGF/p75 (Aqil et al., 2015). MECP2 has also been 
implicated in Parkinson's disease (Xie et al., 2013) and autonomic cardiovascular control 
(Bissonnette et al., 2007). Additionally, MECP2 was identified as a reversibly repressed 
gene in mouse hearts in response to transverse aortic constriction (TAC); its expression 
normalized after removal of the constriction. Data from patients in the same study 
showed that MECP2 mRNA was significantly repressed in failing human hearts; its 
expression normalized after unloading by a ventricular assist device (LVAD) (Mayer et 
al., 2015), confirming an important role of MECP2 in heart disease. 
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1.6 Hypothesis, Project Aims, and Objectives 
Hypothesis:  
As discussed above, a growing number of studies suggest that miRNA-22 is a critical 
regulator of cell cycle progression and/or arrest. Given that cell cycle arrest or exit from 
cell cycle progression is a critical process during cell differentiation (Kim et al., 2006, 
Cardinali et al., 2009), miRNA-22 could be a major regulator of cell differentiation from 
stem cells. Importantly, Ruohola-Baker’s group has shown that miRNA-22 is upregulated 
during human ES cell differentiation, implying a role for miRNA-22 in stem cell 
differentiation (Stadler et al., 2010). Furthermore, our previous study showed that miR-22 
is one of the top upregulated miRNAs in our SMC differentiation model (Yu et al., 2015). 
Therefore, we hypothesized that miR-22 and its target gene(s) play a part in SMC 
differentiation from stem cells.  
Aims: 
This PhD project investigated the functional involvement of miRNA-22 and its potential 
target gene(s) in SMC differentiation from ES cells in vivo and in vitro and the molecular 
mechanisms involved. 
Objectives: 
1) Use real-time qPCR to confirm previous results obtained from miRNA microarray 
analyses showing that miR-22 is upregulated during SMC differentiation from stem cells.  
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2) Use our group’s well-established in vitro SMC differentiation model to study the 
functional importance of miRNA-22 in ES cell differentiation towards SMCs.  
3) Determine if miR-22 plays a similar role in SMC differentiation in vivo by generating 
miR-22-overexpressing and control ES cell lines and using a Matrigel implant model. 
4) Confirm the functional importance of miR-22 in SMC differentiation from adult blood 
vessel stem/progenitor cells. 
5) Identify and validate the target gene(s) of miR-22 in SMC differentiation. 
6) Elucidate the underlying molecular mechanisms by which miR-22 and its target gene(s) 
regulate genes involved in SMC differentiation. 
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Chapter 2 
2. Materials and Methods 
2.1. Materials 
Name Company 
Antibodies against MECP2 (Goat, N-17, sc-
5755) 
Santa Cruz Biotech, USA 
Antibodies against SRF (Rabbit, G-20, sc-
335) 
Santa Cruz Biotech, USA 
Antibody against Smooth Muscle Myosin 
Heavy Chain (SM-MHC) (Rabbit, AHP1117) 
AbD Serotec 
Antibodies against calponin (Rabbit, 
Ab46794) 
Abcam, UK 
Antibodies against MECP2 (Rabbit, ab2828, 
CHIP grade) 
Abcam, UK 
Antibodies against SM22α (Rabbit, 
Ab14106) 
Abcam, UK 
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Monoclonal anti-α smooth muscle actin 
(SMαA) (Clone 1A4, A5228) 
Sigma 
Antibodies against GFP (G6539) Sigma 
Antibody against H3K9me3 (Mouse, 05-
1250) 
Millipore 
Anti-rabbit IgG (whole molecular)-
Peroxidase antibody produced in goat 
(A9169) 
Sigma 
Antibodies against α-tubulin (mouse) Sigma 
Anti-trimethyl Histone H3(Lys9) (CMA308) Millipore 
Majority secondary antibodies 
Sigma, and 
Santa Cruz Biotech, USA 
Majority enzymes and buffers for gene clone 
and mutation 
Promega, New England Biolabs
®
 Ins. And 
Invitrogen 
Table 1 Antibodies, enzymes, and buffers used for gene research  
Other materials used in this study were purchased from Sigma unless specifically indicated.  
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2.2. ES Cell Culture  
2.2.1. Medium preparation 
2.2.1.1. ES cell basic medium (BM) 
ES cell basic medium (BM), the main medium used for ES cell culture, consisted of 
KnockOut™ D-MEM (Gibco/Invitrogen), 100 U/ml penicillin, and 100 µg/ml 
streptomycin. BM was typically stored at 4°C in a refrigerator. 
 
2.2.1.2. ES cell complete culture medium (CM) 
ES cell complete culture medium (CM) was prepared in small amounts (usually 50 ml) 
and placed at 4°C in a refrigerator for short-term storage. ES cell complete CM contained 
90% BM, 10% foetal bovine serum (FBS) for stem cells (Invitrogen), 1% 100× MEM 
Non-Essential Amino Acids Solution (MEM-NEAA; Invitrogen), 0.1% recombinant 
human leukaemia inhibitory factor (LIF, 10 µg/ml; ProSpec), and 0.01% 1 M 2-
mercaptoethanol (Sigma-Aldrich).  
 
2.2.2. Mouse ES cell maintenance 
Detailed protocols for mouse ES cell (ES-D3 cell line, CRL-1934; ATCC, Manassas, 
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USA) culture and SMC differentiation have been described in our previous reports 
(Huang et al., 2013, Xiao et al., 2012, Wang et al., 2012, Xiao et al., 2011, Zhang et al., 
2010b, Pepe et al., 2010, Margariti et al., 2009, Xiao et al., 2009, Xiao et al., 2007a). 
Briefly, mouse ES cells were usually cultured in T25 flask with 5 ml ES cell complete 
CM and maintained in an incubator at 37°C with 5% CO2. The growth status and 
morphology of the ES cells were checked daily. Once cell confluence (coverage) reached 
~80% (normally every 2–3 days), ES cells were sub-cultured at a ratio of 1:6 to 1:10 as 
described below. 
 
2.2.3. Mouse ES cell passaging/sub-culturing 
Before ES cell passaging/sub-culturing, a new T25 flask was coated with pre-warmed 
0.04% gelatin (Sigma-Aldrich) in PBS and incubated at 37°C for at least 30 min. After 
removal of the old CM, ES cells were washed once with pre-warmed 1× PBS and then 
rinsed with 2 ml trypsin-EDTA for 10 s. Excess trypsin-EDTA (1.8 ml) was removed 
from the ES cells, and the cells were incubated in the incubator for less than 2 min. Pre-
warmed CM was then added to the flask to neutralize the reaction, and the ES cells were 
dissociated into a single-cell suspension by pipetting several times. To achieve a typical 
ES cell passage ratio of 1:4 to 1:10, a suitable amount of ES cell suspension was added to 
the pre-coated T25 flask. Additional fresh ES cell CM (up to 5 ml) was added to the T25 
flask, and the cells were cultured at 37°C in a 5% CO2 incubator for 2–3 days. 
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2.2.4. Mouse ES cell freezing and defrosting 
Mouse ES cells were frozen in freezing medium (FM), which consisted of 50% DMEM 
(Sigma-Aldrich), 40% FBS, and 10% dimethyl sulphoxide (DMSO; Sigma-Aldrich). The 
ES cells were washed with 1× PBS once after removal of the culture medium from the 
flask and then treated with trypsin-EDTA (Sigma-Aldrich) for about 1 min in a 37°C 
incubator. BM containing 10% FBS was then quickly added to the flasks to neutralize the 
reaction. The cell suspension was transferred into a new 15 ml tube and spun at 1,200 × g 
for 3 min. The supernatant was discarded, and the ES cells were re-suspended in 4 ml of 
FM. The ES cell suspension was split into several cryovials at a ratio of 1:4. The vials 
were placed into a freezing container (Mr Frosty) and stored in a -80°C freezer overnight. 
All cryovials were transferred to a liquid nitrogen vessel the day after for long-term 
storage. 
For ES cell defrosting/recovery, the cryovial containing the cells was warmed in a 37°C 
water bath until the cells were defrosted completely. The thawed cells were transferred 
into a 15-ml conical centrifuge tube, and 4 ml DMEM was added to the tube. Cells were 
spun at 1,200 × g for 3 min and re-suspended in 5 ml fresh ES cell CM. Cells were 
transferred to a T25 culture flask pre-coated with 0.04% gelatin and cultured in the 
incubator at 37°C with 5% CO2 until passaging. The ES cells were usable when the 
growth rate became normal.  
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2.3. Smooth muscle cell in vitro differentiation from ES 
cells 
2.3.1. SMC differentiation medium (DM) 
The MEM, alpha modification (α-MEM) was the basal medium used to prepare the SMC 
differentiation medium (DM). In brief, 1 vial of Minimum Essential Medium Eagle 
(M0644, Sigma) and 2.2 mg NaHCO3 were dissolved with 1 litre warmed, autoclaved 
ddH2O. The mixture was then filtered with a Nalgene® Disposable Bottle Top Filter (500 
ml; Thermo Scientific) into a new autoclaved bottle. The fresh α-MEM was stored at 4°C 
in a refrigerator for later use. 
Fresh SMC differentiation medium, known as DM, composed of α-MEM, 10% FBS 
(Invitrogen), 0.05 mM 2-mecraptoethanol, 100 U/ml penicillin, and 100 µg/ml 
streptomycin, was stored at 4°C in a refrigerator for up to 2 weeks. 
 
2.3.2. SMC differentiation from ES cell 
Detailed protocols for SMC differentiation from ES cells have been described in our 
previous reports (Huang et al., 2013, Xiao et al., 2012, Wang et al., 2012, Xiao et al., 
2011, Zhang et al., 2010b, Pepe et al., 2010, Margariti et al., 2009, Xiao et al., 2009, Xiao 
et al., 2007a). Briefly, before cell seeding, cell culture flasks or plates were coated with 5 
μg/ml collagen I/IV in cold PBS for more than 2 h at room temperature in a clean hood. 
- 71 - 
 
Undifferentiated ES cells were washed once with pre-warmed 1× PBS and trypsinized into 
single cells with 0.05% trypsin-EDTA. Cells were counted and seeded onto pre-coated 
flasks or plates at the optimal cell density and cultured in warm DM in an incubator at 37°C 
with 5% CO2 for the indicated times. DM was refreshed every other day from day 2. 
 
 2.4. SMC differentiation from vascular stem/progenitor 
cells 
Detailed protocols for mouse adventitia stem cell antigen 1-positive (AdSca-1+) cell 
isolation and culture have been described in our previous reports (Hu et al., 2004, Xiao et 
al., 2012). Briefly, thoracic arteries were harvested, and the periadventitial fat was carefully 
removed. The arteries were then washed with PBS and digested for 10–15 min in a 
digestion solution containing 1 mg/ml collagenase (Sigma, C0130-1G). The adventitia 
layer was carefully peeled away from the media layer under a stereomicroscope and cut 
into small pieces. The second digestion was applied to the small adventitia pieces in a 
mixed solution with 3 mg/ml of collagenase and 500 µg/ml elastase. Next, the digested cell 
suspension was placed onto a shaker at 37°C for 2–2.5 h, with vortexing every 20–30 min. 
The suspension was then collected and filtered through a 70-µm BD Falcon® cell strainer 
to obtain single cells. Fresh cells isolated from 8–10 mice were combined and sorted using 
the Anti-Sca-1 MicroBead Kit (MACS Miltenyi Biotec). Isolated AdSca-1+ cells were 
induced to SMCs in the SMC differentiation medium (DMEM, 10% FBS, 0.05 mM 2-
mercaptoethanol, 100 U/ml penicillin, 100 µg/ml streptomycin, and 5 ng/ml TGF-β) for 2 
to 6 days before further treatment. The medium was refreshed every other day. 
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2.5. Transfection 
2.5.1. Plasmid transfection 
To determine the optimal transfection efficiency, plasmids and related controls were 
transfected into cells using two transfection reagents, FuGENE-6 (Roche) or TurboFect 
transfection agent (Thermo), according to the manufacturers’ instructions. As 
suggested, the optimal confluence for adherent cells was 70–90% at the time of 
transfection. Fresh α-MEM containing 5% FBS was added to the culture flasks or 
plates to replace the old culture medium 1 h before the transfection. The plasmids 
and respective controls were first diluted in serum-free DMEM or other serum-free 
growth medium such as Opti-MEM. The appropriate volume of transfection reagent 
was added to the diluted DNA mixture and mixed immediately by pipetting. The best 
ratio of transfection agent to DNA was 3:1 for FuGENE-6 and 2:1 for TurboFect. 
After incubation for 15–20 min at room temperature, the complex was pipetted 
several times and added to the cell culture in a drop-wise manner. The plate was 
shaken gently to distribute the transfection complexes evenly before placing the plate 
in the incubator. After incubation for 5 to 8 h, the same volume of cell culture 
medium (α-MEM) with 15% FBS was added to restore the level of FBS to 10%, and 
the cells were incubated at 37°C in an incubator with 5% CO2 overnight. The next 
day, the old medium was replaced with fresh normal differentiation medium (DM), 
and the cells were harvested at the indicated times. 
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2.5.2. Transfection of miRNA precursors or inhibitors 
MicroRNA reverse transfection, which involves simultaneously transfecting and plating 
cells, is similar to the procedure used for suspension cell transfection. It was performed 
according to the protocol provided by the manufacture. In brief, ES cells were first 
trypsinized into a single-cell suspension using 0.05% trypsin-EDTA. After counting the cell 
number with a haemocytometer chamber (Hauser Scientific), normal growth medium (DM) 
was used to dilute the cells to the appropriate concentration. The diluted cells were placed in 
an incubator at 37°C with 5% CO2. As the first step of reverse transfection, siPORT™ 
NeoFX™ Transfection Agent (Invitrogen) was diluted in OPTI-MEM® I Reduced Serum 
Medium 1× (Gibco) and incubated for 10 min in the clean hood at room temperature. 
MicroRNA mimics or inhibitors were diluted into the appropriate volume of OPTI-MEM®
 
I medium and mixed with an equal volume of pre-diluted siPORT™ NeoFX™ 
Transfection Agent mixture. After incubating the mixture at room temperature for another 
10 min, the transfection reagent/microRNA complex was dispensed onto a culture plate. 
Finally, the cell suspension was overlaid onto the transfection complexes, and the plate was 
gently tilted back and forth to distribute the complexes and cells evenly. According to our 
preliminary data, the optimised final concentration for Anti-miR™ miRNA Inhibitor and 
Pre-miR™ miRNA Precursor was 30 nM. After overnight incubation, transfected cells 
were refreshed with fresh DM and incubated at 37°C under normal cell culture conditions 
until ready to assay. 
2.5.3. MiR-22 and MECP2 co-overexpression  
The pre-generated miR-22 overexpression ES cells (pLL3.7-GFP-miR-22) or control ES 
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cells (pLL3.7-GFP) were seeded on culture flasks or plates coated with 5ug/ml collagen 
I/IV to induce to SMCs in fresh DM for 2-3 days prior to transfection. After washed with 
warm 1×PBS, miR-22 overexpression ES cells or control ES cells was transfected with 
MECP2 overexpression plasmid (pCMV5-MECP2) or control plasmid, respectively, by 
using TurboFect Transfection Reagent (Thermo Fisher Scientific Inc.). The flaks or plates 
were gently tilted back and forth to evenly distribute transfection complex and cells, and 
incubated in 37°C and 5% CO2 overnight. The culture medium was replaced with fresh 
DM every other day prior to cell collection for analysis. 
 
2.5.4. MECP2 siRNA transfection 
A pool of small interfering RNAs (siRNAs) for MECP2 (MISSION® esiRNA, esiRNA 
targeting mouse Mecp2, EMU085661-20UG) and MISSION® siRNA Universal 
Negative Control #1 (SIC001-10NMOL) were purchased from Sigma. A suitable amount 
of ES cells was cultured on collagen I-coated 6-well plates with fresh made DM for 2–3 
days before transfection. As usual, differentiating ES cells were washed with warm 1× 
PBS once. For each well of the 6-well plate, 5 µl siIMPORTER™ reagent was diluted 
into 25 µl serum-free medium in a 1.6-ml microcentrifuge tube, and the mixture was 
pipetted gently, according to the manual. Meanwhile, 25 µl siRNA Diluent was diluted 
into 10 µl serum-free medium in a fresh microcentrifuge tube and then mixed with 6 μl 20 
μM siRNA, followed by the siIMPORTER™ reagent mixture. After incubation for 5–30 
min, the siRNA/siIMPORTER™ mixture was overlaid onto cells, and the plate was 
gently tilted back and forth to distribute the transfection complex evenly. The transfected 
cells were incubated at 37°C for 48–72 h before harvesting.  
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2.6. SMC in vivo differentiation 
2.6.1. Generation of lentiviral particles for miR-22 
overexpression 
The lentiviral particles for miR-22 overexpression were produced using a miR-22 
plasmid (pLL3.7-GFP-miR-22), cloned by us, and the pLL-3.7-GFP vector (Addgene, 
Plasmid 11795). Approximate 606 bp of a genomic fragment containing the mmu-miR-
22 precursor (95 bp) and its flanking sequence (256 bp and 261 bp, respectively) was 
amplified by PCR with a specific primer set as shown in Table 2 from differentiating 
stem cells and cloned into the Hpa-I/Xho-I sites of the pLL3.7-GFP expression vector, 
generating pLL3.7-GFP-miR-22. All vectors were verified by DNA sequencing, and the 
vectors with the correct sequence were further amplified and used to produce lentiviral 
particles. Briefly, 2–2.5 × 106 293T cells were plated on a 10-cm plate or T75 flask 1 
day before transfection. The pLL3.7-GFP (control) or pLL3.7-GFP-miR-22 (miR-22 
overexpression) was co-transfected with the 3
rd
 generation packaging plasmids 
pMDLg/pRRE (Addgene, 12251) and pRsv-Rev (Addgene, 12253) and the envelope 
plasmid pMD2.G (Addgene, 12259) into 293T cells using FuGENE-6, according to the 
manufacturer's instructions. After incubation at 37°C in 5% CO2 overnight, the old 
medium was replaced with normal medium (DMEM) containing 10% FBS. The 
supernatant containing the lentivirus was harvested 48 h later, filtered, aliquoted, and 
stored at -80°C for future use. 
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Gene 
names 
Forward (5’-3’) Reverse (5’-3’) Application 
U6 
snoRNA 
GATGACACGCAAATTC
GTG 
miRNA universal 
reverse primer 
(Invitrogen, A11193-
051) 
Real-time 
RT-PCR 
(RT-qPCR) 
18s 
CCCAGTAAGTGCGGGTC
ATAA 
CCGAGGGCCTCACTAA
ACC 
RT-qPCR 
miR-22 
(mu/hu) 
AAGCTGCCAGTTGAAGA
ACTGT 
miRNA universal 
reverse primer 
(Invitrogen, A11193-
051) 
RT-qPCR 
miR-22 
precurso
r (mu) 
ACCTGGCTGAGCCGCAG
TAG 
AGGGGCAGAGGGCAA
CAGTTC 
RT-qPCR to 
detect miR-
22 precursor 
RNA 
miR-
22 
Primar
y (mu) 
AAAGGGGCACAAAGCA
AGTG 
CAGGAAAGCTGGGTG
ACAGG 
RT-qPCR to 
detect miR-
22 primary 
RNA 
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SMαA 
TCCTGACGCTGAAGTAT
CCGAT 
GGCCACACGAAGCTCG
TTATAG 
RT-qPCR 
SM22α 
GATATGGCAGCAGTG 
CAGAG 
AGTTGGCTGTCTGTG 
AAGTC 
RT-qPCR 
h1-
Calponin 
GGTCCTGCCTACGGC 
TTGTC 
TCGCAAAGAATGATC 
CCGTC 
RT-qPCR 
SM-
myh11 
AAGCAGCCAGCATCA 
AGGAG 
AGCTCTGCCATGTCC 
TCCAC 
RT-qPCR 
SRF 
CCTACCAGGTGTCGGAA
TCTGA 
TCTGGATTGTGGAGGT
GGTACC 
RT-qPCR 
Myocd 
TCAATGAGAAGATCGCT
CTCCG 
GTCATCCTCAAAGGCG
AATGC 
RT-qPCR 
MEF2C 
AAGCCAAATCTCCTCCC
CCTAT 
TGATTCACTGATGGCA
TCGTGT 
RT-qPCR 
MECP2 
GGCTGTGGTAAAACCCG
TCCG 
GGCTTGTCTCTGAGGC
CCTGGA 
RT-qPCR 
Nox4 
ATTTGCCTGGAAGAACC
CAAG 
CATCGGTAAAGTCTCT
CCGCA 
RT-qPCR 
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HDAC7 
CCCAGTGTGCTCTACAT
TTCCC 
CACGTTGACATTGAAG
CCCTC 
RT-qPCR 
Nrf3 
TGCCAGATGCAGGCGGA
TGC 
TTGCCTGGGCTGACAC
CCCT 
RT-qPCR 
Cbx3 
GAACGAATAATCGGCGC
CA 
ATGTTCGCCTCCTTTGC
CA 
RT-qPCR 
hnRNPA
1 
TTCATCCAGTCAGAGAG
GTCGC 
TGAAGTTCCCTCCTCG
ACCAA 
RT-qPCR 
hnRNPA
2B1 
CTGCAAGCAAAAGATCA
AGAGG 
GCTCAACTACCCTGCC
ATCAA 
RT-qPCR 
Pla2g7 
CACTGGCAAGACACATC
TTC 
ATCAGATCTGTACAAC
CGAC 
RT-qPCR 
SMαA-
P1 
CATAACGAGCTGAGCTG
CCTC 
CCAAACAAGGAGCAAA
GACG 
CHIP assay 
(with CArG 
region) 
SMαA-
P2 
GATCAGAGCAAGGGGCT
ATA 
CTACTTACCCTGACAG
CGAC 
CHIP assay 
(without 
CArG region) 
SM22α- GCAGGTTCCTTTGTCGG CTGCTTGGCTCACCAC CHIP assay 
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P1 GCCA CCCG (with CArG 
region) 
SM22α-
P2 
CTTTAAACCCCTCACCC
AGC 
ATGACTTGCACTTACA
AGG 
CHIP assay 
(without 
CArG region) 
SRF- 
P_F1
/R1 
GGCTGGGCCCTCCCCCA
TTT 
TGGCTGGTTTGCTGGTT
TGGCA 
CHIP assay 
SRF- 
P_F3
/R3 
TCAGGCCTGTGCTTTAG
CCTCG 
GATGGGGGCAGGGCGG
AAAG 
CHIP assay 
(Adjacent 
region) 
Myo
cd- 
P_F2
/R2 
ACGTGGGACCCTGTCAC
CCC 
GGATTCGGTGGCCTGG
GCAAG 
CHIP assay 
Myo
cd- 
P_F3
/R3 
CGGGAGTTGCAAGCCAA
CCCA 
TCCCCAGCTTACTGCA
GGGCT 
CHIP assay 
(Adjacent 
region) 
Pla2g7- GGGCTCCTAGCTGGCAC TCTCCACCCCAACCCA
CHIP assay 
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p2 GTC CCCC 
Pla2g7-
p10 
GGGATGGGCACAGCTCG
TCG 
CTCGACCCTCCCCTCCT
CCG 
CHIP assay 
(Adjacent 
region) 
Nox4-p 
CCATTGCACACTCCTCA
CCT 
GAAGCTCAGATTCCCT
CTAGGA 
CHIP assay 
Nox4-p-
adj 
TGGACCATGGCTTCAGT
GTT 
CAGCACACCGGGCTTT
GAA 
CHIP assay 
(Adjacent 
region) 
HDAC7-
p 
CACTGGCAGGTGAATCC
TGT 
GGACAGAGGATTGTGC
AGGT 
CHIP assay 
HDAC
7-p- 
adj 
TCCAGGACACTCAAGAA
GGG 
GCCTGGGGTGTCCCTTT
ATC 
CHIP assay 
(Adjacent 
region) 
mus 
miR-22 
precurs
or 
GTGCTCGTTAACCTGCC
CTTTGAATGCCGAAG 
GTGCTCCTCGAGGGG
GAGGTGGAG 
TCACCTAT 
pLL3.7-
GFP-miR22 
clone 
Mus CTCGTCACGCGTTTGGC
CTCCACTCTAGA 
TCAGCTAACTCTCTCG
pCMV5-
MECP2 
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MECP2 CGCCGCTGCCGCCAC GTCACGG clone 
pmiR-
Luc- 
MECP2-
A 
GCTGTCACGCGTGCGGA
TTGCAAAG 
CAAACCAACA 
GTCGACGAGCTCACCT
GGCACTGGC 
AATGGGA 
MECP2 
3’UTR 
reporter-
A clone 
pmiR-
Luc- 
MECP2-B 
CTACTGACGCGTCCCAA
CCTGCCCCA TGCACTC 
TCCTCAGAGCTCTGCA
CACCAAGGG 
CAGCAGTT 
MECP2 
3’UTR 
reporter-
B clone 
pmiR-
Luc- 
MECP2-C 
CTGCTGACGCGTCCGG
CATGAGATG 
GGGGCAGA 
CTGTGTGAGCTCTCCT
TTCCCTCCTG 
GCACTCCTA 
MECP2 
3’UTR 
reporter-
C clone 
pmiR-
Luc- 
MECP2-
A- bs2
mu
 
TCTTCTGTTCCATTTGA
AGGCAGTGCTGAACC 
GGTTCAGCACTGCCT
TCAAATGGAACAG 
AAGA 
miR-22 
binding 
site 2 
mutation 
in 
reporter-
A 
pmiR- CCAACAAGAATAAATT TCTTCTGTTCCATTTG miR22 
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Luc- 
MEC
P2-A- 
bs1/2 
mu
 
TGAAGGTTG 
TCTCTTCTCC 
AAGGCAGTGCTGAA 
CC 
binding site 
1 and 2 
combination
al mutation 
in reporter-A 
pmiR-
Luc- 
MEC
P2-C- 
bs
mu
 
ATGTTTCTGTTTGAAGG
GACAATGGAGTGC 
GCACTCCATTGTCCCTT
CAAACAGAAACAT 
miR-22 
binding site 
mutation in 
reporter-C 
 
Table 2 Primer sets used in the present study 
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2.6.2. Lentiviral infection and cell sorting 
For lentiviral infection, mouse ES cells were seeded on 0.04% gelatin- coated T25 flaks 24 
hours early and incubated in 37°C and 5% CO2 incubator. On following day, the old culture 
medium was replaced with 4 ml of fresh ES cell complete medium, followed by adding 5µl 
of 10µg/ml of Polybrene (Hexadimethrine Bromide, H9268; Sigma-Aldrich) and 1ml of 
respective lentiviral particles. Medium containing viral constructs was replaced with fresh 
complete medium after 24 hours of infection. Infected cells were cultured for further 2 to 3 
day, and the GFP-positive cells were sorted out by using FITC-anti-GFP antibody and anti-
FITC microbeads (Miltenyi Biotec Ltd). GFP-positive ES cells were cultured in ES cell 
medium for 2 to 3 passages before using.  
 
2.6.3. SMC differentiation in vivo from miRNA-22-
overexpressing ES cells  
Control (pLL3.7-GFP) or miRNA-22 over-expression (pLL3.7-GFP-miRNA-22) ES cells 
were generated as described earlier and induced to SMCs differentiate from ES cells. The 
procedures and principles for SMCs differentiation in vivo were similar to that as described 
in our previous study (Xiao et al., 2012, Huang et al., 2013). Briefly, control or miRNA-22 
over-expression ES cells (1×10
6
 cells in 50µl medium) were mixed with 50µl of Matrigel 
(Becton Dickinson Labware) and PDGF-BB (100ng/ml) on ice, and subcutaneously 
injected into C57BL/6J mice. After 10~13 days, mice were sacrificed and the implants 
(Matrigel plugs) were harvested from relate mice before stored in liquid nitrogen for future 
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using. Nearly half of each Matrigel plug were sectioned for detection of cell markers and 
the other were lysed and extracted total RNA to examine related gene expression levels, 
respectively. All animal experiments were performed basing on the protocols and principles 
approved by the Institutional Committee for Use and Care of Laboratory Animals.  
 
2.6.4. Immunofluorescence staining for sections 
For the optimum cutting temperature (Harvey et al.) compound–embedded Matrigel 
implants, all sections were cut to a thickness of 8 µm, every 40 µm along the longitudinal 
axis of the Matrigel plug. Every section was numbered using an oil pen and stored at -20°C 
for future use. Numbered sections (for instance, sections 5, 15, and 25) were subjected to 
immunohistological analysis with the appropriate antibody. Briefly, frozen sections were 
air-dried for at least 30 min and fixed in cold acetone for 15 min. After using a PARA Pen 
to circle the tissue zone, all section slides were placed in a staining chamber containing 1× 
PBS and washed three times with PBS for 10 min each. All sections were blocked with 5% 
BSA in PBS (Sigma) for 1 h at room temperature in a humidified chamber and then 
incubated with primary antibodies (SM-MHC and GFP) or IgG controls at a dilution of 
1:400 in blocking buffer in a cold room (4°C) overnight. The sections were washed three 
times with 1× PBS for 10 min each and then incubated with the appropriate FITC- or 
TRITC-conjugated secondary antibodies. Sections were incubated with DAPI (1:1000; 
Sigma) for 5 min and mounted with anti-fade mounting medium (Fluoroshield™ with 1,4-
diazabicyclo[2.2.2]octane; Sigma, F6937). Images were taken and assessed with an 
Axioplan 2 Imaging Microscope (Plan-NEOFLUAR 20×, NA 0.5, objective lenses, 
AxioCam camera) and AxioVision software (Carl Zeiss MicroImaging, Inc.) at room 
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temperature. Photoshop software (Adobe) was used for further image analyses. Two well-
trained independent investigators blinded to the treatments determined the percentage of 
GFP-labelled SM-MHC-positive cells per field. Four random high-power fields (200×) in 
each section, with three sections from each implant and four implants for each group, were 
analysed. 
 
2.7. RNA extraction and analysis 
2.7.1. Total RNA extraction from cells 
To avoid contamination when extracting RNA, all work areas were cleaned with 70% 
ethanol; whole cell scrapers were sterilized in 75% ethanol for 15 min and then washed 
with sterilized cold 1× PBS. The cell culture medium from flasks or plates was removed 
by pipet or vacuum pump, and cells were washed with warm 1× PBS once and cold 1× 
PBS twice. Cells were scraped in cold PBS to minimum enzyme activity, and the collected 
cells in cold PBS were transferred to a sterilized 1.5-ml tube. The cells were centrifuged 
for 2 min at 4°C and 5,000 rpm, and the cell pellet at the bottom of the tube was stored at -
80°C for future use. 
Total RNA was isolated from cells using the GenElute™ Mammalian Total RNA 
Miniprep Kit (Sigma-Aldrich) according to the manufacturer’s instructions. Briefly, before 
RNA extraction, an appropriate amount of Lysis Solution was freshly prepared by adding 
the suggested amount of 2-mercaptoethanol (2-ME), required to fully inactivate RNases, to 
the lysis buffer provided in the kit. For each RNA preparation, 250 or 500 µL of the Lysis 
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Solution/2-ME mixture was added to cell pellets containing less than 5 × 10
6
 cells or 5 × 
10
6
 to 1 × 10
7
 cells, respectively. The cell solution was vortexed until all clumps 
disappeared. The mixture was then transferred to a GenElute™ Filtration Column placed 
in a 2-ml collection tube and centrifuged at room temperature for 2 min at maximum speed. 
To precipitate the RNA, an equal volume of 70% ethanol was added to the flow-through 
solution and mixed thoroughly. The lysate/ethanol mixture (~700 µL) was transferred to a 
clear binding column and centrifuged at maximum speed for 15 s. The column was 
returned to the same collection tube after removal of the flow-through. If the volume of 
lysate/ethanol mixture was greater than 700 µl, the previous step was repeated to allow all 
RNA to bind to the column. Thereafter, the column was respectively washed twice with 
500 µL Wash Solution 1 and 2 by centrifuging at maximum speed for 15 s. After the final 
wash, the flow-through was removed from the collection tube, and the sample column was 
centrifuged at maximum speed for 2 min to fully remove the ethanol from the column. The 
RNA binding column was placed in a fresh collection tube, and 50 µl of Elution Solution 
was added to the column. After incubation for 1 min at room temperature, the column was 
centrifuged at maximum speed for 1 min to elute the RNA. The RNA concentration was 
measured using a NanoDrop spectrophotometer. RNA samples were used immediately or 
stored at -80°C. The RNA was kept on ice after thawing. 
 
2.7.2. Small RNA extraction from cells 
Total RNA containing small RNA (microRNA) was extracted from cells (1–5 × 106) using 
the mirVana™ Protein and RNA Isolation System™ Kit (Applied Biosystems, Ambion 
Inc.) or TRI Reagent (Sigma) according to the manufacturers’ instructions.  
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For RNA extraction using the mirVana™ Protein and RNA Isolation System™ Kit, cell 
pellets were mixed with 625 μl ice-cold cell disruption buffer. Samples were vortexed to 
completely lyse the cells and to obtain a homogeneous lysate. An equal volume of 2× 
denaturing solution at room temperature was immediately added to the lysate to prevent 
RNA degradation. After mixing, 1250 μl acid-phenol:chloroform was added to the mixture 
and vortexed for 1 min to mix. To separate the mixture into aqueous (upper) and organic 
(lower) phases, the mixture was centrifuged for 5 min at 13,200 rpm at room temperature. 
The upper aqueous phase was carefully removed and transferred into a fresh centrifuge 
tube. The volume of 100% ethanol (room temperature) added to the aqueous phase was 
1.25 times the volume of the recovered aqueous phase. Each lysate/ethanol sample was 
mixed thoroughly and aliquoted onto a filter cartridge placed in one of the collection tubes. 
The mixture was centrifuged at 13,200 rpm for 30 s. The flow-through was discarded, and 
centrifugation was repeated until all of the lysate/ethanol samples had filtered through the 
cartridge. MiRNA Wash Solution 1 (700 µl) was added to the filter cartridge and 
centrifuged for roughly 30 s. The flow-through was discarded, and the filter cartridge was 
washed with 500 μl Wash Solution 2/3. A repeat wash with 500 μl Wash Solution 2/3 was 
carried out, and the flow-through was discarded. The residual fluid was removed from the 
filter cartridge by centrifuging the assembly for 1 min. The filter cartridge was transferred 
into a fresh collection tube, and 100 μl Elution Solution, pre-heated to 95°C, was aliquoted 
to the centre of the filter. The miRNA eluate was recovered by centrifugation for 30 s, and 
the concentration of miRNA in each sample was determined using a spectrophotometer. 
The samples were either stored at -80ºC or further processed. 
For RNA extraction using TRI Reagent, 1 ml TRIzol®
 
Reagent (for 1–5 × 106 trypsinized 
cells) was added to cell pellet and mixed by pipetting. For cells cultured in 6-well plates, 
- 88 - 
 
12-well plates, or 24-well plates, TRIzol® Reagent was added directly to each well after a 
wash with 1× PBS, and the cell lysate was drawn repeatedly through the pipette tip to form 
a homogeneous lysate. The homogeneous samples were incubated for 5 min at room 
temperature to permit complete dissociation of nucleoprotein complexes. The lysate was 
centrifuged for 1 min at 13,200 rpm, and the suspension was transferred to a new RNase-
free Eppendorf tube. Chloroform (0.2 ml; Sigma-Aldrich) was added to each tube, 
vortexed vigorously for 15 s, and incubated at room temperature for 2 to 3 min. The 
sample was centrifuged at 12,000 × g for 15 min at 2–8°C. Subsequently, the colourless 
upper aqueous phase containing RNA was transferred to a new tube, and isopropanol 
(volume equal to that of TRIzol®
 
Reagent) was added to each tube and mixed for 5 s. 
Samples were left at room temperature for 10 min and then centrifuged at 12,000 × g for 
10 min at 2–8°C. The supernatant was carefully removed, and the RNA precipitate at the 
bottom of the tube was washed with 75% ethanol (volume equal to that of TRIzol®
 
Reagent) twice by centrifuging at 7,500 × g for 5 min at 2–8°C. The supernatant was 
discarded after the final wash. The pellet was air dried for 10 min and then dissolved in 
50–100 µl RNase-free distilled water. The RNA concentration was measured using a 
NanoDrop machine, and the RNA samples were stored at -80°C for future use.  
 
2.7.3. Normal RT-PCR 
2.7.3.1. Normal reverse transcription (RT) 
For normal cDNA synthesis, RevertAid Reverse Transcriptase (Thermo Scientific) or the 
ImProm-II™ RT Kit (Promega, Madison, WI, USA) was used.  
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When using RevertAid Reverse Transcriptase, the RNA sample was removed from the -
80°C freezer and thawed on ice. In accordance with the RevertAid Reverse Transcriptase 
product manual, 0.1 ng–5 μg template RNA was mixed gently with 1 µl Random Primer 
(C118A, Promega) and up to 12.5 µl DEPC-treated water. When the RNA template was 
GC-rich or known to contain secondary structures, the mixture was centrifuged briefly at 
maximum speed at 2–8°C and incubated at 65°C for 5 min. Subsequently, the treated 
RNA/primer mixture was mixed with the following components: 4 µl 5× Reaction Buffer, 
0.5 µl Thermo Scientific RiboLock RNase Inhibitor (EO0381), 2 µl dNTP mixture (10 
mM), and 1 µl RevertAid Reverse Transcriptase. The final volume of each reaction was 20 
µl. The RNA was converted to cDNA by incubating the mixture at 25°C for 10 min, 42°C 
for 60 min, and 70°C for 10 min in the PCR thermocycler. The cDNA product was diluted 
to a working concentration of 5 ng/μl and stored at -20°C for future use. 
When using the ImProm-II™ Reverse Transcription System, up to 1 µg template RNA 
was mixed with random primer, denatured at 70°C for 5 min, and chilled on ice for 5 min. 
Subsequently, the reverse transcription reaction mixture containing 4.5 µl nuclease-free 
water, 5 µl ImProm-II™ Reaction Buffer, 1 µl ImProm-II™ Reverse Transcriptase, 3 µl 
magnesium chloride (MgCl2), 1 µl dNTPs, and 0.5 µl Ribonuclease Inhibitor was added in 
each reaction. Following an initial annealing step at 25°C for 5 min, the reaction complex 
was incubated at 42°C for 1 hour. The cDNA product was diluted to a working 
concentration of 5 ng/μl and stored at -20°C for future use. 
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2.7.3.2. MiRNA reverse transcription 
The miRNA cDNA was synthesized using the NCode™ VILO™ miRNA cDNA Synthesis 
Kit (A11169, Invitrogen) by following the instructions provided with the kit. Briefly, up to 
2 µg RNA was mixed with the 10× SuperScript® Enzyme Mix, 5× Reaction Mix, and 
DEPC-treated water. The final volume of the mixture was 20 µl. The miRNA was then 
transcribed into cDNA by incubating the mixture at 37°C for 60 min and 95°C for 5 min in 
a PCR thermocycler. The final cDNA product was diluted to 5 ng/ml for immediate use or 
placed in a -20°C freezer for long-term storage. 
 
2.7.3.3. Polymerase chain reaction (PCR) 
To set up parallel reactions and to minimize the possibility of pipetting errors, the PCR 
mixture was prepared by mixing 13 µl nuclease-free water, 2.5 µl 10× DreamTaq Buffer, 
2.5 µl dNTP mix (final concentration 2 mM), 2 µl primers including the respective 
forward primer and reverse primer (Table 2), and 0.14 µl DreamTaq DNA Polymerase for 
each PCR reaction. The PCR mixture was vortexed, centrifuged, and aliquoted to 
individual PCR tubes. The template DNA was then added. Finally, the reactions were 
placed in a Peltier thermal cycler (DNA Engine Tetrad 2; MJ Research), and the PCR 
programme was performed using the recommended thermal cycling conditions outlined in 
Table 3.  
The final PCR product was detected by performing UltraPure™ Agarose (Invitrogen) gel 
electrophoresis. The percentage of agarose gel typically used for different purposes is 
shown below (Table 4). Accordingly, the appropriate amount of agarose powder was 
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dissolved in 60–70 ml 1× TBE buffer (or TAE) in a beaker and boiled in a microwave 
oven. The breaker was shaken gently every 30 s to prevent the formation of agarose 
clumps. The agarose was completely dissolved by microwaving the solution for 1–3 min. 
Next, an appropriate amount of GelRed Nucleic Acid Stain (10,000× in DMSO; Biotium) 
was added to the agarose gel solution when the agarose gel had cooled to 50–60°C 
(assessed by touch). The gel solution was poured into the casting tray of the gel box with 
the well comb in place. After the gel solution had completely solidified, 20–30 µl of each 
sample mixed with 6× DNA loading buffer or 10–15 µl of DNA ladder was added to each 
well of the gel, and the gel box was filled with 1× TAE buffer (or TBE) until the gel was 
covered. The gel was run at a maximum of 70 V until the dye front reached the end of the 
gel. The gel was transferred to the AlphaImager® HP System (Alpha Innotech) with dual 
wavelength ultraviolet illumination (365 nm or 302 nm). The image was captured and 
analysed using Automatic Image Capture software (Alpha Innotech). 
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Step Temperature, °C Time Number of cycles 
Initial denaturation 95 5 mins 1 
Denaturation 95 1 min 
35 Annealing 55 1 min 
Extension* 72 1 min/kb 
Final Extension 72 5-10 mins 1 
 
Table 3 Normal PCR conditions 
 
Fragment Size % Agarose (in 1X TBE) 
100bp-2kb 2 
200bp-4kb 1.5 
400bp-10kb 1 
 
Table 4 Percentage of agarose according to DNA or RNA size 
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2.7.4. Real-time PCR (qPCR) 
2.7.4.1. mRNA 
To avoid potential contamination, the working area was cleaned with 70% ethanol, and 
only sterilized pipette tips and tubes were used to prepare the real-time PCR (qPCR) 
mixtures. cDNA samples were thawed from -20°C and placed on ice. 
A KAPA SYBR®
 
FAST qPCR Kit Master Mix (KAPA Biosystems) was used in qPCR. 
The qPCR master mix containing the appropriate volume of the following components was 
first prepared: 2× KAPA SYBR® FAST qPCR Master Mix, 2 μM forward primer, 2 μM 
reverse primer, and DEPC-treated water. The final volume in each well of a 384-well plate 
was 10 µl, comprising 8 µl qPCR master mix and 2 µl cDNA sample. The 384-well plate 
was then sealed with MicroAmp® PCR film, vortexed briefly, and centrifuged at 1,200 × g 
for 2 min. An Applied Biosystems 7900 HT TaqMan Real-Time PCR System was used to 
run the qPCR reactions with the following program: 95°C for 3 min and 40 cycles of 95°C 
for 1–3 s and 60°C for 1 min. Once the reaction finished, the raw Ct values were 
automatically acquired with SDS 2.3 software (Applied Biosystems). The relative 
expression abundance of the mRNAs of interest were analysed and calculated using 
relative quantification methods (∆∆C methods). The respective control treatment was set at 
1.0. GAPDH, 18S rRNA, or β-actin was used as the endogenous control in mRNA 
detection. 
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2.7.4.2. MiRNA 
For microRNA detection, EXPRESS SYBR® Green™ qPCR SuperMix (Invitrogen) was 
used to amplify the microRNAs of interest. For each qPCR reaction, the qPCR mixture 
consisted of 1.5 µl RNase-free water, 5 µl NCode™ EXPRESS SYBR® Green™ qPCR 
SuperMix, 0.75 µl 2 µM miRNA-specific forward primer, and 0.75 µl 2 µM miRNA 
Universal Primer (Invitrogen). The mixture was vortexed, and 8 µl aliquots were added to 
each well of a 384-well plate (MicroAmp® Optical 384-well Plate). Subsequently, 2 µl of 
each cDNA sample was added to the appropriate well. Each sample was assessed in 
duplicate. Real-time qPCR was performed using default conditions (50°C for 2 min, 95°C 
for 10 min, and 40 cycles of 95°C for 15 s and 60°C for 1 min) in 10-µl reactions using an 
Applied Biosystems 7900 HT TaqMan Real-Time PCR System. Data were analysed using 
relative quantification methods (∆∆ C methods) as described above. U6 snRNA was used 
as the endogenous control to normalise the expression levels of small RNAs. 
 
2.8. Protein extraction and analysis 
2.8.1. Chemicals and buffers 
All chemicals/reagents used in the following buffers (Table 5) were purchased from 
Sigma-Aldrich unless otherwise indicated. 
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Name Components 
RIPA buffer 
Tris-HCl: 50 mM, PH 7.4.  
NP-40:1 % 
Na-deoxycholate: 0.25 %  
NaCl: 150 mM 
5× SDS loading buffer 
Tris-Cl (0.25 M, pH 6.8) 
SDS (sodium dodecyl sulphate; 10 %)  
Glycerol (50 %) 
Bromophenol blue (0.25 %) 
DTT (dithiothreitol; 0.5 M) 
10× Tris-glycine buffer, pH 8.4, 1 litre 
Tris base: 30.3 g 
Glycine:144.1 g 
Distilled Water to 1 litre 
1× Running buffer, 1 litre 
10 ×  Tris-glycine buffer: 100 ml 
10% SDS: 10 ml 
- 96 - 
 
Distilled Water to 1 litre 
1 × Transfer buffer, 1 litre 
10 × Tris-glycine buffer: 100 ml 
Methanol : 200 ml 
Distilled Water to 1 litre 
10 × TBS buffer, 1 litre 
Tris HCl: 24 g   
Tris Base: 5.6 g  
NaCl: 88 g 
Distilled Water to 1 litre 
1 × TBST, 1 litre 
10 × TBS: 100 ml 
Tween® 20:500 µl 
Distilled Water to 1 litre 
 
Table 5 Recipes of buffers used in protein analysis 
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2.8.2. Protein extraction from cells 
As with the total RNA extraction protocol, all work areas were cleaned with 70% ethanol 
to avoid contamination. To the same end, all cell scrapers used for protein extraction were 
sterilized in 75% ethanol diluted in distilled water for about 15 min and then washed in 
cold 1× PBS. 
The cell culture medium from flasks was removed by pipet and vacuum pump. Cells were 
washed with warm 1× PBS once and cold 1× PBS twice. Cells were scraped from T25 or 
T75 flasks with cold 1× PBS and transferred to a sterilized 1.5-ml tube. Cells were 
centrifuged for 2 min at 4°C and 5,000 rpm. The cell pellet was lysed with 100 µl cold 
lysis buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1 mM EDTA, pH 8.0) supplemented 
with Protease Inhibitor Cocktail (Sigma-Aldrich) and 0.5% Triton on ice. The lysate was 
vortexed briefly and then sonicated for 3–5 s at 4°C to disrupt the cell membrane and 
release the protein contents. For complete cell lysis, the lysates were placed on a shaker 
with gently stirring in the cold room for 1 hour. The lysed samples were then centrifuged 
at 13,200 rpm for 10 min at 2–8°C. Up to 100 µl of supernatant from each sample was 
transferred to a new 0.5-ml Eppendorf tube and placed on ice. Bio-Rad Protein Assay 
Reagent (Bio-Rad) was used to measure the protein concentration. The assay solution 
mixture was first diluted at a ratio of 1:5 using distilled water. To each protein sample (2 
µl), 998 µl diluted Bio-Rad Protean assay solution was added. The samples were vortexed 
and incubated for 10 min at room temperature. A negative control was prepared by adding 
2 µl lysis buffer to 998 µl diluted protein assay solution and used to normalize the final 
readings. The protein concentration was measured with a spectrophotometer (SmartSpec™ 
3000; Bio-Rad), and the OD value was measured at 595 nm. Lysis buffer was added to 
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each sample to adjust the protein concentration to equal levels, and a suitable amount of 
pre-warmed 5× sodium dodecyl sulphate (SDS) protein loading buffer was added to each 
sample. The protein samples were placed in a heat block, denatured at 95°C for 10 min, 
vortexed, and centrifuged briefly. When the samples had cooled to room temperature after 
several minutes, they were used for western blotting analyses immediately or placed in a -
80°C freezer for long-term storage.  
 
2.8.3. Western blotting 
Detail protocols for western blot electrophoresis have been described in our previous 
reports (Yu et al., 2015, Huang et al., 2013). Briefly, western blot electrophoresis was 
carried out using a Mini-PROTEAN® Tetra Cell system (Bio-Rad, UK), and protein was 
separated using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
with 6–10% Tris-glycine gels. The 10% separating gel (4 ml) and 6% stacking gel (2.5 ml) 
were freshly prepared. The 10% separating gel consisted of 1.6 ml double-distilled water, 
1.635 ml 30% acrylamide (National Diagnostics, USA), 1 ml 1.5 M Tris-HCl buffer (pH 
8.8), 40 µl 10% SDS, 40 µl 10% APS, and 4 µl TEMED (Sigma). The 6% stacking gel 
contained 1.3 ml double-distilled water, 0.5 ml 30% acrylamide, 0.625 ml 0.5 M Tris-HCl 
buffer (pH 6.8), 25 µl 10% SDS, 25 µl 10% APS, and 2.5 µl TEMED. The 10% separating 
gel was prepared first and added to the glass casting chamber. The gel surface was levelled 
by layering 1 ml butanol (Sigma-Aldrich) onto the 10% separating gel. The upper butanol 
was discarded from the chamber, and the solidified separating gel was washed with 
distilled water to remove the remaining butanol. Subsequently, 2.5 ml of the 6% stacking 
gel was added onto the 10% separating gel, and a plastic comb was inserted immediately 
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to create 10 wells per gel. The stacking gel was incubated at room temperature for 10–15 
min until it solidified. Thereafter, the chamber was placed in the electrophoresis running 
system, and a suitable amount of 1× Running buffer was poured into the chamber. 
ColorPlus Prestained Protein Ladder (15 µl; New England BioLabs® Inc.) was loaded into 
the first well of the gel, and 40 µl of each protein sample was added to the remaining wells. 
The gel was typically run at a fixed voltage of 160 V for 70–90 min at room temperature 
until the indicator dye reached the bottom of gel.  
Before the gel transfer procedure, a polyvinylidene difluoride (PVDF) membrane (GE 
Healthcare) was placed in a box containing methanol (Sigma) for 15 min to activate the 
membrane. The used methanol was discarded, and the membrane was soaked in cold 1× 
Transfer buffer for another 15 min. Meanwhile, the western blot sponges were washed 
with distilled water and soaked in cold 1× Transfer buffer with filters for 15 min. After the 
completion of electrophoresis, the gel was assembled with the pre-coated membranes, pre-
wetted blotting sponges, and filter papers in the correct order/direction and transferred to a 
western blotting cassette. Importantly, air bubbles within the cassette were removed by 
rolling a roller over the surface of the gel before transfer. The blotting cassettes were 
placed into a Mini Trans-Blot Central Core (Bio-Rad) filled with cold 1× Transfer buffer. 
The whole transfer procedure was performed in a cold room for about 150 min at 60 V. 
After the transfer, the membrane was blocked in 5% skim milk diluted in 1× TBST buffer 
on a 2D rocker, with the protein facing upwards, for 1 h at room temperature. The 
membrane was then incubated with the appropriate primary antibody on a slow-speed 
roller for 12–16 h or overnight in the cold room. 
On the following day, the membrane was removed from the bottle containing the primary 
antibody and washed three times with 1× TBST for 10 min each on a 2D shaker. The 
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membrane was then incubated with horseradish peroxidase-conjugated secondary antibody 
with gentle shaking for 1 h at room temperature, followed by three washes with 1× TBST 
(10 min each). The membrane was then incubated with ECL-PLUS Reagent (Amersham 
Biosciences, Stockholm, Sweden) for 1–3 min at room temperature. Excess ECL reagent 
was removed, and the membrane was placed in an autoradiographic cassette and covered 
with a piece of X-ray film in the dark room. Eventually, the film was developed with an X-
Ray Film Processor (SRX-101A; Konica Minolta, USA) using Fix Buffer and Develop 
Buffer in the dark room for 2 s to 15 min, depending on the signal strength of the 
examined proteins.  
 
2.9. Gene cloning and mutation 
2.9.1. MECP2 3′-UTR cloning and miR-22 binding site 
mutation 
As shown in Figure 11, four miR-22 binding sites (1577, 2797, 4537, and 8347) have 
been found within the MECP2 3′-UTR. Three murine MECP2 gene fragments (MECP2-
A: 1567–2698, MECP2-B: 4142–4968, and MECP2-C: 8173–9137; NM-001081979) 
containing miR-22 binding sites 1 and 2 (Reporter-A), 3 (Reporter-B), and 4 (Reporter-C), 
respectively, were amplified with PCR using the respective primers, as shown in Table 2. 
The insert DNA fragments and the pmiR-Luc-report vector (Ambion, Applied 
Biosystems) were first digested with MluI (Promega) at 37°C overnight. After 
purification, the purified inserts and vectors were digested with HindIII or SacI (Promega) 
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at 37°C for 12 h. On the following day, 1 µl bacterial alkaline phosphatase (BAP; 
Invitrogen) was added to the digested vector, mixed by pipetting, and incubated at 65°C 
for 1–2 h for vector dephosphorylation. The DNA inserts and vectors were purified with 
agarose gel electrophoresis, and the DNA concentration of the inserts and vectors was 
measured using a NanoDrop spectrophotometer. The purified DNA inserts were ligated 
into pmiR-Luc vectors in a solution containing T4 DNA ligase and 10× Ligase Buffer 
(New England BioLabs) at room temperature overnight. The self-ligation of vector was 
used as a control. After the overnight incubation, the ligation mixture was transformed 
into JM109 competent cells. The resulting clones were picked and identified by PCR. The 
correct clones were further amplified, and plasmid DNA was extracted using a 
GenElute™ Plasmid Miniprep Kit (Sigma). The DNA was sequenced for final 
verification. The resulting vectors were designated pmiR-Luc-MECP2-A [harbouring 
miR-22 binding sites 1 (~1577 bp) and 2 (~2797 bp)], -B (harbouring binding site 3, 
~4537 bp), and -C (harbouring binding site 4, ~8347 bp).  
Mutations in miR-22 binding sites 1 and 2, alone or combination with reporter A or C, 
were introduced into the pmiR-Luc-MECP2 reporter using the QuikChange Multi Site-
Directed Mutagenesis Kit (Agilent Technologies). According to manufacturer’s 
instructions, the pmiR-Luc-MECP2 reporter was removed from the -20°C freezer and 
thawed on ice. The site-directed mutagenesis reactions containing 10× QuikChange Multi 
Reaction Buffer, double-distilled H2O, QuikSolution, dsDNA template, mutagenic 
primers, dNTP mix, and QuikChange Multi Enzyme Blend were prepared for thermal 
cycling with the following parameters: 95°C for 2 min; 30 cycles of 95°C for 30 s, 55°C 
for 30 s, and 65°C for 5 min (1 min/1 kb); 10 min at 65°C; and 2 min at 4°C. Just before 
digesting the amplification products with 1.5 µl DpnI at 37°C for 5 min, XL10-Gold 
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ultracompetent cells were thawed from -80°C on the ice for transformation. XL10-Gold 
ultracompetent cells (45 µl) were aliquoted to a pre-chilled 1.5-ml tube and mixed with 2 
µl β-ME. The tube was placed on ice and swirled gently every 2 min five times. DpnI-
treated DNA (2 µl) from each mutagenesis reaction was added to the ultracompetent cells. 
The mixture was incubated on ice for 30 min, heated for 30 s at 42°C in a water bath, and 
chilled for 2 min at 2–8°C. The treated mixture was mixed with 250 µl pre-heated Luria 
Broth (LB) medium without ampicillin and incubated for 1 h on a shaker at 37°C and 200 
rpm. The bacteria were spread on a culture dish [LB medium containing 1000× ampicillin 
(50 µg/ml)] and incubated at 37°C for 16–24 h. The resultant vectors were designated 
pmiR-Luc-MECP2-A-bs2mu, pmiR-Luc-MECP2-A-bs1/2mu, and pmiR-Luc-MECP2-C-
bsmu. All mutants were verified by both PCR and DNA sequencing. Vectors with the 
correct mutations were amplified and used in the following experiments. 
 
2.9.2. MECP2 gene clone 
Two MECP2 overexpression plasmids were generated in my project. The protocol was 
similar to that described above. Briefly, the target DNA was amplified by PCR with two 
primers as shown in Table 2 and cloned into the pCMV5-HA vector (Addgene). After 
double digestions of the DNA inserts and pCMV5-HA vector with the MluI and XbaI 
enzymes (Promega) in a 37°C water bath overnight, the digested pCMV5-HA vector 
DNA was treated with BAP to remove the phosphate group. The purified insert DNAs 
were ligated into the pCMV5-HA vector using T4 DNA ligase as described above and 
transformed into bacteria. The final products with the correct DNA sequence were named 
pCMV5-MECP2-TV1 and pCMV5-MECP2-TV2. The pCMV5-MECP2-TV2 was used 
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to overexpress MECP2 because this is the main isoform of MECP2 detected in 
differentiating ES cells. 
 
2.9.3. MiR-22 precursor clone 
Using similar procedures, miR-22 precursor (~557 bp) was cloned into the pLL3.7 vector 
(~7650 bp; Addgene) to generate a miR-22-overexpressing ES cell line, as described 
above. The amplified inserts and pLL3.7 vector DNA were digested by HpaI and XhoI 
(Promega). The remaining procedure was similar to that described above. After 
confirmation with DNA sequence analysis, the resulting vector was designated pLL3.7-
mmu-miR-22. 
 
2.9.4. Plasmid amplification and extraction 
2.9.4.1. Plasmid amplification 
Plasmid transformation was used to amplify the plasmid DNA. The plasmid, stored in the -
80°C freezer, was thawed on the ice. Plasmid/DNA (1 µl) or negative control (ddH2O) was 
added to 50 µl of aliquoted JM109 bacteria (Promega) for each amplification reaction. The 
plasmids and JM109 cells were vortexed gently, and the mixture was incubated on ice for 
30 min, at 42°C for 1 min, and at 2–8°C for 1 min. The plasmid/bacteria mixture was then 
added to 500 µl LB medium without antibiotics (ampicillin), incubated on a floor shaker 
for 1 h at 37°C and 210 rpm, and then centrifuged for 5 min at 5,000 rpm. After discarding 
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400–450 µl of supernatant, the remaining liquid (~50 µl) containing the plasmid/bacteria 
was resuspended and dispensed onto the surface of a culture dish in a drop-wise manner 
and incubated overnight in a 37°C incubator. Distinct single clones were picked and 
incubated with 5 ml LB with ampicillin in a 14-ml polystyrene round-bottom tube (Falcon) 
for 12–16 h on a floor shaker. The samples were then centrifuged at 4,000 × g for 10 min, 
and the supernatant was discarded to collect the plasmids.  
 
2.9.4.2. Plasmid extraction 
The plasmids were isolated and extracted from bacteria according to the manufacturer’s 
instructions using a GenElute™ Plasmid Miniprep Kit (Sigma), which included 
Resuspension Solution, Lysis Solution, Neutralization Solution, Column Preparation 
Solution, Wash Solutions 1 and 2, and Elution Solution. All steps in the protocol described 
below were carried out at room temperature.  
Briefly, the collected bacterial pellet obtained as described in the previous section was 
resuspended in 200 μl Resuspension Solution containing RNaseA Solution in a 14-ml 
polystyrene round-bottom tube (Falcon), pipetted thoroughly to homogeneity, and 
transferred to a 1.5-ml microcentrifuge tube. The resuspended mixture was lysed by 
adding 200 μl Lysis Solution and inverted gently to mix the samples. To avoid prolonged 
lysis that permanently denatures supercoiled plasmid DNA and renders it unsuitable for 
most downstream applications, the lysis procedure was terminated within 5 min. The lysed 
bacterial debris was mixed with 350 μl Neutralization Solution to precipitate the cell debris; 
the tube was inverted and centrifuged at 12,000 × g for 10 min. To collect the DNA 
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precipitate, the clear lysate containing the DNA plasmid was transferred to a binding 
column with a 2-ml collection tube, which had been pretreated with 500 µl Column 
Preparation Solution. The flow-through in the collection tube was discarded after 
centrifuging the sample briefly at 13,000 rpm. Optional Wash Solution (500 µl) was added 
to the column to avoid nuclease contamination of the final plasmid product when the 
bacterial strains used contained the wild-type EndA
+
 gene. After the addition of 750 µl 
Wash Solution diluted with ethanol, the column was centrifuged at 12,000 × g for 1 min, 
and the flow-through was discarded prior to the final elution. The column was placed into 
a new 2-ml collection tube. Elution Solution (75 µl) was added, incubated for 1 min, and 
centrifuged at 12,000 × g for 1 min. The plasmid DNA product in the eluate was placed at 
-20°C for long-term storage. 
 
2.10. Luciferase assay 
2.10.1. Gene promoter activity assays 
Differentiating ES cells (Day 2 or Day 3) cultured in a 24-well plate coated with collagen 
were co-transfected with individual gene reporters (pGL3-Luc-SMαA, pGL3-Luc-SM22α, 
pGL3-Luc-SMαA-SRFmu, pGL3-Luc-SM22α-SRFmu, pGL3-Luc-SRF, pGL3-Luc-
MEF2c, pGL3-Luc-Myocd, pGL3-Luc-Pla2g7-P2, pGL3-Luc-Pla2g7-P10, pGL3-Luc-
HDAC7, pGL3-Luc-Nox4, 150-200ng/well) and control (pCMV5-HA) or MECP2 
overexpression (pCMV5-HA-MECP2) plasmids (200 ng/well), as indicated in the figure 
legends, using FuGENE-6 (Roche) or TurboFect transfection agent (Thermo) according 
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to the manufacturers’ instructions. pShuttle2-LacZ (200 ng/well) or pRenilla (20 ng/well) 
was included as a control for normalisation. The differentiation medium (DM) was 
refreshed the day after transfection, and the luciferase assay was processed 48–72 h post 
transfection.  
For luciferase analysis used the Renilla gene as control, the cells were washed with warm 
1× PBS once and cold 1× PBS once after removal of the old culture medium from the 
wells. Reporter Lysis Buffer (100 µl; Promega) was added to each well. The culture plate 
was then placed on a 2D rocker for 30 min (40–50 rpm), incubated in a -80°C freezer for 
at least 2 h, and shaken for 30 min at room temperature. The cell lysates were harvested 
into 1.5-ml Eppendorf tubes, and the supernatant obtained after a 5-min centrifugation at 
4°C and 13,200 rpm was discarded. A single-tube luminometer (Turner BioSystem, 
Sunnyvale, CA, USA) was turned on before the luciferase analysis was conducted. For 
luciferase activity measurement, 15 µl supernatant from each lysate was mixed with 100 
µl luciferase assay substrate (E151A, Promega) diluted in luciferase assay buffer (E152A, 
Promega) for detection with a luminometer. The procedure for measurement of Renilla 
activity was similar to that for measurement of luciferase activity. The same amount of 
clear lysate (15 µl) was added to 100 µl Renilla assay substrate [Coelenterazine (S200A, 
Promega, 2000×)] diluted in Renilla substrate buffer (25 mM Tris-HCl, pH 7.5, 120 mM 
NaCl). A relative luciferase unit (RLU) was defined as the ratio of luciferase activity to 
Renilla activity, with the activity of the control set at 1.0. 
The activity of LacZ was detected using a β-Gal Kit (Invitrogen) when the pShuttle2-
LacZ was used as the internal control for DNA transfection. The early steps of the β-Gal 
assay were similar to those described for the luciferase assay. Briefly, 15 µl cell lysate 
was used to measure luciferase activity, as described previously. For β-galactosidase 
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activity analysis, 1–10 µl cell lysate was diluted to a final volume of 30 µl with distilled 
water and transferred to a fresh 1.5-ml microcentrifuge tube. Ortho-nitrophenyl-β-D-
galactopyranoside (ONPG; 70 µl) and 1× cleavage buffer with β-mercaptoethanol (β-Me; 
200 µl) were added to the diluted cell lysate, vortexed, and then centrifuged briefly at 
maximum speed (13,200 rpm). The mixture was incubated in a water bath at 37°C for 30 
min. Because hydrolysis of ONPG to the ONP anion by β-galactosidase produces a bright 
yellow colour, yellow colour was observed when β-galactosidase was present in the 
samples. Finally, 500 µl of stop buffer was added to the mixture to stop the reaction, and 
the absorbance was read at 420 nm against a blank containing lysis buffer, ONPG, and 
cleavage buffer. A relative luciferase unit (RLU) was defined as the ratio of luciferase 
activity to β-galactosidase activity, with the activity of the control set at 1.0.  
 
2.10.2. pmiR-Luc-MECP2 reporter activity assays 
The pmiR-Luc-MECP2 (3′-UTR) reporter activity assay was similar to that described for 
the gene promoter activity analysis. Briefly, differentiating ES cells (Day 2 or Day 3) 
cultured in a 24-well plate coated with collagen were co-transfected with individual 
pmiR-Luc-MECP2 3′-UTR reporters (pmiR-Luc-MECP2-A, pmiR-Luc-MECP2-B, 
pmiR-Luc-MECP2-C, pmiR-Luc-MECP2-A-miR-22 BS1
mu
, pmiR-Luc-MECP2-A-miR-
22 BS1/2
mu
, pmiR-Luc-MECP2-C-miR-22 BS
mu
; 150–200 ng/well) and control 
(precursor: control) or miR-22 precursor/mimics (precursor: miR-22) (30 nM), as 
indicated in the figure legends, using siPORT™ NeoFX™ Transfection Agent 
(Invitrogen), according to the manufacturer’s instructions. pShuttle2-LacZ (200 ng/well) 
or pRenilla (20 ng/well) was included as a control for normalisation. The differentiation 
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medium (DM) was refreshed the day after transfection, and the luciferase assay was 
processed 48–72 h post transfection using methods similar to those described for the gene 
promoter activity analyses.  
 
 2.11. Chromatin immunoprecipitation (ChIP) assay 
Differentiating ES cells were co-transfected with control (pCMV5) or MECP2 
overexpression (pCMV5-MECP2) plasmids in T75 flasks using TurboFect transfection 
agent (Thermo) and cultured for 48 h with one medium change at 24 h. The culture 
medium was refreshed before the ChIP assay. Formaldehyde (1%) was added to the 
culture medium, and the flask was swirled gently to mix the solution before incubation at 
room temperature for 10 min. To each flask, 1 ml 10× glycine was added to quench any 
unreacted formaldehyde. The flask was swirled and incubated for 10 min at room 
temperature. The cells on the surface of the flask were scraped directly into a 15-ml tube 
and then centrifuged for 2 min at 1,000 rpm and 4°C. After discarding the supernatant, the 
cell pellets were washed twice with 3 ml 1× PBS containing Protease Inhibitor Cocktail II 
and then precipitated with 1 ml 1× PBS containing Protease Inhibitor Cocktail II by 
centrifuging. After removal of the supernatant, the cells were resuspended in 1 ml SDS 
lysis buffer containing Protease Inhibitor Cocktail II, and 300–400 μl aliquots were added 
to each microfuge tube. All samples were placed on ice before sonication. The cells were 
sheared eight times for 20 s each using an EpiShear™ Probe Sonicator (Active Modif® 
Inc.). The sheared samples were diluted into 500 µl Dilution Buffer containing Protease 
Inhibitor Cocktail II. Dynabeads® Protein G (30–50 µl; Novex) was pre-washed three 
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times with Dilution Buffer containing Protease Inhibitor Cocktail II, added to the sheared 
samples, and incubated on a roller in the cold room for 1–2 h to pre-clear the sheared 
samples. After centrifugation of the mixture, the clear supernatant was transferred to a new 
1.5-ml tube and mixed with antibodies (2 µg/immunoprecipitation) raised against MECP2 
(rabbit, ab2828, Abcam), SRF (rabbit, G-20, sc-335, Santa Cruz), or H3K9me3 (mouse, 
05-1250, Millipore). An equal amount of normal rabbit IgG or mouse IgG was used as 
control. A suitable amount of dilution buffer was added to the tube to bring the final 
volume of each sample to 1 ml, and the sample was incubated on a roller in the cold room 
overnight. The following day, 30–50 µl Dynabeads® Protein G (Novex) was pre-washed 
three times with dilution buffer containing Protease Inhibitor Cocktail II, added to each 
immunoprecipitation sample, and incubated on a roller in the cold room for 1–2 h to pull 
down the chromatin/protein complexes. After removal of the supernatant, the remaining 
precipitate was washed with Low Salt Immune Complex Wash Buffer (Catalogue #20-
154), High Salt Immune Complex Wash Buffer (Catalogue #20-155), and TE Buffer 
(Catalogue #20-157). The washed immunoprecipitation reactions were then eluted from 
the beads using 200 µl Elution Buffer (50 mM NaHCO3, 1% SDS) and incubated at room 
temperature for 30 min. The supernatant was collected, mixed with 8 μl 5 M NaCl, and 
incubated at 65°C for 4–5 h to reverse the DNA-protein crosslinks. After the addition of 1 
μl RNase A to sample and incubation for 30 min at 37°C, 1 µl of proteinase K solution 
was added to each sample and incubated in a heat block at 45°C for 1–2 h. 
Immunoprecipitated DNA was extracted, purified, and used to amplify target DNA 
sequences in real-time PCR using the specific primers shown in Table 2. Promoter DNA 
enrichment with a specific antibody was defined as the ratio of promoter DNA to input, 
with that of the control sample (pCMV5) set at 1.0. PCR amplification of the adjacent 
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promoter regions or a promoter without a CArG region was used as an additional control 
for specific promoter DNA enrichment.  
 
2.12. Flow cytometry 
Differentiated ES cells were dissociated into single cells with trypsin-EDTA 
(Gibco/Invitrogen) after washing the cells once with warm 1× PBS. The cells were washed 
with cold 1× PBS containing 10% FBS once after collection, mixed with 1 ml cold 4% 
paraformaldehyde (PFA; 1 × 10
5
 to 5 × 10
5
 cells/ml), and incubated on ice for 15 min. 
After centrifugation, the supernatant was discarded, and the cell pellet was re-suspended in 
1 ml cold permeabilization buffer (PBS/0.1% Triton X-100, 1 × 10
5
 to 5 × 10
5
 cells/ml) 
and incubated on ice for 5–10 min for intracellular marker detection. After removal of the 
permeabilization buffer with centrifugation, the cell pellets were resuspended in 10% FBS 
diluted in 1× PBS to bring the cell concentration to 1 × 10
7
 cells/ml. After incubation on 
ice for 20 min to block non-specific antibody binding, 100 µl aliquots of the single cell 
suspension were added to tubes and incubated for 1 h at room temperature in a dark box 
with antibodies against GFP or SM-MHC or IgG as a negative control. The samples were 
washed with 1 ml cold 1× PBS and centrifuged. The supernatant was removed completely. 
The cell pellet was mixed with an appropriate amount of secondary antibody (1:50 to 
1:100) diluted in 1× PBS containing 10% normal FBS and incubated for 30 min in a dark 
box. Cold 1× PBS was then added to wash the sample. PBS was removed, and the cells 
were resuspended in 400 µl 1% PFA. A FACSCalibur sorting system (Becton Dickinson) 
was used to analyse the data. 
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2.13. PDGF-BB, TGF-beta, and ActD treatment 
Platelet-derived growth factor-BB (PDGF-BB) and transforming growth factor beta 1 
(TGF-β1) have been widely reported as two important SMC differentiation inducers 
(Kumar and Owens, 2003, Donovan et al., 2013, Sone et al., 2003, Xiao et al., 2010). 
Undifferentiated ES cells were seeded on cell culture flasks or plates and cultured with 
differentiation medium (DM) for 2–3 days to initiate SMC differentiation. The cells were 
then treated with different amounts of PDGF-BB or TGF-β for 12 h and 3 h, respectively. 
The final concentration of PDGF-BB and TGF-β used in the following experiments was 5 
ng/ml and 2 ng/ml, respectively. 
For actinomycin D (ActD) treatment, 2–3 days pre-differentiated ES cells were treated for 
6 h with PDGF-BB or TGF-β in the absence or presence of 1 µg/ml ActD.  
 
2.14. Statistical analysis 
GraphPad Prism 5 (GraphPad Software Inc.) was used for statistical analysis. Data were 
presented as the mean ± SEM of ≥3 independent experiments. A two-tailed Student’s t-test 
was used to compare two groups. One-way ANOVA was used to compare different groups. 
A value of P < 0.05 was considered statistically significant. 
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Chapter 3 
3. Results 
3.1. SMC differentiation from ES cell 
 3.1.1. SMC-specific genes were upregulated during ES cell 
differentiation 
Our previous studies have shown that two extracellular matrix proteins (Djarmati et al.), 
collagen type I and IV, promote SMC differentiation by activating several signalling 
pathways (Xiao et al., 2012, Huang et al., 2013, Pepe et al., 2010, Xiao et al., 2011, Xiao 
et al., 2007a). To confirm these findings, undifferentiated ES cells were plated on flasks 
coated with collagen I and cultured in SMC differentiation medium (DM) to promote SMC 
differentiation. Undifferentiated ES cells (Day 0) and differentiated ES cells (Day 2, 4, 6, 
and 8) were harvested respectively at different time points. The mRNA expression of 
SMC-specific genes, including smooth muscle alpha actin (SmαA) and smooth muscle 
myosin heavy chain (SM-MHC), were significantly upregulated from Day 4 to Day 8 
(compared to undifferentiated ES cells, Day 0). SmαA expression reached a maximum 
level at Day 6, and SM-myh11 expression peaked at Day 8 (Figure 4).  
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Figure 4 Gene expression of SMC-specific genes during stem cell differentiation 
toward SMCs. 
Undifferentiated ES cells were cultured on pre-coated flasks with 5 µg/ml collagen and 
cultured for 2, 4, 6, and 8 days. Day 0 represents undifferentiated ES cells. Cells were 
harvested at the indicated time points. Total RNA was extracted and transcribed to cDNA. 
The cDNA were subjected to real-time PCR analysis with SMC-specific primers for SmαA 
and SM-MHC. The data represent the mean ± SEM of three independent experiments. The 
mRNA abundance was normalized to the 18S rRNA level and presented to expression on 
Day 0. Significant difference from control (Day 0), *P < 0.05. 
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3.2. The role of miR-22 in SMC differentiation from stem 
cells 
3.2.1. Functional involvement of miR-22 in SMC differentiation 
from ES cells in vitro and in vivo 
3.2.1.1. Previous studies: miRNAs and SMC differentiation 
To identify potential miRNA candidates involved in SMC differentiation, total RNA 
including small RNA was harvested from undifferentiated ES cells (Day 0), differentiating 
SMCs (Day 4), and differentiated SMCs (Day 8) and subjected to miRNA microarray 
analysis (Miltenyi Biotec GmbH) in our previous study. Data from the microRNA 
microarray analysis revealed that miR-22 was upregulated during SMC differentiation 
from Day 0 to Day 8 (Yu et al., 2015).  
Our microarray results also identified miRNAs other than miR-22 that were also 
upregulated in SMC differentiation from ES cells, such as miR-34a. Some miRNAs related 
to SMC differentiation, such as miR-143, miR-145, and miR-133, were upregulated in the 
early stage of SMC differentiation (Day 4) when compared with expression in 
undifferentiated ES cells (Day 0). In contrast, miR-21, which is involved in SMC 
proliferation, was undetectable at the early stage of differentiation (Day 4) but upregulated 
at the late stage (Day 8). MiR-146a, miR-203, miR-126-3p, and miR-34b-5p or miR-214 
were increased at the early stage of differentiation and undetectable or downregulated at 
the late stage.  
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3.2.1.2. The role of miR-22 in SMC differentiation in vitro 
Data from our miRNA microarray analyses showed that miR-22 was one of the top 
upregulated miRNAs during SMC differentiation from mouse ES cells in vitro. To further 
confirm the finding that miRNA-22 was induced during SMC differentiation, the gene 
expression of miRNA-22 during SMC differentiation was detected with RT-qPCR. The 
results confirmed our microarray results, showing that miRNA-22 gene expression was 
upregulated during ES cell differentiation toward SMCs (Figure 5). MiRNA-22 gene 
expression reached a maximum level at the differentiated SMC time point (Day 8). 
In addition, to investigate whether miR-22 induction was important for SMC 
differentiation, gain-of-function experiments using Pre-miR™ mmu-miR-22 miRNA 
Precursor (Ambion) were performed in differentiating ES cells. The data showed that the 
gene expression (Figure 6A) of four smooth muscle differentiation specific markers, 
SMαA, smooth muscle 22 alpha (SM22α), h1-calponin, and SM-myh11, were significantly 
upregulated by miR-22 overexpression. Western blot results also showed that miRNA-22 
overexpression increased the protein expression of SMC-specific markers (Figure 6B). On 
the other hand, data from loss-of-function experiments using Anti-miR™ miR-22 inhibitor 
(Ambion)  clearly revealed that the gene expression of the same SMC-specific markers 
was inhibited by miR-22 knockdown (Figure 6E). The western blot results showed the 
same trend (Figure 6F). ImageJ software was used to quantify and compare protein 
expression. We observed that the protein level of SMC-specific markers was higher or 
lower in gain-of-function or loss-of-function miR-22 experiments, respectively, when 
compared with the level in the respective negative control. Both miRNA experiments 
suggest a critical role for miR-22 in SMC differentiation from stem cells. 
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Figure 5 Gene expression of miRNA-22 during stem cell differentiation. 
Undifferentiated ES cells were seeded on T25 flasks coated with 5 µg/ml collagen I and 
cultured for 2, 4, 6, or 8 days in normal differentiation medium (DM). Undifferentiated ES 
cells (Day 0), differentiating ES cells (Day 2, 4, and 6), and differentiated SMCs (Day 8) 
were harvested at different time points (Day 0, 2, 4, 6, and 8). Total mRNA/miRNA was 
extracted with TRIzol reagent and subjected to RT-qPCR analysis. U6 snRNA was used as 
an internal control for normalisation. The data represent the mean ± SEM of three 
independent experiments. *P < 0.05 (vs. Day 0) 
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Figure 6 MiRNA-22 is involved in SMC differentiation from stem cell. 
Undifferentiated ES cells were placed in T25 flasks coated with 5 µg/ml collagen I and 
differentiated to SMCs. (A–C) MiR-22 overexpression promotes SMC marker expression 
at the gene and protein levels. ES cells were transfected with miR-22 precursor or negative 
control and cultured in SMC differentiation medium for 48–72 h. (D–F) Knockdown of 
miR-22 impairs SMC marker expression. Day 3 differentiating ES cells were transfected 
with miR-22 inhibitor or negative control and cultured in SMC differentiation medium for 
48 h. Total RNA and protein were harvested and subjected to RT-qPCR and western blot 
A B
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analyses, respectively. (C and F) Blots were subjected to densitometric analysis with ImageJ 
software. The data presented here are representative or the mean ± SEM of three 
independent experiments. *P < 0.05 (vs. respective control). 
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3.2.1.3. The role of miR-22 in SMC differentiation in vivo 
The data presented above suggest that miRNA-22 plays an important role during SMC 
differentiation from ES cells in vitro. To determine whether miR-22 has a similar role in 
SMC differentiation in vivo, miR-22-overexpressing (pLL3.7-GFP-miR-22) and control 
(pLL3.7-GFP) ES cells were generated, sorted, and characterised. As shown in Figure 7A, 
up to 91.2% of cells were GFP-positive (Figure 7A) in the sorted miR-22-overexpressing 
and control ES cell populations, indicating that the pLL3.7-GFP lentivirus and pLL3.7-
GFP-miR-22 lentivirus were successfully infected into the undifferentiated ES cells. No 
significant differences were detected between the sorted cells and their parent ES cells in 
terms of morphology, self-renewal, and pluripotency when cells were cultured in ES cell 
culture medium for up to at least five passages (data not shown). Compared with the 
expression of miR-22 in the differentiated ES cells (Day 8), the expression of miR-22 was 
low in the parental ES cells, control cells, and miR-22-overexpressing ES cells. 
Additionally, the expression in control and miR-22-overexpressing ES cells was similar 
under ES cell culture conditions (Day 0, undifferentiated) (Figure 7B), indicating that the 
expression machinery for miR-22 was inhibited under stem cell culture conditions. After 
differentiation in DM for 8 days, the parental ES cells, control ES cells (pLL3.7-GFP), and 
miR-22-overexpressing ES cells (pLL3.7-GFP-miR-22) were collected for further analysis. 
Similar to expression in the parent cells, the expression of miR-22 in control and miR-22-
overexpressing cells significantly increased during differentiation. In contrast to 
expression in the control ES cell group (pLL3.7-GFP), expression of miR-22 in miR-22-
overexpressing ES cells (pLL3.7-GFP-miR-22) was further upregulated at Day 8 of 
differentiation (Figure 7B), suggesting that the mechanism inhibiting miR-22 expression 
under stem cell culture conditions had been removed, enabling upregulation of miR-22 in 
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these cells during SMC differentiation. Additional quantitative data from flow cytometry 
analysis showed an increased number of SmαA-positive cells among the parental ES cell 
(65.6% ± 10.1%), control cell (pLL3.7-GFP) (69.9% ± 7.3%), and miR-22-overexpressing 
cell (87.69% ± 15.6%) populations at Day 8 of differentiation, when compared with the 
number in undifferentiated cell populations at Day 0 (3.25% ± 2.3%, 2.5% ± 1.5%, and 
3.5% ± 2.1%, respectively). The results provided additional evidence that the ES cells 
differentiated to SMCs successfully (Figure 7C). Importantly, more SmαA-positive cells 
were observed in the miR-22-overexpressing cell population than in the control ES cell 
population at Day 8 of differentiation (Figure 7C), suggesting that a greater number of 
SMCs differentiated from miR-22-overexpressing ES cells and confirming that miR-22 
promotes SMC differentiation.  
To investigate the functional relevance of miR-22 in SMC differentiation from stem cells 
in vivo, pLL3.7-GFP and pLL3.7-GFP-miR-22 cells were mixed with Matrigel and PDGF-
BB and injected into mice. The Matrigel implants were collected two weeks later for 
immunofluorescence staining analysis. We observed a higher percentage of GFP-positive 
SMCs in miR-22-overexpressing Matrigel grafts than in control Matrigel implants (Figure 
8A and B). As expected, the majority of cells in the Matrigel implants were GFP-positive 
(Figure 8A), implying an exogenous origin. Moreover, total RNA was extracted from 
control and miR-22-overexpressing implants, and the expression in the implants of two 
SMC differentiation markers (SmαA and SM-MHC) and miR-22 was detected with RT-
qPCR. Our data showed that the expression of miR-22, SmαA, and SM-MHC was higher 
in the Matrigel implants of pLL3.7-GFP-miR-22 ES cells than in those of control cells 
(Figure 8C), confirming the efficiency of miR-22 overexpression and the importance of 
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miR-22 in SMC differentiation in vivo. Taken together, our data clearly support a 
regulatory role of miR-22 in SMC differentiation from stem cells in vitro and in vivo. 
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Figure 7 Generation of miRNA-22-overexpressing ES cells and differentiation 
towards SMCs. 
Parental ES cells (control ES cells), control (pLL3.7-GFP) cells, and miR-22-overexpressing 
(pLL3.7-GFP-miR-22) ES cells were seeded on collagen-coated flasks to induce SMC 
differentiation. Control and miR-22-overexpressing cells were harvested after 8 days of 
culture in SMC differentiation medium (DM). Day 0 (undifferentiated) and Day 8 
A B
C
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(differentiated) cells were then subjected to flow cytometry analysis using an SMαA 
antibody. (A) Sorted ES cells were GFP-positive. (B) MiR-22 increased significantly 
during SMC differentiation in vitro. *P < 0.05 (vs. Day 0), #P < 0.05 (pLL3.7-GFP-miR-
22 vs. pLL3.7-GFP). (C) A greater number of SMCs differentiated from miR-22-
overexpressing ES cells. Representative flow cytometry histograms and the mean ± SEM 
of three independent experiments are shown here. 
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Figure 8 MiRNA-22 promotes SMC differentiation in vivo. 
pLL3.7-GFP and pLL3.7-GFP-miR-22 ES cells were subcutaneously injected into 
C57BL/6J mice with Matrigel containing 100 ng/ml of PDGF-BB to promote in vivo SMC 
differentiation. Matrigel plugs implanted with control (pLL3.7-GFP) or miR-22 
overexpressing (pLL3.7-GFP-miR-22) ES cells were harvested, sectioned, and stained 
with antibodies against GFP and SM-MHC. Representative images (A) and quantitative 
data (B) showing the percentage of SM-MHC-positive cells are shown. Cells with green 
fluorescence signal are GFP-positive cells (implanted cells) within the Matrigel plugs. The 
percentage of GFP-labelled SM-MHC-positive cells per field in four random high-power 
B C
A
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fields (200×) in each section was examined by two well-trained independent investigators 
blinded to the treatments. Three sections from each implant and four implants for each 
group were analysed. *P < 0.05. (C) Gene expression within Matrigel implants. Total 
RNA samples were extracted from partial Matrigel implants and subjected to RT-qPCR 
analysis. The data presented here are the mean ± SEM of four Matrigel implants. *P < 
0.05. 
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3.2.1.4. MiR-22 upregulates SMC transcription factors 
Using the miRNA-22 overexpression and inhibition experiments described in Figure 6, we 
also investigated the relationship between miRNA-22 and some smooth muscle cell 
transcription factors (Figure 6). The SMC transcription factors examined were serum 
response factor (SRF), myocardin (Myocd), and myocyte enhancer factor 2C (MEF2c). 
Undifferentiated ES cells were placed on a collagen-coated T25 flask in DM. MiR-22 
precursor, miR-22 inhibitor, or negative controls were transfected into differentiating ES 
cells at Day 2. RNA was collected, and cDNA was synthesized. In qPCR analysis, we 
found that the gene expression of SRF and Myocd increased when cells were transfected 
with miR-22 precursor (Figure 9A), but decreased when cells were transfected miR-22 
inhibitor (Figure 9B) during SMC differentiation, indicating that SRF and Myocd were 
regulated by miR-22 in a manner similar to that of SMC-specific genes. However, as 
shown in Figure 9, the gene expression of the third transcription factor, MEF2C, did not 
differ from that of the negative control group in the miR-22 loss-of-function and gain-of-
function experiments, suggesting that miR-22 modulation in differentiating ES cells has no 
effect on the expression of MEF2C. The above data suggest that miR-22 works in concert 
with SRF and Myocd, but not MEF2C, during SMC differentiation from stem cells. 
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Figure 9 Modulation of miR-22 expression in differentiating ES cells regulates SMC 
transcription factors. 
Total RNA was harvested as described in Figure 5 and subjected to real-time PCR with 
specific primers for SRF, Myocd, and MEF2C. MiR-22 overexpression (A) increased and 
miR-22 inhibition (B) reduced SRF and Myocd expression. Data represent the mean ± 
SEM of three independent experiments (n = 3). The mRNA abundance was normalized to 
18S rRNA levels and presented relative to the respective control. Significant difference 
from the negative control, *P < 0.05. 
A B
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3.2.1.5. Functional importance of miR-22 in adventitia stem/progenitor 
cell differentiation towards SMCs 
Stem cell antigen 1-positive (Sca-1
+
) cells can accelerate re-endothelialisation of injured 
arteries and reduce neointima formation through differentiation into functional endothelial 
cells (ECs) (Xiao et al., 2006). In addition, differentiation of Sca-1
+
 cells, one of the major 
blood vessel residential stem/progenitor cell populations, into SMCs that contribute to vein 
graft atherosclerosis has been reported (Hu et al., 2004). Furthermore, our group 
demonstrated that collagen IV plays a crucial role in SMC differentiation from Sca-1
+
 
progenitor cells (Xiao et al., 2007a). Adventitia Sca-1
+
 cells isolated from vessel adventitia, 
described in our previous study (Xiao et al., 2012), were induced to differentiate into 
SMCs in order to investigate the role of miR-22 in SMC differentiation. Real-time qPCR 
analyses showed that the expression of various SMC differentiation genes (SMαA and 
SM-myh11) increased as cells transitioned from undifferentiated cells (Day 0) to 
differentiated cells (Day 6), indicating that Sca-1
+
 cells  successfully differentiated into 
SMCs. Importantly, the gene expression of miR-22 was upregulated during SMC 
differentiation from adventitia stem cell antigen 1-positive cells from Day 2 to Day 4, but 
not to Day 6 (Figure 10A). To clarify the functional role of miR-22 in Sca-1
+
 progenitor 
cell differentiation to SMCs, miR-22 overexpression and knockdown experiments were 
performed. The results showed that enforced expression of miR-22 by its precursor notably 
increased all SMC genes, including those encoding SMαA, SM22α, h1-calponin, and SM-
myh11, while knockdown of miR-22 by its inhibitor markedly decreased SMC gene 
expression, suggesting functional involvement of miR-22 in SMC specification of vascular 
residential stem/progenitor cells (Figure 10B and C). Interestingly, the gene expression 
levels of methyl CpG binding protein 2 (MECP2), a putative target gene of miR-22, was 
- 129 - 
 
significantly downregulated and upregulated by overexpression and inhibition of miR-22, 
respectively, in differentiating Sca-1
+
 progenitor cells, indicating a negative correlation 
between miR-22 and MECP2 expression in adventitia stem/progenitor cell differentiation 
towards SMCs (Figure 10B and C). 
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Figure 10 Functional importance of miR-22 in adventitia stem/progenitor cell 
differentiation towards SMCs. 
(A) Induction of miR-22 during SMC differentiation from mouse adventitia stem cell 
antigen 1-positive (AdSca-1
+
) cells. Freshly isolated Day 0 samples served as 
undifferentiated controls. (B) The expression of a number of SMC markers was 
upregulated by miR-22 overexpression. AdSca-1
+
 cells were transfected with miR-22 
precursor or a negative control and cultured in SMC differentiation medium for 48–72 h. 
(C) MiR-22 inhibition reduced SMC marker expression in differentiating AdSca-1
+
 cells. 
MiR-22 inhibitor or a negative control was transfected into Day 2 differentiating AdSca-1
+
 
A
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cells, which were then cultured for 2 days before collection. Total RNA was harvested and 
subjected to RT-qPCR analysis. The data presented here are the mean ± SEM of three 
independent experiments. *P < 0.05. 
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3.3. MiR-22 target gene in SMC differentiation from ES 
cells 
3.3.1. MECP2 is a predicted miR-22 target gene 
A critical step in miRNA research is identifying the target gene(s) of a specific miRNA. In 
searching for potential target genes of miR-22, several computational algorithmic 
databases were utilised, including PicTar (www.pictar.mdc-berlin.de), miRanda 
(www.microrna.org), and microRNA target (www.GeneCopoeia.com). Methyl CpG 
Binding Protein 2 (MECP2) was predicted as one of the top targets of miR-22. MECPT2 is 
the founding member of a family of methyl-CpG binding proteins, which repress gene 
transcription directly, prevent the binding of activating trans factors, or recruit enzymes 
that catalyse histone post-translational modifications and chromatin-remodelling 
complexes that alter the structure of chromatin and actively promote transcriptional 
repression (Miranda and Jones, 2007).  
Moreover, the information retrieved from the online computational algorithmic databases 
revealed that the seed sequence of miR-22 is predicted to hybridize with several regions of 
the MECP2 3′-UTR, which is evolutionarily conserved among different vertebrate species. 
At least four conserved binding sites for miR-22 have been identified within the MECP2 
3′-UTR (Figure 11). 
Finally, a favourable minimum loop-free energy in the formation of the miR-22:MECP2 
3′-UTR duplex stem loop for all four examined miR-22 binding sites was acquired using 
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mfold (http://mfold.rna.albany.edu/?q=DINAMelt/Two-state-melting), suggesting that 
miR-22 is involved in the translational repression of MECP2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 134 - 
 
 
 
 
 
Figure 11 Schematic illustration of MECP2 3′-UTR regions and pmiR-Luc-MECP2 
reporters. 
The positions of four miR-22 binding sites (BS1–4, black rectangles) within the 3′-UTR of 
the MECP2 gene are shown, along with the individual 3′-UTR segments of MECP2 in 
pmiR-Luc-MECP2 reporter-A, -B, and -C. 
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3.3.2. MECP2 is repressed during SMC differentiation 
To establish that MECP2 is a target gene of miRNA-22, we examined MECP2 expression 
patterns during SMC differentiation from ES cells. As expected, MECP2 gene expression 
was downregulated, as demonstrated by RT-qPCR analyses (Figure 12A). Consistently, 
western blot analysis showed decreased production of MECP2 protein during SMC 
differentiation from ES cells (Figure 12B). Together, these results indicate a negative 
relationship between miR-22 and MECP2 expression during SMC differentiation. 
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Figure 12 Downregulation of MECP2 during SMC differentiation from ES cells. 
Undifferentiated ES cells were seeded onto T25 flasks pre-coated with 5 µg/ml collagen
and cultured in DM for 2, 4, 6, and 8 days in a 37°C incubator. Cells were harvested at the 
indicated time points, and RNA and protein were extracted. (A) Total RNA from these 
cells was immediately isolated using the TRIzol method, as described in the Materials and 
Methods. RNA from the different collection time points was reverse transcribed into 
cDNA, and RT-PCR was performed using MECP2 and 18S rRNA specific primers. The 
mRNA abundance was normalized to the mRNA level of 18S rRNA and presented relative 
to expression on Day 0 (undifferentiated ES cells). The data presented here are the average 
of three independent experiments. *P < 0.05. (B) Total protein was harvested at the 
A
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indicated time points and detected by western blot with a MECP2 antibody. α-Tubulin was 
included as an internal control.  
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3.3.3. MECP2 is a miR-22 target gene in SMC differentiation 
The causal relationships between MECP2 and miR-22 were first studied in miR-22 
overexpression and inhibition experiments using RT-PCR and western blot analysis. Pre-
miR™ mmu-miR-22 miRNA precursor (Ambion) or Anti-miR™ miR-22 inhibitor 
(Ambion) was transfected into differentiating cells at Day 2. The cells for gain-of-function 
and loss-of-function experiments were harvested 48 h after transfection and analysed with 
RT-qPCR. The data showed that miR-22 overexpression downregulated MECP2 gene 
expression and that miR-22 knockdown upregulated MECP2 gene expression, indicating a 
negative correlation between the expression of miR-22 and MECP2 during SMC 
differentiation (Figure 13A).  
To confirm these observations, a miR-22 overexpression plasmid (pLL3.7-miR-22) and its 
control (pLL3.7 vector) were generated and transfected at the same time point (Day 2) into 
differentiating cells. Western blot analysis was performed to assess the protein expression 
of MECP2. The analysis showed that MECP2 protein expression was reduced when cells 
were transfected with pLL3.7-miR-22 (Figure 13B and C). These findings indicate that 
MECP2 is negatively regulated by miR-22 and strongly suggest that MECP2 is a miR-22 
target gene during SMC differentiation. 
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Figure 13 MECP2 is a miR-22 target gene during SMC differentiation. 
(A) The gene expression of MECP2 after transfection of either Pre-miR™ mmu-miR-22 
miRNA precursor (Ambion) or Anti-miR™ miR-22 inhibitor (Ambion) into differentiating 
A B
C
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cells at Day 2. The data presented here are the mean ± SEM of three independent 
experiments. *P < 0.05 (vs. the respective negative control). (B) pLL3.7-miR-22 or a 
control plasmid was transfected into differentiating cells at Day 2. The samples were 
analysed by western blot with a MECP2 antibody (goat, N-17, sc-5755). The data 
presented here are representative of two independent experiments. (C) The blots were 
subjected to densitometric analysis with ImageJ software. *P < 0.05 (vs. control). 
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3.3.4. MECP2 is a specific target of miR-22 
Our data suggest that MECP2 is a target of miR-22 during SMC differentiation from ES 
cells. We further wondered whether the MECP2 gene is a specific target gene of miR-22. 
To address this question, the precursors of miR-22, miR-34a (another SMC differentiation 
miRNA reported by our group (Yu et al., 2015)), and miR-150 (an endothelial cell 
differentiation miRNA reported by our group (Luo et al., 2013)) were transfected into 
HEK293 cell using TurboFect transfection agent (Thermo) as described in the Materials 
and Methods. Western blot results showed that MECP2 expression was clearly inhibited 
by miR-22 overexpression, but not by overexpression of miR-34a and miR-150, 
suggesting that MECP2 is a specific target of miR-22 (Figure 14). 
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Figure 14 MECP2 protein expression is specifically inhibited by miR-22 
overexpression. 
The precursors of miR-34a, miR-22, and miR-150 and controls were transfected into 
HEK293 cells. At 48 h after transfection, total protein was harvested and subjected to 
western blot analyses with a MECP2 antibody. α-Tubulin was included in the western blot 
as an internal control. 
 
 
 
 
 
- 143 - 
 
3.3.5. MECP2 is negatively regulated by miR-22 through binding 
sites in the 3′-UTR 
As mentioned previously, four conserved miR-22 binding sites with high scores have 
been identified in the 3′-UTR of the MECP2 gene using TargetScan 
(www.targetscan.org) (Figure 15A). To determine if MECP2 is regulated by miR-22 
directly or indirectly, we first attempted to generate a miRNA reporter containing the 
full-length 3′-UTR of MECP2, which is about 8700 bp. Unfortunately, we were 
unsuccessful. Instead, we generated three separate MECP2 3′-UTR reporters, as 
indicated in Figure 11. The three reporters contained the first two miR-22 binging sites (~21 
bp and 1241 bp), the third binding site (~2981 bp), and the fourth binding site (~6791 bp), and 
they were respectively designated pmiR-Luc-MECP2-A, -B, and -C (Figure 15A). A miRNA 
reporter assay demonstrated that the luciferase activity of reporters A and C, but not reporter B, 
was downregulated by miR-22 overexpression (Figure 15B). To determine which binding site 
within the 3′-UTR is the specific and direct binding site for miR-22, mutations in the miR-22 
binding sites within the MECP2 3′-UTR were introduced, in accordance with the QuikChange 
Multi Site-Directed Mutagenesis Kit manual (Agilent Technologies). Luciferase activity 
analyses using the mutated miR-22 binding sites showed that the second binding site (within 
reporter A) and the forth binding site (within reporter C) were required for miR-22-mediated 
inhibition of MECP2 3′-UTR reporter activity (Figure 15C). 
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Figure 15 Binding sites within the 3′-UTR are required for MECP2 gene repression 
by miR-22. 
(A) The potential binding sites of miR-22 within the MECP2 3′-UTR as predicted by 
TargetScan are depicted. (B and C) Binding sites located around ~1241 and ~6791 of the 
A
B C
A
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MECP2 3′-UTR are required for miR-22-mediated MECP2 gene repression. 
Undifferentiated ES cells were seeded in flasks coated with 5 µg/ml collagen and cultured 
for 2 days in DM before transfection. According to the co-transfection protocol, miR-22 
and an individual reporter were co-transfected into Day 2 differentiating cells, and the 
luciferase activities were measured at 48 h post transfection. (B) MiR-22 precursor or a 
negative control and three wild-type MECP2 3′-UTR reporters (pmiR-Luc-MECP2-A, -B, 
and -C) were co-transfected into differentiating ES cells, and their luciferase activity was 
assayed. (C) The luciferase activities of the three indicated mutants [pmiR-Luc-MECP2-A 
bindings site 2 (bs2-mu), combined mutations (bs1/2-mu), and pmiR-Luc-MECP2-C 
bindings site (bs-mu)] were analysed when miR-22 was overexpressed at the same time. 
The data presented here are the mean ± SEM of three to four independent experiments. *P 
< 0.05 (treatment vs. control). The ratio of luciferase activity to Renilla activity in the 
control samples was set at 1.0. 
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3.4. MECP2 inhibition is required for miR-22-mediated 
SMC differentiation from ES cells 
3.4.1. MECP2 knockdown increases SMC gene expression 
We have provided solid evidence to support that MECP2 is an authentic miR-22 target 
during SMC differentiation. Therefore, MECP2 was knocked down in differentiating ES 
cells using a specific MECP2 small interfering RNA (MISSION® esiRNA, EMU085661-
20UG) to investigate the functional involvement of MECP2 in the differentiation of ES 
cells toward SMCs. qPCR was used to analyse the gene expression of various SMC 
markers (SMαA, SM22α, h1-calponin, and SM-myh11) and MECP2. As expected, 
MECP2 gene expression was downregulated by MECP2-specific siRNA (Figure 16). 
Meanwhile, the gene expression of four SMC differentiation markers was markedly 
increased by MECP2 knockdown, suggesting that MECP2 inhibition can recapitulate the 
effect of miR-22 in the differentiation of ES cells to SMCs (Figure 16).  
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Figure 16 MECP2 knockdown increases SMC gene expression.  
Day 2–3 differentiating embryonic stem (ES) cells were respectively transfected with 
control small interfering RNA (ctrl siRNAs) or MECP2-specific siRNA (MECP2 siRNAs) 
and cultured for 48 or 72 h in SMC differentiation medium (DM). Total RNA was 
harvested and subjected to RT-qPCR analyses. The data presented here are the mean ± 
SEM of three to four independent experiments. *P < 0.05 (MECP2 siRNA vs. control 
siRNA). 
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3.4.2. MECP2 overexpression inhibits SMC gene expression 
As mentioned earlier, MECP2 knockdown increased SMC gene expression. To investigate 
the function of MECP2 in the regulation of SMC genes, control (pCMV5) and MECP2 
overexpression (pCMV5-MECP2) vectors were generated and transfected into Day 2 or 
Day 3 differentiating ES cells, respectively. The data showed that overexpression of 
MECP2 increased MECP2 expression at the gene and protein levels (Figure 17). The gene 
expression of four SMC specific markers (SMαA, SM22α, SM-myh11, and h1-calponin) 
was significantly repressed by MECP2 overexpression (Figure 17A), suggesting that 
MECP2 acts as a repressor of SMC differentiation genes during SMC differentiation. 
Western blot data showed a similar trend for MECP2, SMαA, and SM-MHC expression at 
the protein level (Figure 17B and C).  
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Figure 17 MECP2 overexpression inhibits SMC gene and protein expression.  
Day 2–3 differentiating ES cells were transfected with a control (pCMV5) or MECP2 
overexpression (pCMV5-MECP2) plasmid per the manufacturer’s instructions and 
cultured in SMC differentiation medium (DM) for 48 or 72 h at 37°C in a 5% CO2 
incubator. Total RNA and protein were harvested and subjected to RT-qPCR (A) and 
A B
C
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western blotting (B and C) analyses, respectively. (B) α-Tubulin was used as a control. (C) 
The blots were subjected to densitometric analysis with ImageJ software. The data presented 
here are representative or the mean ± SEM of three independent experiments, *P < 0.05 vs. 
control (pCMV5 vector). 
 
 
 
 
 
 
 
 
 
 
 
- 151 - 
 
3.4.3. MECP2 overexpression abolishes SMC gene expression 
induced by miR-22. 
To investigate further the functional importance of MECP2 in miR-22-mediated SMC 
differentiation, a control or MECP2 overexpression vector was transfected into Day 2–3 
differentiating control (pLL3.7-GFP) or miR-22-overexpressing (pLL3.7-GFP-miR-22) ES 
cells, and the gene expression of MECP2, miR-22, SMC differentiation genes (SMαA and 
SM-MHC), SMC transcription factors (SRF, Myocd, and MEF2C), and other reported 
SMC differentiation regulators (Nox4, HDAC7, and Pla2g7) were analysed with RT-qPCR. 
Data showed that the MECP2 expression was successfully downregulated and upregulated 
by miR-22 (2
nd
 columns) and MECP2 (3
rd
 columns) overexpression in differentiating ES 
cells, respectively (Figure 18A). Consistent with our previous observation, SMαA and 
SM-MHC gene expression was upregulated and downregulated by miR-22 (2
nd
 columns) 
and MECP2 (3
rd
 columns) overexpression, respectively (Figure 18B). Importantly, our co-
transfection data (4
th
 columns) showed that re-activation of MECP2 almost completely 
abolished the SMC-specific gene (SMαA and SM-MHC) upregulation induced by miR-22 
overexpression (compare 4
th
 columns with 2
nd
 columns) (Figure 18B), implying that 
MECP2 inhibition/repression is required for miR-22-mediated SMC gene expression. 
Additional analyses with these samples revealed a similar trend for SMC transcription 
factors (SRF and Myocd) and other SMC differentiation regulators (Nox4, HDAC7, and 
Pla2g7) (Figure 19), suggesting that miR-22 and MECP2 work in concert with these 
transcription factors and SMC differentiation regulators to modulate SMC differentiation 
from stem cells.  
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Figure 18 MECP2 overexpression abolishes SMC gene expression induced by miR-22. 
Day 2 or 3 differentiating control ES cells (pLL3.7-GFP) and miR-22-overexpressing ES 
cells (pLL3.7-GFP-miR-22) were transfected with control (pCMV5) or MECP2 
overexpression (pCMV5-MECP2) plasmids, respectively. The transfected cells were 
cultured in normal SMC differentiation medium (DM) for 48 to 72 h before cell collection. 
Total RNA was harvested and subjected to RT-qPCR analysis with primers for MECP2 (A) 
and miR-22, SmαA, and SM-MHC (B). The data presented here are the mean ± SEM of 
three independent experiments. *P < 0.05 (vs. control group/1
st
 columns). 
 
A B
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Figure 19 MECP2 overexpression abolishes the gene expression of SMC transcription 
factors and other reported SMC differentiation regulators mediated by miR-22. 
Total RNA and cDNA were obtained from the experiments described in Figure 18 and 
subjected to RT-qPCR analysis with specific primers as indicated. The data presented here 
are the mean ± SEM of three independent experiments. *P < 0.05 (vs. control group/1
st
 
columns), #P < 0.01 (vs. 2nd columns). 
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3.5. Mechanism underlying MECP2-mediated SMC gene 
repression 
3.5.1. Functional importance of the SRF binding site within 
SMC-specific gene promoters in MECP2-mediated SMC gene 
expression 
As shown above, we have demonstrated clearly that SMC-specific gene expression is 
repressed by MECP2 gene activation. To understand the underlying molecular mechanism 
of MECP2-mediated SMC gene expression, two SMC gene promoter reporters, used in 
our group’s previous study (Huang et al., 2013), pGL3-Luc-SMαA and pGL3-Luc-SM22α, 
were transfected into Day 2 differentiating ES cells. The luciferase activities of the 
reporters were measured according to the protocol described in the Materials and Methods. 
Overexpression of MECP2 significantly inhibited SMαA and SM22α gene promoter 
activities in differentiating ES cells (Figure 20A), indicating that overexpression of 
MECP2 represses specific SMC gene expression at the transcriptional level.  
It has been widely reported that the SRF binding element (CArG) within the promoter 
region of SMC-specific genes is important not only for SMC gene regulation but also for 
SMC differentiation from vascular CD34
+
 stem/progenitor cells and normal 
stem/progenitor cells (Miano et al., 2004, Wu et al., 2015, Huang et al., 2013). Therefore, 
we asked whether the SRF element also plays a role in MECP2-mediated SMC gene 
repression. To answer this question, two SMC-specific gene promoters with SRF binding 
site mutations (pGL3-Luc-SMαA-SRFmu and pGL3-Luc-SM22α-SRFmu), produced in our 
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previous study (Huang et al., 2013), were transfected into differentiating ES cells. 
Luciferase assays were performed 48 to 72 h post transfection. Mutation of the SRF 
binding element within the SMC gene promoters almost completely nullified the 
inhibitory effects of MECP2 overexpression on SMC gene transcriptional activity (Figure 
20A), suggesting that the SRF binding site within the promoters is required for MECP2-
mediated SMC gene repression. To determine whether MECP2 bound directly to the 
promoters of the SMC genes during SMC differentiation, a control (pCMV5) or MECP2 
overexpression (pCMV5-MECP2) plasmid was transfected into differentiating ES cells, 
and binding was analysed with the ChIP assay, as described in the Materials and Methods. 
We observed no significant enrichment of MECP2 within the promoter regions of the 
SMC genes (SMαA and SM22α) in ChIP assays using a MECP2-specific antibody 
(Abcam), suggesting no direct binding of MECP2 to SMC gene promoters (Figure 20B).  
Furthermore, another set of ChIP assay using an SRF antibody (Sigma) was performed to 
assess whether MECP2 modulates SRF binding to SMC-specific gene promoters. As 
expected, we observed a significant enrichment of SRF within SMαA and SM22α gene 
promoters (up to 10-fold enrichment). However, no significant difference in SRF 
enrichment at either SMC gene promoter was observed in control and MECP2 
overexpressing cells (Figure 20C), indicating that MEPC2 plays no major role in 
regulating the direct binding of SRF to SMC gene promoters.  
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Figure 20 SRF binding site is required for MECP2-mediated SMC gene expression. 
(A) SRF binding site mutations abolish the promoter activity of SMC differentiation genes 
induced by MECP2 overexpression. Undifferentiated ES cells were cultured in 24-well 
plates. Plasmids and mutants were transfected into the cells at 48 h or 72 h post 
differentiation. The data presented here are normalized from three independent 
experiments. *P < 0.05 (vs. pCMV5 control group). (B and C) Undifferentiated ES cells 
were cultured in T75 flasks. Control (pCMV5) or MECP2 overexpression (pCMV5-
MECP2) plasmids were transfected into Day 2 or 3 differentiating ES cells. ChIP assays 
were performed using antibodies against MECP2 and SRF, as well as respective normal 
IgG, as described in the Materials and Methods. PCR amplification of the non-CArG 
C
A B
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regions was included as an additional control for specific promoter DNA enrichment. (B) 
The ChIP assay showed no direct binding of MECP2 to the promoter regions of SMC 
differentiation genes. (C) The binding capacity of SRF at the promoter regions of SMC 
differentiation genes was not affected by MECP2 overexpression. 
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3.5.2. MECP2 represses SMC transcription factors 
Our previous data showed that the gene expression of SRF and Myocd, but not MEF2c, 
was upregulated by miR-22 overexpression and downregulated by miR-22 knockdown 
(Figure 9), suggesting that miR-22 regulates SMC differentiation from stem cells by 
regulating these two SMC transcription factors. Therefore, we wondered whether MECP2, 
as a miR-22 target, regulates SMC transcription factors during SMC differentiation. To 
answer this question, the pCMV5 (control) or pCMV5-MECP2 (MECP2 overexpression) 
plasmid was transfected into differentiating cells, and the gene expression of SRF, Myocd, 
and MEF2C was analysed with RT-qPCR. The RT-qPCR results showed that two 
transcription factors, SRF and Myocd, were regulated by MECP2 in a manner opposite to 
that induced by miR-22, implying an important role for MECP2 in the regulation of these 
two transcription factors during SMC differentiation (Figure 21A). Consistently, no 
distinct change in the expression of another transcription factor, MEF2C, was observed in 
cells overexpressing MECP2, suggesting that neither miR-22 nor its target MECP2 
regulates MEF2C gene expression during SMC differentiation. To confirm the findings, 
luciferase activity assays were performed using the SRF, MEF2C, and Myocd gene 
promoter reporter plasmids (pGL3-Luc-SRF, pGL3-Luc-MEF2c, and pGL3-Luc-Myocd) 
generated in our previous study (Huang et al., 2013) under MECP2 overexpression 
conditions. The luciferase activities of the SRF and Myocd reporters were downregulated 
by MECP2 overexpression. On the other hand, MECP2 overexpression did not affect the 
luciferase activity of the MEF2C reporter (Figure 21B), confirming that MECP2 regulates 
SMC differentiation through modulation of the transcription factors SRF and Myocd.  
- 159 - 
 
CHIP assays with a MECP2-specific antibody were conducted to examine whether 
MECP2 directly interacts with the SRF and/or Myocd gene promoters. In our previous 
study (Huang et al., 2013), four pairs of specific primers spanning the promoter regions of 
the SRF, MEF2c, and Myocd genes were designed and used to detect the regions within 
the promoters of these genes that potentially interact with hnRNPA1. In this study, the four 
primer pairs for the SRF and Myocd gene promoters were assessed in a preliminary study, 
and the best primer pairs were chosen for use in the following ChIP experiments. As 
shown in Figure 21C, a significant enrichment of MECP2 within the promoter regions of 
SRF (up to 3-fold) and Myocd (up to 20-fold) was observed, and the enrichment were 
enhanced by MECP2 overexpression (Figure 21C), suggesting that MECP2 directly binds 
to the SRF and Myocd gene promoters. Taken together, our data demonstrate that MECP2 
transcriptionally represses the gene expression of two SMC transcription factors (SRF and 
Myocd) during SMC differentiation from stem cells through its direct binding to the 
promoter regions of SRF and Myocd. 
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Figure 21 MECP2 negatively regulates SMC transcription factor gene expression. 
(A) The expression of SRF and Myocd, but not MEF2c, is significantly downregulated by 
MECP2 overexpression. Total RNA was harvested as described in Figure 17A. (B) The 
promoter activities of the SRF and Myocd genes are modulated by MECP2. Day 2–3 
differentiating ES cells were transfected with the luciferase reporter plasmid pGL3-Luc-
C
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SRF, pGL3-Luc-MEF2c, or pGL3-Luc-Myocd (0.15 μg/2.5 × 104 cells) together with 
pCMV5 or pCMV5-MECP2 (0.2 μg/2.5 × 104 cells). pShuttle-LacZ (0.2 μg/2.5 × 104 cells) 
was included as a control. Luciferase and β-galactosidase activities were detected 48 h 
after transfection. The data presented here are the mean ± SEM of four independent 
experiments. *P < 0.05 (vs. control). (C) MECP2 binds directly to the promoter regions of 
the SRF and Myocd genes. ChIP assays were performed using antibodies against MECP2 
or normal IgG as described in the Materials and Methods. PCR amplification of the 
adjacent regions was included as an additional control for specific promoter DNA 
enrichment. The data presented here are the mean ± SEM of three independent 
experiments. *P < 0.05 (vs. control). 
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3.6. Other SMC differentiation regulators are regulated by 
miR-22 and MECP2 
In our previous studies, several genes were identified as SMC differentiation regulators, 
including nuclear factor erythroid 2-related factor 3 (Nrf3) (Pepe et al., 2010), NADPH 
oxidase 4 (Nox4) (Xiao et al., 2009), platelet-activating factor acetylhydrolase (Pla2g7) 
(Xiao et al., 2012), histone deacetylase 7 (HDAC7) (Margariti et al., 2009) and DNA/RNA 
binding proteins [heterochromatin protein 1γ (Cbx3) (Xiao et al., 2011), heterogeneous 
nuclear ribonucleoprotein (hnRNP) A2B1 (Wang et al., 2012) and A1(Huang et al., 2013)]. 
Thus, we wondered whether miR-22 and MECP2 play a role in the regulation of these 
genes. To this aim, the gene expression of the aforementioned SMC differentiation 
regulators was therefore examined in miR-22- or MECP2-overexpressing cells. RT-qPCR 
data showed that the expression of Nox4, HDAC7, hnRNPA2B1, and Pla2g7, but not 
Cbx3, hnRNPA1, and Nrf3, was significantly upregulated in differentiating cells with 
miR-22 overexpression (Figure 22A). Importantly, only Nox4, HDAC7, and Pla2g7 were 
downregulated by MECP2 overexpression (Figure 22B). Taken together, our data showed 
that three SMC differentiation factors, Nox4, HDAC7, and Pla2g7, were inversely 
regulated by miR-22 (Figure 22A) and MECP2 (Figure 22B), suggesting that miR-22 
works in concert with MECP2 in the regulation of these three genes. Interestingly, these 
three genes were co-regulated by miR-22 and MECP2 in a manner similar to that of other 
SMC differentiation genes, such as SRF and Myocd (Figure 19). In summary, we 
demonstrated that miR-22 and MECP2 mediate SMC differentiation at least partially 
through regulation of the SMC differentiation modulators Nox4, HDAC7, and Pla2g7.  
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To study the relationship between MECP2 and Pla2g7, luciferase assays were carried out 
in Day 2–3 differentiating ES cells using a functional Pla2g7 gene promoter reporter 
(pGL3-Luc-Pla2g7-P2, harbouring 387 bp of a Pla2g7 gene promoter fragment located 
~2.4 to 2.0 kb upstream of the translation start site of the Pla2g7 gene) and a control 
reporter (pGL3-Luc-Pla2g7-P10, located within exon 1 of the Pla2g7 gene) generated in 
our previous study (Huang et al., 2013). The data from the luciferase assays showed that 
the promoter activity of pGL3-Luc-Pla2g7-P2, but not pGL3-Luc-Pla2g7-P10, was 
regulated by MECP2 overexpression (Figure 22C).  
Furthermore, ChIP assays were conducted using an antibody against MECP2 in 
differentiating ES cells to verify that MECP2 regulates Pla2g7 gene expression by binding 
directly to it promoter. The results showed MECP2 enrichment (up to 4-fold) at the Pla2g7 
gene promoter (region 2); MECP2 overexpression increased the accumulation of MECP2 
at the Pla2g7 gene promoter, while no apparent enrichment of MECP2 at an adjacent 
promoter area (region 10) was observed (Figure 22D). Taken together, these findings 
demonstrate that MECP2 regulates Pla2g7 gene expression through direct interaction with 
region 2 (-2.4 to -2.0 kb) of the Pla2g7 gene promoter. Likewise, enrichment of MECP2 
observed in the promoter regions of Nox4 and HDAC7 was increased by MECP2 enforced 
expression (Figure 22F), suggesting that MECP2 also binds directly to the promoters of 
Nox4 and HDAC7. The findings indicate that MECP2 binds directly to the promoter 
regions of three SMC differentiation regulators. Luciferase activity analysis using the gene 
promoter reporters for Nox4 and HDAC7 demonstrated that MECP2 overexpression 
inhibited not only the promoter activity of Pla2g7, but also that of Nox4 and HDAC7 
(Figure 22E).  
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Figure 22 MECP2 negatively regulates other reported SMC differentiation regulators.  
C D
A B
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(A) Undifferentiated control (pLL3.7-GFP) cells or miR-22-overexpressing (pLL3.7-GFP-
miR-22) cells were cultured in differentiation medium for 2–3 days. RNA was harvested, 
and qPCR was performed using primers for SMC regulators (Nox4, Nrf3, HDAC7, Cbx3, 
hnRNPA1, hnRNPA2B1, and Pla2g7) and miR-22. (B) Three reported SMC 
differentiation regulators were regulated by MECP2. A control (pCMV5) or MECP2 
overexpression (pCMV5-MECP2) plasmid was transfected into Day 2–3 differentiating ES 
cells, and total RNA was harvested after 48 h culture as described in Figure 17A. (C) The 
promoter activity of the Pla2g7 gene was repressed by MECP2 overexpression. Day 2–3 
differentiating ES cells were transfected with the luciferase reporter plasmids pGL3-Luc-
Pla2g7-2 or pGL3-Luc-Pla2g7-10 (0.15 μg/2.5 × 104 cells) together with a control 
(pCMV5) or MECP2 overexpression (pCMV5-MECP2) plasmid at a concentration of 0.2 
μg/2.5 × 104 cells. The data presented here are the mean ± SEM of four independent 
experiments. (D) MECP2 binds directly to the promoter (region 2) of the Pla2g7 gene. 
ChIP assays were performed as usual. PCR amplification of the adjacent region (region 10) 
was included as an additional control for specific promoter DNA enrichment. The data 
presented here are the mean ± SEM of three independent experiments. (E) The promoter 
activities of the Nox4 and HDAC7 genes were suppressed by MECP2 overexpression. Day 
2–3 differentiating ES cells were transfected with the luciferase reporter plasmids pGL3-
Nox4-Luc or pGL3-HDAC7-Luc (0.15 μg/2.5 × 104 cells) together with pCMV5 or 
pCMV5-MECP2 (0.2 μg/2.5 × 104 cells). pShuttle-LacZ (0.2 μg/2.5 × 104 cells) was used 
as a control. Luciferase and β-galactosidase activities were measured 48 h after 
transfection. (F) MECP2 binds directly to the promoter regions of the Nox4 and HDAC7 
genes. PCR amplification of the adjacent regions was included as an additional control for 
specific promoter DNA enrichment. The data presented here are the mean ± SEM of four 
independent experiments. *P < 0.05 (vs. control). 
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3.7. MECP2 represses SMC gene expression by increasing 
H3K9 methylation within gene promoters 
It has been well-documented that MECP2 participates in Rett syndrome (Coughlan et al.) 
by binding specifically to methylated DNA, and methylation of lysine H3K9 is closely 
associated with gene transcriptional repression (Rosenfeld et al., 2009, Chen et al., 2015). 
In addition, MECP2, a member of the methyl CpG-binding domain (MBD) family, is a 
candidate for the readout of DNA methylation because members of the family recruit 
chromatin remodellers, histone deacetylases, and methylases to methylated DNA 
associated with gene repression (Du et al., 2015).  
To elucidate the molecular mechanism by which MECP2 represses SMC gene expression 
during SMC differentiation from ES cells, we first examined whether MECP2 regulates 
H3K9me3 levels using western blot. Data from MECP2 overexpression experiments 
showed that the levels of H3K9me3 in control and MECP2-overexpressing cells were 
similar (Figure 23A), suggesting that H3K9me3 levels were not significantly affected by 
MECP2 overexpression. However, ChIP assays using an H3K9me3-specific antibody 
showed variations in H3K9me3 enrichment within the promoter regions of the examined 
genes: up to 2.5-fold for SmαA and SM22α, 23-fold for SRF, 40-fold for Myocd, and 96-
fold for Pla2g7. Importantly, MECP2 overexpression enhanced H3K9me3 enrichment 
within the gene promoters of SRF, Myocd, and Pla2g7 (Figure 23C and D), consistent 
with the enrichment of MECP2 within the promoters of these genes as shown in the CHIP 
assays with a MECP2 antibody (Figure 21C and Figure 22D). On the other hand, no 
further enrichment of H3K9me3 with MECP2 overexpression was observed in the 
promoters of SmαA and SM22α (Figure 23B). As described earlier, both MECP2 and 
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miR-22 are involved in the regulation of some SMC differentiation regulators, such as 
SRF, Myocd, and Pla2g7. Therefore, additional ChIP assays using an H3K9me3 antibody 
or IgG were performed in cells with or without miR-22 enforced expression. The ChIP 
assay data showed that miR-22 overexpression did not affect H3K9me3 enrichment levels 
in the promoters of the SMαA (Figure 24A) and SM22α genes (Figure 24B). As expected, 
enrichment of H3K9me3 within the promoter regions of SRF (Figure 24C), Myocd 
(Figure 24D), and Pla2g7 (Figure 24E) was decreased by miR-22 overexpression, 
indicating that enforced miR-22 expression significantly suppressed the enrichment of 
H3K9me3 within the three promoter regions. 
In summary, our data demonstrate that MECP2 inhibits SMC-specific gene expression 
partially by increasing H3K9 trimethylation within the gene promoters of SMC-specific 
transcription factors (SRF and Myocd) and differentiation modulators (e.g. Pla2g7). 
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Figure 23 MECP2 increases the binding of H3K9me3 to the gene promoter regions of 
SRF, Myocd, and Pla2g7. 
(A) H3K9me3 protein levels were not affected by MECP2 overexpression. Total protein 
was harvested as described in the Material and Methods. α-Tubulin was included as an 
internal control. Data presented here are representative of three experiments. (B–D) 
H3K9me3 CHIP assays. ChIP assays were performed using an antibody against H3K9me3 
(Millipore) or normal mouse IgG. The data presented here are the mean ± SEM of three 
independent experiments. *P < 0.05 (vs. control). (B) The enrichment of H3K9me3 within 
the promoter regions of the SMαA and SM22α genes is not affected by MECP2 
A B
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overexpression. (C) MECP2 overexpression increases H3K9me3 binding to the promoter 
regions of the SRF and Myocd genes. (D) The enrichment of H3K9me3 within the 
promoter region of the Pla2g7 gene was significantly increased by overexpression of 
MECP2.  
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Figure 24 MiR-22 overexpression decreases H3K9 methylation within the SRF, 
Myocd, and Pla2g7 gene promoters. 
ChIP assays were performed using an antibody against H3K9me3 or normal mouse IgG, 
following the protocol described previously. The enrichment of H3K9me3 within the 
promoter regions of the SMαA (A), SM22α (B), SRF (C), Myocd (D), and Pla2g7 (E) 
genes was examined using two pairs of primers specific for the regions of interest and 
adjacent regions of each individual gene as indicated. The data presented here are the mean 
± SEM of three independent experiments. *P < 0.05 (vs. control). 
A B
C D E
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3.8. PDGF-BB and TGF-β upregulate miR-22 during SMC 
differentiation through a transcriptional mechanism 
Our previous studies suggested that, during stem cell differentiation, an auto-secreted 
growth factor, PDGF-BB, and transforming growth factor β (TGF-β) from differentiating 
cells activate their respective downstream signal pathways (e.g. Nox4), which in turn 
trigger the SMC differentiation program (Xiao et al., 2009, Zhang et al., 2010b). Thus, we 
wondered whether miR-22 is involved in signalling during SMC differentiation. To 
address this question, Day 2 or 3 differentiating ES cells were treated with four different 
doses of PDGF-BB or TGF-β as indicated to determine the best concentrations for 
subsequent experiments. Data showed that PDGF-BB and TGF-β upregulated miR-22 
expression in a dose-dependent manner. Importantly, the expression of miR-22 reached the 
highest levels with 2.5 ng/ml PDGF-BB and 1 ng/ml TGF-β (Figure 25A and B), 
suggesting that these concentrations should be used in the following studies. Moreover, 
qPCR data showed that both PDGF-BB and TGF-β treatments increased the expression of 
miR-22 precursor and primary miR-22 (Figure 25C and D), suggesting that miR-22 is 
regulated by PDGF-BB and TGF-β at the transcriptional level. This notion was confirmed 
by the finding that incubation of differentiating ES cells with the RNA synthesis inhibitor 
actinomycin D (ActD) (1 μg/mL) nearly abolished the effect of PDGF-BB and TGF-β 
treatments on the expression of miR-22 (Figure 25E and F). 
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Figure 25 PDGF-BB and TGF-β upregulate miR-22 through a transcriptional 
mechanism. 
A B
C D
E F
- 173 - 
 
(A) PDGF-BB upregulates miR-22 expression. Pre-differentiating ES cells (Day 2-3) were 
incubated with the indicated dose of PDGF-BB as indicated for 12 h. (B) The gene 
expression of miR-22 is also upregulated by TGF-β. The differentiating cells were 
incubated for 3 h with different concentrations of TGF-β. (C) MiR-22 precursor and 
primary miR-22 levels are upregulated by PDGF-BB treatment. Day 2–3 differentiating 
ES cells were incubated with PDGF-BB (2.5 ng/ml) for 12 h prior to cell collection. (D) In 
cells treated with 1 ng/ml TGF-β, expression of miR-22 precursor and primary miR-22 
also increase. (E) Actinomycin D (ActD) represses the effect of PDGF-BB treatment on 
the expression of miR-22. Day 2–3 differentiating ES cells were incubated with 2.5 ng/ml 
PDGF-BB in the presence or absence of ActD in DMSO (1 µg/ml) for 6 h. Total RNA was 
harvested and subjected to RT-qPCR analysis with specific primers for primary miR-22. 
(F) ActD also suppresses the effect of TGF-β treatment on the expression of miR-22. 
Differentiating ES cells were treated with or without TGF-β (1 ng/ml) in the presence or 
absence of ActD in DMSO (1 µg/ml) for 6 h. The data presented here are the mean ± SEM 
of three independent experiments. *P < 0.05 (vs. control/DMSO), #P < 0.05 (ActD vs. 
DMSO in the presence of PDGF-BB or TGF-β). 
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Chapter 4 
4. Discussion, Conclusion, and Future Plans 
4.1. SMC differentiation from ES cells 
SMCs are normally quiescent and are programmed for contraction under normal 
physiological conditions. However, in response to local inflammation, they migrate from 
the media to the intima where they can proliferate and synthesize extracellular matrix 
proteins as well as inflammatory cytokines, causing vascular lesion formation and/or 
intima thickening. As such, it is well accepted that SMCs play critical roles in 
cardiovascular diseases such as stroke, hypertension, and atherosclerosis. Moreover, there 
is a rate-limiting step in constructing autologous human vessels in vitro to replace diseased 
or injured vasculature because of the limited lifespan of adult vascular smooth muscle cells 
(SMCs) and rare sources of adult artery. Therefore, it would be helpful and important to be 
able to generate vascular tissue or grafts in vitro if alternative cell sources can be used to 
obtain large amounts of functional SMCs. To resolve such a problem, major efforts have 
been put into stem/progenitor cell research in the past decades, and significant 
achievements have been obtained in the field of stem/progenitor cell research.  
Accumulating evidence has shown that the gene regulatory program of SMC 
differentiation from pluripotent stem cells is orchestrated by a coordinated molecular 
network comprising various signalling pathways and molecules, such as the Myocd-SRF 
complex, extracellular matrix, integrins, retinoid receptor, TGF family, notch family, ROS, 
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microRNAs (such as 34a and 22), HDACs, and others (e.g. paired-like homeodomain 2 
and protein inhibitor of activated STAT-1) (Xie et al., 2011b, Xiao et al., 2010, Huang et 
al., 2013, Zhao et al., 2015, Chen et al., 2015, Yu et al., 2015). Despite enormous efforts 
have been put into this field in the past decades, our understanding of the molecular 
mechanisms underlying SMC differentiation are far from complete because the SMC 
differentiation procedure is complicated and only a few processes have been found to 
regulate several signalling pathways. In the present study, we have advanced our 
understanding of this topic by uncovering an important role for miR-22 in regulating 
SMC-specific gene expression and SMC differentiation from murine ES cells in vitro and 
in vivo. Furthermore, we present evidence for a functional role of MECP2 in SMC 
differentiation and SMC-specific gene regulation. Importantly, we have provided 
compelling evidence to support that the identified target gene, MECP2, functions as an 
important repressor of SMC differentiation genes during SMC differentiation from stem 
cells.  
As described in our previous studies, we have successfully established a simple but very 
efficient model for the differentiation of ES cell towards SMCs. In 2007, Xiao et al. 
reported that collagen type IV stimulated ES cells to differentiate into Sca-1
+
 cells and 
further differentiate into SMCs, implying that signalling pathways mediated by collagen 
type IV are important for SMC lineage specification (Xiao et al., 2007a). Our group also 
reported that collagen type I could regulate SMC differentiation from ES cells through a 
pathway similar to that used by collagen type IV. In our studies, SMC-specific markers 
such as SMαA, SM22α, h1-calponin, and SM-MHC were examined to verify that ES cells 
had been successfully induced to differentiate into SMCs (Huang et al., 2013, Yu et al., 
2015). Therefore, the same panel of SMC differentiation markers was used in this project 
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to study SMC differentiation and the molecular mechanisms involved. As expected, the 
gene expression of SMαA and SM-MHC was upregulated during SMC differentiation and 
reached a maximum level at Day 6 (SMαA) or Day 8 (SM-MHC) (Figure 4), confirming 
SMC lineage specification from ES cells. In 2004, Owens’s group suggested that SMαA 
and SM22α are markers for the early SMC differentiation stage, while calponin and SM-
MHC represent late/mature SMC differentiation markers (Owens et al., 2004). This 
classification provides an explanation for our finding that the levels SMαA and SM-MHC 
gene expression peak at different times during SMC differentiation. Moreover, data from 
our time course study also suggest that the best period for modulating SMC differentiation 
or investigating the underlying mechanisms of SMC differentiation in our model is Day 2 
to Day 6. Hence, most treatments during SMC differentiation in this project were 
conducted during this period to investigate the mechanisms by which miR-22 and MECP2 
regulate SMC differentiation from ES cells.  
 
4.2. MiR-22 and SMC differentiation from ES cell and 
adventitia stem/progenitor cell 
The human miR-22 gene is located in a minimal loss of heterozygosis region between 
markers D17S1866 and D17S1574 on chromosome 17 (17p13.3) (close to TP53) in cancer 
cells, overlapping the exon 2 region of the spliced non-coding C17orf91 transcript 
(Rodriguez et al., 2004). Primary miR-22 is processed from a capped polyadenylated 
transcript (Cai et al., 2004). The mouse counterpart also maps to a cancer-associated 
genomic region (Xiong et al., 2010), implying an important role for miR-22 in cancers. 
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Indeed, several studies have independently identified miR-22 as a tumour suppressor (Ling 
et al., 2012, Zhang et al., 2012a, Xu et al., 2011). Moreover, it was recently reported that 
miR-22 contributes to cardiac aging by inducing cellular senescence and promoting the 
migratory activity of cardiac fibroblasts through its targeting of osteoglycin (Jazbutyte et 
al., 2013), suggesting that miR-22 plays a role in cardiovascular disease. Furthermore, 
miR-22 is upregulated during human ES cell differentiation (Stadler et al., 2010), induced 
by 12-O-tetradecanoylphorbol-13-acetate (TPA) during monocytic differentiation from 
HL-60 leukaemia cell lines (Ting et al., 2010), and associated with erythroid maturation 
(Choong et al., 2007), implying that miR-22 could play a role in hematopoietic cell 
differentiation and maturation. However, the functional role of miR-22 in SMC 
differentiation from pluripotent stem cells remained unclear. 
In a previous study, miR-22 was identified in microRNA microarray experiments as one of 
the top miRNA candidates with high expression during SMC differentiation from ES cells 
(Yu et al., 2015). The gene expression of miR-22 was measured with qPCR during SMC 
differentiation, from the undifferentiated stage (Day 0) to a late stage (Day 8). The results, 
described in Figure 5, showed that miR-22 was upregulated in the SMC differentiation 
process (Figure 5). Importantly, utilizing miRNA gain/loss-of-function analyses, we 
confirmed a critical role for miR-22 in SMC differentiation from ES cells in vitro (Figure 
6).  
Furthermore, to determine whether miR-22 regulates SMC differentiation from ES cells in 
vivo, miR-22-overexpressing and control ES cell lines were generated and used with our 
well-established in vivo SMC differentiation model (Matrigel-stem cells-PDGF-BB 
complex implantation) (Huang et al., 2013, Xiao et al., 2012, Yu et al., 2015). Data from in 
vitro experiments with these cell lines showed that more SMCs derived from the miR-22-
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overexpressing ES cells (pLL3.7-GFP-miR-22 ES cells) than from control ES cells 
(Figure 7), further supporting a role for miR-22 in promoting SMC differentiation. 
Importantly, additional supporting evidence was obtained from in vivo experiments using 
the aforementioned miR-22-overexpressing cell lines combined with the in vivo Matrigel 
implantation model. Data from immunofluorescence staining and RT-qPCR analyses 
showed that more SMCs and higher levels of SMC-specific genes were detected in the 
Matrigel implants with miR-22-overexpressing ES cells than in those with control ES cells 
(Figure 8). These data provide the first evidence to support that miR-22 plays an important 
role in embryonic SMC differentiation in vitro and in vivo. They also demonstrate that 
miR-22 is an important SMC differentiation regulator. 
We have also provided evidence that miR-22 plays a similar role in SMC differentiation 
from adult vascular stem/progenitor cells, Sca-1
+
 cells, (Figure 10), which could translate 
into a vascular disease setting.  
 
4.3. MECP2 is a downstream target gene of miR-22 during 
SMC differentiation 
The fundamental and most difficult step of miRNA studies is identifying and validating 
bona fide mRNA target(s) that mediate a given function of the examined miRNA(s). It has 
been suggested that an average miRNA has approximately 100 target genes and regulates a 
large fraction of protein-coding genes, which form a regulatory network (Brennecke et al., 
2005). Therefore, it is not easy to identify the actual targets of any miRNA. Having 
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demonstrated that miR-22 can regulate SMC differentiation in vitro and in vivo, we sought 
to identify the downstream mRNA target(s) responsible for miR-22-mediated SMC 
differentiation from stem cells. MECP2 was identified as a top target gene of miR-22 
during SMC differentiation using several computational algorithmic databases, including 
TargetScan (www.targetscan.org), PicTar (www.pictar.mdc-berlin.de), and miRanda 
(www.microrna.org). Interestingly, MECP2 mRNA has a long 3′-UTR of about 8.7 kb that 
bears many evolutionarily conserved miRNA target sites, suggesting that it might be 
regulated by miRNAs. Using information from computer databases, we identified four 
highly conserved binding sites for miR-22 within the 3′-UTR of MECP2, as shown in 
Figure 11, implying that MECP2 is a potential mRNA target of miR-22. To establish that 
our prediction was correct, several experiments involving miR-22 loss/gain-of-function 
were conducted in differentiating ES cells. As shown in Figure 12, MECP2 gene and 
protein expression decreased during SMC differentiation from stem cells (Figure 12A) 
and showed a negative correlation with miR-22 expression levels (Figure 5). Moreover, 
MECP2 gene and protein expression was negatively regulated by miR-22, as demonstrated 
in miR-22 overexpression and inhibition experiments (Figure 13A and B). Importantly, 
miR-22, but not miR-34a and miR-150, were shown to downregulate MECP2 (Figure 14), 
confirming that MECP2 is a specific target of miR-22 during SMC differentiation. 
Furthermore, data from luciferase activity assays with MECP2 3′-UTR reporters 
containing wild-type and mutant versions of the miR-22 binding site demonstrated that, of 
the four miR-22 binding sites, two mediated MECP2 gene repression by miR-22 (Figure 
15). Interestingly, the two binding sites located around ~1241 bp and ~6791 bp were 
responsible for miR-22-mediated MECP2 gene regulation in this study, but not the one 
located in the middle of the 3′-UTR (~2891 bp), consistent with an essential rule of 
microRNA–mRNA interactions, in which the site efficacy improves markedly for some 
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genes with long 3′-UTRs when the position of the miRNA binding site is not too distal 
from the poly(A) tail or the termination codon (Filipowicz et al., 2008). However, because 
we failed to obtain a mutant in which with only the 1
st
 miR-22 binding site (~21 bp) was 
affected, we cannot exclude the importance of this binding site in mediating the effects of 
miR-22 on MECP2 3′-UTR activity. Nonetheless, our data demonstrate that MECP2 is a 
genuine mRNA target of miR-22. Finally, but importantly, the MECP2 gene expression 
levels in the Matrigel plugs implanted with miR-22-overexpressing ES cells were much 
lower than in the Matrigel plugs implanted with control ES cells (Figure 8C), suggesting 
that MECP2 gene expression is negatively regulated by miR-22 and that MECP2 is a true 
mRNA target of miR-22 during in vivo SMC differentiation from stem cells. 
Studies to determine if miR-22 has other mRNA targets during SMC differentiation are 
warranted. Several other miR-22 mRNA targets, including oncogene EVI-1 (Patel et al., 
2011), HDAC4 (Zhang et al., 2010a), PTEN (Bar and Dikstein, 2010), estrogen receptor α 
(ERα) (Pandey and Picard, 2009), c-Myc binding protein (MYCBP) (Xiong et al., 2010), 
MYC-associated factor X (Mann et al.) (Ting et al., 2010), and TET2 (Song et al., 2013), 
have been reported in cancer cells. However, none has been shown to be a true miR-22 
mRNA target during SMC differentiation. Among them, only the expression of EVI-1 was 
negatively associated with miR-22 expression in the miR-22 overexpression and/or 
inhibition experiments, but overexpression of miR-22 failed to downregulate EVI-1 3′-
UTR luciferase activity. These data suggest that target gene regulation by miR-22 is 
dependent on the cellular context or that miR-22 plays different role under various 
physiological and pathological conditions by targeting distinct target gene(s).  
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4.4. MECP2 regulates the expression of genes involved in 
SMC differentiation through a transcriptional 
mechanism 
Two novel mechanistic findings in the present study are that MECP2 repression is required 
for miR-22-mediated SMC differentiation from stem cells and that MECP2 inhibits the 
gene expression of SMC differentiation. MECP2 negatively regulated the expression of 
SMC-specific markers such as SMαA, SM22α, SM-myh11, and h1-calponin (Figure 16 
and Figure 17), suggesting that MECP2 acts as a repressor of SMC differentiation genes 
during SMC differentiation. Furthermore, as shown in Figure 17, miR-22 or MECP2 
overexpression alone in differentiating ES cells upregulated or downregulated the 
expression of various SMC-specific genes, respectively. In addition, re-activation of 
MECP2 almost completely abolished the SMC-specific gene upregulation induced by 
miR-22 overexpression, suggesting that MECP2 repression is required for miR-22-
mediated SMC gene expression during SMC differentiation from ES cells (Figure 18). 
Moreover, it has been reported that MECP2 plays different roles in gene regulation, 
including transcriptional repression, activation of transcription, nuclear organization, and 
splicing (Bogdanovic and Veenstra, 2009). Our data showed that MECP2 is a 
transcriptional repressor not only for SMC differentiation genes (SMαA, SM22α), but also 
for SMC transcription factors (SRF and Myocd) and other genes that regulate SMC 
differentiation (e.g. Nox4, HDAC7, and Pla2g7) (Figure 18, Figure 19, Figure 20, Figure 
21 and Figure 22). Taken together, our data suggest that MECP2 is a repressor of SMC 
differentiation whose inhibitory effect on SMC differentiation is de-repressed by the 
upregulation of miR-22 during SMC differentiation from stem cells. 
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4.5. Epigenetic regulation of SMC genes by MECP2 
during SMC differentiation 
MECP2 is the founding member of the methyl CpG-binding domain protein family, whose 
members specifically bind to methylated and unmethylated DNA and recruit distinct 
interacting protein partners to establish a repressive or active chromatin environment 
(Bogdanovic and Veenstra, 2009), respectively. MECP2 is involved in a variety of 
biological processes and diseases, such as Rett syndrome and neural development (Chen et 
al., 2001, Guy et al., 2001), modulation of human iNOS gene expression (Chan et al., 
2005), regulation of myofibroblast differentiation during pulmonary fibrosis (Hu et al., 
2011), myogenesis (Agarwal et al., 2007), neural differentiation from ES cells (Okabe et 
al., 2010) or neural precursors (Tsujimura et al., 2009), adult neurogenesis (Szulwach et al., 
2010), neuron electrophysiological properties (Zhang et al., 2010c), and embryonic 
development (Tate et al., 1996). At the molecular level, MECP2 recognizes and binds to 
epigenetic modifications such as DNA methylation and chromatin marks and recruits 
various protein complexes that can modify epigenetic states to regulate gene expression 
(Zimmermann et al., 2015). 
DNA methylation is associated with gene silencing. However, the mechanisms by which 
DNA methylation inhibits transcription have been uncovered only recently. Numerous 
processes by which DNA methylation can influence transcription have been proposed. One 
model suggests that DNA methylation directly inhibits the binding of transcription factors 
to their target sites, thus prohibiting transcription. Other proposed mechanisms are based 
on the idea that methylation of CpG sequences alters chromatin structure by affecting 
histone modifications and nucleosome occupancy within the promoter regions of genes 
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(Miranda and Jones, 2007). Importantly, a recent study suggests that MECP2 can switch 
transcriptional activity in the epigenetic regulation of neural chromatin and gene 
expression by binding hydroxymethylcytosine (5hmC)- or 5-methylcytosine (5mC)-
containing DNA with a similar affinity. It has been reported that MECP2 binding to 5hmC 
can facilitate transcription in neural cell types while at the same time acting as a repressor 
when bound to 5mC-containing DNA (Mellen et al., 2012). 
Another important finding of the present study is that MECP2 acts as a potential 
transcriptional repressor of SMC gene regulation by modulating the epigenetic 
modification of SMC-specific transcription factors and/or SMC differentiation modulators. 
DNA methylation and histone modifications are the two major epigenetic mechanisms 
implicated in the regulation of gene transcription in mammals. It is widely accepted that 
hypomethylation of DNA surrounding the proximal promoter region is a prerequisite for 
gene activation, whereas hypermethylation leads to gene silencing. In addition, MECP2 
recognizes and binds to epigenetic modifications such as DNA methylation and chromatin 
marks and recruits various protein complexes that can modify epigenetic states to regulate 
gene expression at the molecular level (Zimmermann et al., 2015). A study published in 
2003 reported that MECP2 is associated with histone methyltransferase activity in vivo and 
that such activity is directed against Lys9 of histone H3 (Fuks et al., 2003). Moreover, our 
group found that H3K9 methylation was enriched within SMC-specific gene promoter 
regions in differentiating stem cells (Xiao et al., 2011). These studies prompted us to 
investigate whether DNA methylation, especially H3K9, regulated MECP2 repression via 
SMC-specific gene markers during ES cell differentiation to SMCs.  
The data shown in Figure 23 and Figure 24 revealed that the expression level of 
trimethylation on Lys 9 of histone 3 (H3K9me3) was not regulated by MECP2. Instead, 
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enrichment of H3K9me3 within the promoters of several SMC-specific transcription 
factors (e.g. SRF and Myocd) and other SMC differentiation regulators (e.g. Pla2g7) was 
modulated by MECP2 as well as miR-22, implying that epigenetic regulation of SMC gene 
expression by miR-22 and/or MECP2 is a major mechanism involved in miR-22-mediated 
SMC differentiation from stem cells.  
 
4.6. Conclusion 
In conclusion, this project has established a novel role for miR-22 in mouse ES cell 
differentiation toward SMCs in vitro and in vivo. It has also provided compelling evidence 
to support the conclusion that MECP2 is a genuine mRNA target of miR-22 during SMC 
differentiation and that repression of MECP2 in differentiating ES cells is required for 
miR-22-mediated SMC differentiation. Additionally, our data indicate that MECP2 
regulates SMC gene expression through a transcriptional mechanism as well as an 
epigenetic signalling pathway. Furthermore, we have demonstrated that both miR-22 and 
MECP2 regulate SMC-specific gene expression by modulating other SMC differentiation 
regulator (Pla2g7, Nox4, and HDAC7) and that MECP2 transcriptionally regulates the 
gene expression of several transcriptional regulators (SRF and Myocd) through direct 
binding within their promoter regions. Finally, MECP2 increases H3K9 trimethylation 
within gene promoters. On the basis of these findings and those of our previous studies, 
we propose an SMC differentiation mechanism model mediated by miRNAs (Yu et al., 
2015, Zhao et al., 2015). During stem cell differentiation, PDGF-BB and/or TGF-β, auto-
secreted from differentiating cells, upregulate the expression of miR-22 and/or miR-34a in 
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SMC differentiation. On one hand, upregulation of miR-22 attenuates the inhibitory 
effects of MECP2 on SMC-specific transcription factors (SRF and Myocd) and other 
master regulators of SMC differentiation (e.g. Pla2g7, Nox4 and HDAC7), thus triggering 
an SMC-specific gene expression programme and promoting SMC differentiation. On the 
other hand, miR-34a upregulates its target gene, SirT1, in an unusual manner, which in 
turn regulates the transcription of three SMC transcription factors (SRF, Myocd, and 
MEF2C), resulting in the activation of SMC differentiation genes and SMC differentiation 
(Yu et al., 2015). Undoubtedly, the findings presented in this study significantly increase 
our understanding of the molecular mechanisms of SMC differentiation and will benefit 
clinical research in cardiovascular disease. 
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Figure 26 Proposed model of miRNA-mediated SMC differentiation. 
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4.7. Future Plans 
We have presented compelling evidence in this study to support that miR-22 acts as an 
important SMC differentiation regulator in vitro and in vivo. However, the functional 
importance of miR-22 in embryonic SMC differentiation and cardiovascular system 
development are still unclear. Currently, little is known about the pathological role of miR-
22 in cardiovascular diseases. All of them warrant further investigation.  
First, it is unclear if the findings presented in this study translated into humans. To this end, 
the functional role of miR-22 in human SMC differentiation and the related mechanisms 
need to be investigated further using a human SMC differentiation model (e.g. human ES 
cells, human iPS cells, or human adult vascular stem/progenitor cells).  
Second, despite demonstrating that the modulation of H3K9 methylation within the gene 
promoters of SMC transcription factors and other SMC differentiation regulators is one of 
the mechanisms responsible for MECP2-mediated SMC differentiation from stem cells, 
the functional involvements of MECP2 in the regulation of other epigenetic modifications 
(e.g. monomethylation of H3K4 and H3K79 and/or trimethylation of H3K27 and H3K9) 
remain to be fully elucidated.  
Third, although we have provided compelling evidence to support that MECP2 is one of 
the functional target genes of miR-22 during SMC differentiation, it is widely accepted 
that a single miRNA can target multiple mRNAs, referred to as a ‘targetome’, to regulate 
gene expression transcriptionally and/or post-transcriptionally and thereby play 
physiological and/or pathological roles in embryonic development and human diseases. 
The miR-22 ‘targetome’ during SMC differentiation remains to be fully defined.  
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Fourth, global and/or VSMC-specific miR-22 knockout mice are required to study the 
functional relevance of miR-22 in VSMC differentiation and embryonic cardiovascular 
development. 
Finally, the potential importance of miR-22 in adult VSMC functions (e.g. proliferation, 
migration, adhesion, apoptosis/senescence, and extracellular matrix protein 
synthesis/remodelling) and vascular diseases (atherosclerosis, post-angioplasty restenosis 
and/or in-stent restenosis) remains to be investigated. 
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